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Axonal and synaptic degeneration occur in response to nerve injury and during 
neurodegenerative disease. Traumatic nerve injury leads to rapid fragmentation of the 
distal axon and loss of synaptic terminals in a process known as Wallerian 
degeneration (WD). This is morphologically distinct from some motor neuron 
diseases, like Spinal Muscular Atrophy (SMA), where axons gradually retract, or die-
back, from the motor endplate. Identifying and understanding factors that can 
influence the rate of degeneration is of significant clinical and biological importance, 
to facilitate our knowledge of the mechanisms of neurodegeneration and to aid in the 
identification of novel therapeutic targets. Factors that can change the speed of axonal 
and synaptic breakdown are interesting, as targeting these could represent an approach 
to slow or prevent breakdown in disease. The work contained within this thesis aims 
to identify factors that can alter the rate of synaptic degeneration in morphologically 
distinct types of synaptic degeneration, including following injury, during disease and 
during postnatal development. Using an ex vivo model of peripheral nerve injury, it is 
apparent that synaptic withdrawal is slower during early postnatal development, and 
that this delay is progressively lost over time. For example, significantly more 
neuromuscular junctions (NMJs) remain fully occupied in the cranial muscle 
preparations at postnatal day (P) 15 than P25. Intermuscular variability was also found 
to be a feature of WD, with less synaptic retraction evident in the abdominal 
preparations compared to cranial muscles. Importantly, differences in synaptic 
responses to injury were not consistent with patterns of neuromuscular vulnerability 
that have been previously described in mouse models of SMA, which is caused by a 
lack of survival motor neuron protein (Smn). To further investigate the relationship 
between SMA and WD, nerve injury was induced in preparations from the Smn2B/- 
mouse model of SMA. In a disease-resistant muscle (rostral band of levator auris 
longus), where there is minimal denervation, the level of synaptic loss in response to 
injury is similar to wild-type, suggesting that loss of Smn alone is not sufficient to 
influence rates of WD, suggesting that WD is Smn-independent. However, in a 
disease-vulnerable muscle with ongoing degeneration (transversus abdominis), the 
level of synaptic loss in response to injury is significantly increased, with the 
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percentage of denervated endplates increasing by 33% following injury. Thus, the 
presence of dying-back pathology appears to accelerate synaptic loss. Next, analysis 
of two independent proteomic datasets highlighted that there are changes in 
mitochondrial proteins during postnatal development that correlate with increases in 
synaptic vulnerability following injury during this time frame. Expanding this analysis 
to assess mitochondrial-associated protein levels and mitochondrial DNA levels in a 
range of different muscles revealed that although there are global changes in 
mitochondrial proteins across development, complex I levels do not correlate with 
differences in the synaptic response to injury. There is evidence, however, that 
increases in complex I in nerve may underlie intermuscular differences. The final part 
of this work was to determine whether reductions in P53, a factor that is involved in 
cell death processes, could alter the rate of synaptic loss under different scenarios. 
Application of the ex vivo model, and immunohistochemical and transcriptional 
analysis in an inducible P53-knockout mouse model demonstrated that postnatal 
reduction in P53 has no effect on the rate of synaptic loss following injury, during a 
die-back, or during development, suggesting P53-independence. Overall, the 
expanded ex vivo model and workflows described here represent powerful tools with 
which to study factors or pathways that can influence the rate of synaptic degeneration 
under different physiological scenarios. This will provide insight into mechanistic 
commonalities in synaptic degeneration that could ultimately facilitate the 
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Motor neurons are the wires of the body that send signals that arrive in the spinal cord 
from the brain to muscles to instruct them to move. If these wires become damaged, 
either by injury or in disease, then these signals are interrupted, and communication 
breaks down. When wires are cut or damaged, they break down very quickly. 
However, in diseases, like some motor neuron diseases, wires pull away gradually 
from the muscle without breaking up, almost as if they are being reeled back in. 
Although we know that these types of breakdown look very different under the 
microscope, it is unclear how the processes that regulate breakdown relate to each 
other. This work aims to better understand this relationship and identify factors that 
can influence the speed of breakdown in different scenarios. Factors that can change 
the speed of breakdown are interesting, as targeting these could represent a treatment 
to slow or prevent breakdown in disease. Here, I firstly expanded an experimental 
model that allows us to take different muscles and the wires that connect them from 
mice, and artificially maintain them. To isolate the muscle from the body, the wire 
must be cut, thereby mimicking an injury. I found that wire breakdown was much 
slower in very young mice compared to adults. However, breakdown rates varied in 
different muscles; while some wires maintained their connections well, others had very 
little remaining after the same amount of time. Also, when an underlying disease 
condition was present, in this case a motor neuron disease, the rate of breakdown after 
injury was accelerated. This suggests that the underlying processes responsible for 
breakdown are shared. Next, I looked at part of the cell that specialises in energy 
production called mitochondria, to determine if changes in energy processing can 
explain slower rates of breakdown in younger animals. Although I did not identify a 
strong connection with age, there was evidence that some changes in mitochondria in 
the wire itself could explain variations between muscles. I then considered P53, a 
factor linked to cell death. If this death factor is involved in regulating the rate of 
breakdown, then reducing it should slow breakdown. Using a mouse where this death 
factor is reduced, P53 reduction was found to have no effect on the rate of breakdown 
after injury, during disease, or during normal development, suggesting it is not 
involved. 
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Motor neurons are vulnerable to degeneration following physical or chemical injury, 
and across a range of neurodegenerative diseases. The descending motor tracts that 
permit voluntary movement involve upper and lower motor neurons. Upper motor 
neurons carry signals from the motor cortex to the brainstem or ventral horn of the 
spinal cord (Bear et al., 2007). Signals are then received by lower motor neurons (α-
motor neurons), which transmit signals peripherally to the target muscle in order to 
elicit a coordinated contraction (Bear et al., 2007). The lower motor neuron cell body 
resides in the ventral horn of the spinal cord, and transmits signals along the axon to 
the presynaptic terminal of the neuromuscular junction (NMJ).  
 
The NMJ represents a critical interface between the motor neuron nerve terminal and 
the muscle, and is the major focus of this thesis. The presynaptic component of the 
NMJ contains vesicles loaded with the neurotransmitter, acetylcholine (ACh) for 
electrochemical signalling (Hirsch, 2007). The presynaptic terminal also contains 
complex networks of microtubules involved in the transport and re-uptake of 
neurotransmitters from the synaptic cleft.  The postsynaptic component of the NMJ 
consists of clustered nicotinic ACh receptors, or motor endplate, located within the 
membrane of the muscle fibre, that are responsible for receiving acetylcholine that 
diffuses across the synaptic cleft (Sine, 2012, Hirsch, 2007). In nerve injury scenarios, 
and in a range of motor neuron diseases, the NMJ is widely recognised as an early and 
significant pathological target (Murray et al., 2008a, Kariya et al., 2008, Martinez-
Hernandez et al., 2013, Wadman et al., 2012, Wishart et al., 2006, Martineau et al., 
2018).  
 
Depending on the original insult, motor neurons can degenerate in morphologically 
distinct ways, although the mechanisms underlying degeneration remain largely 
unknown. Wallerian degeneration (WD) and dying-back neuropathies are two well-
known processes that ultimately lead to axonal degeneration, and are the primary 
degenerative pathologies that I will examine throughout this work. WD occurs 
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following a variety of insults, such as after nerve transection (axotomy). Following 
separation of distal elements from the soma, WD is characterised by spontaneous and 
rapid fragmentation of the distal axon and presynaptic terminal, followed by 
degradation and clearance by phagocytosing cells (Waller, 1851) (Fig. 1). Dissecting 
the mechanisms of WD in humans is challenging, and nerve injury models have 
therefore been extensively utilised in an attempt to elucidate the mechanisms of 
degeneration following injury. Since the timing and origin of the original insult is a 
known factor, it allows us to examine the course of nerve degeneration in both acute 
and latent phases of degeneration. This also facilitates identification of molecular 
changes that may be responsible for degenerative events. The discovery that some 
models with spontaneous or transgenic modifications have different rates of WD 
following injury has accelerated research and enhanced our understanding of the 
mechanisms of WD.  
 
In contrast, dying-back neuropathy does not involve fragmentation, and is seen during 
many neurodegenerative diseases, including some motor neuron diseases (MNDs) like 
Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA) 
(Cavanagh, 1964). Dying-back pathology is characterised as a progressive and 
retrograde retraction of the presynaptic terminal from the NMJ (Fig. 1) (Murray et al., 
2008a, Cavanagh, 1964, Raff et al., 2002, Gillingwater and Ribchester, 2003). The 
most well-known and common form of MND is ALS. In ALS, both upper and lower 
motor neurons are affected, with symptoms including limb paralysis, dysphagia, 
dysarthria and respiratory weakness (Chio et al., 2009). There is currently no cure for 
ALS, with median survival from onset to death reported to be between 20-48 months; 
less than 10% of ALS patients survive more than 10 years (Chio et al., 2009). Patients 
with ALS invariably develop respiratory weakness, with death often a result of 
pulmonary complications. Much research is currently focussed on determining the 
aetiology and mechanisms of cell death in this disease, however in ALS, the majority 
of cases are described as being sporadic, meaning that the cause, or causes, of disease 
are unknown, which presents challenges. On the other hand, SMA is a purely inherited 
childhood motor neuron disease that affects lower motor neurons only. The genetic 
underpinnings of SMA have been well-defined, and this has facilitated the generation 
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of a number of animal models that can be used to investigate the timing and 
mechanisms of motor neuron degeneration. This understanding has accelerated the 
development of a number of therapies that are now available, with clinical trials 
showing promising improvements in motor function and survival (Hagenacker et al., 
2020, Mercuri et al., 2017, Ratni et al., 2018, Mendell et al., 2017b, Mendell et al., 
2017a). In the work I present here, I use an intermediate mouse model of SMA, which 
I will describe in greater depth in the following sections, to ask whether similar 
mechanisms could be responsible for NMJ loss in different degenerative scenarios. 
Overall, using models of neurodegeneration where the genetics and/or timing of 
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Figure 1: Overview of the morphology of different types of axonal and synaptic 
degeneration. (A) Schematic of Wallerian degeneration (WD) which can be induced 
by transection nerve injury; this results in rapid fragmentation along the length of the 
distal axon. (B) Schematic of dying-back pathology which occurs in some motor 
neuron diseases like Spinal Muscular Atrophy (SMA); it is characterised by a 
progressive and retrograde retraction. The presynaptic terminal dissociates from the 
postsynaptic motor endplate and the axon withdraws. (C) Schematic to show 
developmental synapse elimination. During development, an excess number of 
synapses are formed, and motor endplates are predominantly polyinnervated 
(indicated by **). During early postnatal development, excess synapses are eliminated, 
and exuberant branches are ‘pruned’ away. A monoinnervated, mature neuromuscular 
system is thereby established. (D) Micrographs demonstrating different types of nerve 
degeneration under different physiological scenarios. NMJs are labelled with 
antibodies against neurofilament (NF, green) and synaptic vesicle protein 2 (SV2, 
green), and α-bungarotoxin (BTX, red). Top panel: WD micrograph showing 
catastrophic axotomy-induced fragmentation of axonal and synaptic compartments in 
the deep lumbrical muscles from P25 wild-type mice 24 hr after tibial nerve 
transection. Scale bar: 50μm. Adapted from Murray et al., 2008b (Copyright 
permissions obtained (license number can be provided on request). Central panel: 
micrograph showing an example of dying-back pathology in the transversus 
abdominus muscle of the Smn2B/- mouse model of SMA at a late-symptomatic time 
point (P18). Endplates that are devoid of innervation are described as being ‘vacant’. 
Scale bar: 20μm. Bottom panel: across early postnatal development, excess synapses 
are eliminated, and the NMJ shifts from being predominantly polyinnervated to a 
monoinnervated structure. In this micrograph from a P7 wild-type mouse, you can see 
examples of endplates with multiple axonal inputs, and in the bottom right corner, an 
example of an endplate that is monoinnervated. Scale bar: 10μm. Adapted from Tomas 
et al., 2017. Copyright permissions obtained (license not required). Schematics were 
generated using Biorender© and Adobe photoshop software, and based on Murray et 
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Axonal and synaptic loss are also important features of normal development, both 
centrally and peripherally. The NMJ has long been used to investigate synaptic 
development and function as it is easily accessed (Sanes and Lichtman, 2001). In 
neonatal animals, skeletal muscle fibres receive multiple axonal inputs, with NMJs 
therefore being described as being polyinnervated (Lichtman and Colman, 2000). 
Across the first 2-3 weeks of life, synapses compete for resources and inactive 
synapses are eliminated until just one remains (Tapia et al., 2012, Lichtman and 
Colman, 2000, Sanes and Lichtman, 2001, Wyatt and Balice-Gordon, 2003). In this 
way, connectivity becomes refined and specific, and a mature monoinnervated 
neuromuscular system is established, where functional motor units consist of a motor 
neuron and the skeletal muscle fibres that it innervates (Fig. 1). Unlike in disease, only 
specific axonal branches are removed, as opposed to the entire motor neuron. The 
mechanisms by which such refined and segmented degeneration occurs are unclear. It 
should be noted that debate exists over the use of degenerative terminology when 
describing normal, postnatal synapse elimination. Here, I have chosen to view 
elimination of select axonal branches as a regulated, degenerative process, and 
therefore my work, and relating studies, are presented from this perspective. 
 
Despite morphological differences between degenerative pathologies, it remains 
unclear whether mechanistic commonalities exist between different forms of axonal 
and synaptic degeneration. There is evidence to support that WD and dying-back 
pathways may share common molecular features (Conforti et al., 2014), however there 
is other work that provides scope to hypothesise that distinct mechanisms exist. Much 
debate therefore exists in the field as to whether mechanistic convergence or 
divergence exists. Identification of differentiating or common factors that can 
influence the rate of degeneration under different contexts is critical if we are to dissect 
degenerative mechanisms and identify therapeutic targets to slow or prevent 
neurodegeneration in a range of pathophysiological scenarios. In the following 
sections, I will provide overviews of the morphology, molecular features and animal 
models available to study synaptic loss in the contexts of traumatic injury, disease and 
development, and summarise what is known about the extent of their mechanistic 
similarities and differences.  
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1.1 Traumatic nerve injury: an overview 
 
Peripheral nerve injury is common in both humans and animals, and can have 
potentially severe and irreversible physiological and functional consequences. 
Peripheral nerves are vulnerable to injury which can be caused by insult, including 
traumatic or chemical injury. Peripheral nerve injuries have an incidence estimated 
between 13 and 23 per 100,000 people annually (Li et al., 2014), and present many 
challenges for patients that can range from mild discomfort to lifelong impairment of 
motor, sensory or autonomic functions, depending on the severity of the insult 
(Menorca et al., 2013, Hussain et al., 2020). The most common peripheral 
neuropathies are traumatic in origin. Seddon classification is used to grade traumatic 
injuries into three categories depending on severity, which were later subdivided 
further by Sunderland; the Seddon and Sunderland grading system remain in use to 
classify traumatic nerve injuries into categories based on the presence of 
demyelination, extent of axonal damage and extent of damage to connective tissues of 
the nerve (Menorca et al., 2013, Seddon, 1943, Seddon et al., 1943, Seddon, 1948, 
Sunderland, 1951, Chhabra et al., 2014, Caillaud et al., 2019, Hussain et al., 2020). 
Nerve injury models have been invaluable to efforts to better understand mechanisms 
of degeneration, since the origin and timing of insult are known, and the temporal and 
molecular course of nerve degeneration can be studied and dissected. In Chapter 1, I 
will expand upon and apply an ex vivo model of peripheral nerve injury to examine 
levels of NMJ loss after insult, therefore it is important to appreciate what is already 
known with regard to the morphological and molecular changes that are associated 
with WD, and the models that are already used in the field. 
 
1.1.1 Changes in synaptic and axonal morphology following traumatic injury 
 
The earliest characterisation of the neuronal response to traumatic injury can be found 
in descriptions by Waller in 1851 (Waller, 1851). Using severed frog hypoglossal and 
glossopharyngeal nerves, Waller described extensive neuronal fragmentation that 
occurs distal to the injury site, whilst the proximal portions are retained for a longer 
period of time (Waller, 1851). These characteristics are now widely recognised as a 
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process termed ‘Wallerian degeneration’ (WD). WD is a conserved, active and highly 
regulated process that occurs in response to different insults, including traumatic 
injury, but also is seen in some disease scenarios, such as in Multiple Sclerosis 
(Casanova et al., 2003, Ciccarelli et al., 2003, Simon et al., 2000b, Zerres and Rudnik-
Schoneborn, 1995, Gillingwater and Ribchester, 2001, Llobet Rosell and Neukomm, 
2019). 
 
Morphologically, WD is characterised by rapid axonal and synaptic fragmentation, a 
loss of organelles and plasma membranes, a breakdown in the myelin sheath and 
phagocytosis of axonal and synaptic debris by Schwann cells and macrophages 
(Beirowski et al., 2005, Beirowski et al., 2004, Conforti et al., 2014, Waller, 1851, 
Gillingwater and Ribchester, 2001). Distinct molecular events have also been 
described that consist of both acute and latent phases (Wang et al., 2012). Within the 
first 5-30 min following transection, an injured axon enters an acute, degenerative 
phase that is primarily calcium (Ca2+)-dependent. During the immediate acute phase, 
Ca2+- and calpain-dependent processes result in the cleavage of axonal neurofilament 
and microtubule components (Wang et al., 2012). This is followed by a latent phase 
during which initially, the distal severed stump maintains electrical activity and 
morphological integrity (Miledi and Slater, 1968, Lunn et al., 1989, Tsao et al., 1994, 
Ribchester et al., 1995, Gillingwater et al., 2002). Within 24-48 hr after injury in mice 
electrical conductivity fails and, the axon disintegrates distally from the point of injury 
(Beirowski et al., 2005, Beirowski et al., 2004). Axonal fragments are then degraded 
and cleared by phagocytic cells, including macrophages and Schwann cells that influx 
the injury site (Wang et al., 2012, Saxena and Caroni, 2007, Beirowski et al., 2005). 
Schwann cells can also secrete growth factors that promote regeneration of the 
disintegrated nerve terminal (Gillingwater and Ribchester, 2001).  
 
Any circumstance in which the rate of axonal and synaptic degeneration is altered, 
presents an opportunity to investigate the molecular mechanisms of WD and may help 
in the identification of therapeutically useful targets. In this respect, using mice to 
model peripheral nerve injury has provided valuable insight. Investigating 
mechanisms of axonal degeneration in WD is undoubtedly easier than in diseases 
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where the aetiology of pathology is often undefined; in injury models, the origin and 
timing of degenerative triggers are known, thereby facilitating investigation of 
subsequent molecular events. Identifying factors that can influence the rate of 
degeneration after injury will help to advance our understanding of degenerative 
mechanisms, which could also be important during cell death in disease scenarios. 
 
1.1.2 Animal models to investigate the mechanisms of Wallerian degeneration 
 
Much of our knowledge regarding the mechanisms of WD is based on how specific 
mutations influence the rate of axonal degeneration in animal models. Studies 
attempting to elucidate the molecular mechanisms of WD have been aided by the 
discovery of mouse models in which the rate of WD following injury is altered. Injury 
models are particularly useful to investigate the progression and molecular events that 
follow nerve insult, as the origin and timing of the injury can be controlled. 
 
A key finding that has accelerated study into the mechanisms of WD is that acute and 
latent degenerative periods following injury can be extended by the spontaneous 
Wallerian degeneration slow (WldS) mutation. The WldS mutation was fortuitously 
discovered in C57BL/6J mice, and was mapped as a tandem triplication of an 85-kb 
repeating unit distally on chromosome 4 (Coleman et al., 1998).  Mack et al., 
subsequently demonstrated that the gene responsible for conferring the slow WD 
phenotype is a chimeric gene that contains the 5’ end of ubiquitination factor E4B 
(Ube4b), and a murine gene that is identical to the human nucleotide transferase 1 gene 
(NMNAT1) (Mack et al., 2001). Fusion of these genes results in the production of a 
unique and stable protein isoform of the nicotinamide adenine dinucleotide (NAD)-
synthetic enzyme, Nmnat1 (Mack et al., 2001). In mammals, there are three isoforms 
of NMNAT that include nuclear NMNAT1, cytoplasmic NMNAT2 and mitochondrial 
NMNAT3, which catalyse NAD synthesis from nicotinamide mononucleotide (NMN) 
and adenosine triphosphate (ATP). Mitochondrial depolarisation results in reduced 
NMNAT2 synthesis and axonal transport, resulting in decreased NMNAT2 levels 
(Loreto et al., 2020). After injury, levels of NMNAT2 decline sharply, triggering 
fragmentation and axonal degeneration (Beirowski et al., 2005, Beirowski et al., 2009, 
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Babetto et al., 2010, Gilley and Coleman, 2010, Gilley et al., 2013, Milde et al., 2013, 
Di Stefano et al., 2015). It is thought that WldS confers protection to injured axons by 
maintaining axonal NMNAT activity by substituting for cytosolic NMNAT2 (Conforti 
et al., 2009, Beirowski et al., 2009, Avery et al., 2009, Gilley and Coleman, 2010).  
 
The WldS mutation confers ten-fold delays in WD following axotomy; in contrast to 
wild-type axons, transected WldS axons remain structurally intact and functional for up 
to two weeks in vivo, with protection being dose-dependent (Mack et al., 2001, 
Beirowski et al., 2005, Beirowski et al., 2004, Wong et al., 2009). Isolated distal axons 
also maintain electrical and synaptic activity; they are capable of conducting action 
potentials, synapses can release neurotransmitters, and synaptic vesicle recycling 
continues for several days (Ribchester et al., 1995, Tsao et al., 1994, Gillingwater et 
al., 2002, Miledi and Slater, 1968, Lunn et al., 1989). This delay is apparent when 
WldS-expressing nerves are exposed to traumatic, chemical and pathological insult 
(Oyebode et al., 2012). Protection conferred by WldS is age-dependent, with mice over 
the age of 4 months appearing to demonstrate wild-type patterns of degeneration 
(Perry et al., 1992, Tsao et al., 1994, Gillingwater et al., 2002, Crawford et al., 1995). 
Similar delays are also seen centrally following chemical or pathological insult in Wlds 
mice (Oyebode et al., 2012). WldS mutants have been widely used and represent an 
invaluable tool to study the mechanisms of WD. I will use preparations isolated from 
WldS mice in Chapter 1 to optimise an ex vivo model of nerve injury. 
 
A similar, protective phenotype is observed in the Sterile Alpha and TIR motif 
containing 1 (SARM1) knockout mouse. SARM1 was identified in a genetic screen 
undertaken in Drosophila that sought to identify loss of function mutations that could 
delay axonal degeneration following antennal ablation (Osterloh et al., 2012). SARM1 
is critical to the WD pathway, with Sarm1 knockout found to phenocopy WldS gene 
expression, delaying in vivo axonal degeneration for over two weeks post-axotomy 
(Osterloh et al., 2012).  Until relatively recently, the mechanisms by which SARM1 
promotes axonal degeneration were unclear. In 2016, Sasaki et al., demonstrated that 
in response to injury, SARM1-deficient axons exhibit similar NAD+ levels to those 
present in wild-type controls (Sasaki et al., 2016). Since NAD+ loss is associated with 
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degeneration, it was suggested that SARM1 might be involved with regulating NAD+ 
levels. Further work in vitro confirmed that SARM1 can hydrolyse NAD+ directly, and 
is therefore intimately involved with NAD+ metabolism and WD pathway (Essuman 
et al., 2017). WldS (NAD+ synthesis) and SARM1 (NAD+ degradation) are recognised 
to have opposing effects on WD, and have been extensively utilised to investigate 
degenerative pathways. 
 
Experimental models have provided an invaluable tool with which to study nerve 
injury, which is not possible clinically, however a major limitation when studying WD 
in vivo is the accessibility and reproducibility of nerve injuries. A limited number of 
muscles have therefore been studied, with the majority of work focussed on the deep 
lumbrical muscles, due to ease of access of the tibial/sciatic nerve in the hindlimb. 
Recent work has generated an ex vivo model that facilitates study of the mechanisms 
of nerve injury (Brown et al., 2015). Work by Brown et al., used an ex vivo model to 
model peripheral nerve injury in nerve/muscle preparations from the mouse hindlimb. 
Consistent with in vivo work, this group demonstrate that WldS can delay WD, with 
54% innervation remaining in WldS muscles, compared to just 12% innervation 
remaining in wild-type muscles after 25-30 hr (Brown et al., 2015).  
 
Work in both WldS and SARM1 knockout models have attempted to identify molecular 
differences that might be responsible for regulating the rate of axonal degeneration 
following injury. Work in both models has implicated mitochondria as playing an 
important role in WD; proteomic analysis undertaken in WldS mice has identified 
several proteins relating to mitochondrial stability and degeneration (Wishart et al., 
2007). After injury, mitochondrial motility is preserved in axons expressing WldS in 
Drosophila (Avery et al., 2012). Additionally, ultrastructural studies have reported 
morphological changes in mitochondria after injury, including mitochondrial swelling, 
that is thought to be a result of opening of the mitochondrial permeability transitioning 
pore; activation of this pore is considered a key event in axonal degeneration 
(Barrientos et al., 2011). By utilising animal models where the rate of WD is altered, 
a number of modulators have been identified, however attempts to integrate and 
understand degenerative pathways remain limited. Identifying factors that can regulate 
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the rate of axonal and synaptic degeneration, and crucially, how axonal degeneration 
differs mechanistically in different physiological scenarios, is key to targeting 
neurodegeneration in the contexts of injury and disease. 
 
1.1.3 Molecular mechanisms of Wallerian degeneration 
 
Animal models have permitted us to dissect apart the mechanisms that underlie 
different phases of axonal and synaptic degeneration following injury. 
Morphologically, there are proposed to be at least three distinct phases of axonal 
degeneration: an acute degenerative phase affecting the proximal and distal stumps of 
the axon immediately after injury; a latent period where the distal axon maintains its 
morphology and remains excitable; and an abrupt, granular degenerative phase where 
the axonal skeleton distal to the injury site rapidly fragments. In this section, I will 
provide a brief overview of some the molecular events that are thought to underlie 
different phases of WD (for review see Wang et al., 2012). 
 
In vivo, real-time imaging has revealed that within the first 5 to 30 minutes following 
injury, portions immediately proximal and distal to the injury site rapidly recede in 
either direction (Kerschensteiner et al., 2005). This is followed by the slower formation 
of dystrophic bulbs at the terminals of transected ends due to an accumulation of 
axoplasmic organelles, due to ongoing axonal transport (Griffin et al., 1995). Ca2+ 
influx is considered a critical event in initiating acute axonal degeneration; Ca2+ 
blockade can prevent intra-axonal rises in Ca2+, thereby attenuating the progression of 
acute degeneration. The addition of Ca2+ ionophores has been shown to increase the 
number of injured axons undergoing acute axonal degeneration (Knoferle et al., 2010). 
Ca2+ influx activates the serine-theonine protease calpain, which can cleave axonal 
neurofilament and other microtubule-associated components (Billger et al., 1988, 
Johnson et al., 1991, Kampfl et al., 1996). Pharmacologic inhibition of calpain can 
reduce short distance degeneration in spinal cord axons following injury, highlighting 
calpain activity as a modulator of the acute phase (Schlaepfer and Bunge, 1973, 
George et al., 1995). Ca2+ influx also triggers autophagic processes (Knoferle et al., 
2010). The acute phase of degeneration is thought to promote cytoskeletal 
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restructuring and formation of growth cones that aids in regenerative efforts (Spira et 
al., 2003). Clearing space at the lesion site is thought to facilitate glial cell proliferation 
to create an environment more conducive to regeneration. WldS can delay the onset of 
acute degeneration, suggesting that this phase forms part of WD mechanisms (George 
et al., 1995, Knoferle et al., 2010).  
 
This is followed by a latent phase that occurs around 24 to 48 hr after injury, during 
which axons remain morphologically intact and excitable for brief periods of time 
(Wang et al., 2012). Transected motor neurons are capable of producing action 
potentials even 24 hr after injury in vivo, although evoked potentials and the velocity 
of conduction decays with time (Moldovan et al., 2009). Both retrograde and 
anterograde transport also continue in the distal axon during this time (Smith and 
Bisby, 1993). Similar to the acute phase, in the latent phase, increases in intra-axonal 
calcium also occur. Axonal degeneration can be delayed for up to 4 days by culturing 
neurons in a reduced calcium media, or by using a chelating agent, like ethylene glycol 
tetraacetic acid (EGTA), with a high affinity for Ca2+. Complimenting this, increasing 
Ca2+ can induce degeneration in uninjured neurites (Schlaepfer and Bunge, 1973, 
George et al., 1995). The addition of Ca2+ can abolish protection conferred by WldS 
(Glass et al., 1994). Calcium-dependent activation of calpain is also considered a key 
event in the latent phase, however, although inhibition delays the progression of axon 
degeneration for 12-24 hr in vitro, it does not prevent WD (Glass et al., 1994, Wang 
et al., 2000). This suggests that other, as of yet unidentified, pathways are involved in 
cytoskeletal breakdown in WD.  
 
Two hypotheses have emerged to explain the mechanisms that can ultimately signal 
and initiate axonal degeneration. The first is that there is a ‘death signal’ that involves 
a series of kinases that promote axonal degeneration. Genetic or pharmacologic 
inhibition of kinases have been shown to protect axons from injury if administered 
within the first 3 hr after injury (Miller et al., 2009). It remains unclear whether 
increased kinase activity can induce spontaneous degeneration or abolish protection 
conferred by WldS. The second hypothesis is that nerve injury disrupts axonal transport 
or expression of axonal trophic factors, resulting in levels dropping below the critical 
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threshold required to support normal axon integrity and functioning (Wang et al., 
2000). Trophic withdrawal has been shown to lead to cleavage and secretion of 
amyloid precursor protein (APP), a precursor of β-amyloid protein and marker of 
axonal damage (Coleman, 2005). APP ultimately triggers B cell lymphoma-associated 
X (BAX)-dependent, caspase-6-mediated cytoskeletal breakdown (Nikolaev et al., 
2009). Gilley and Coleman recently demonstrated that inhibition of protein translation 
at the cell body, but not in the axon, can lead to degeneration in uninjured neurites 
(Gilley and Coleman, 2010). Thus, it is the synthesis of protein in the soma and 
delivery to the axon that appears to be critical to axon viability, as opposed to local 
translation. This group further demonstrated that Nmnat2 was required for axon 
survival, and that following axotomy, or blockade of axonal transport, expression of 
Nmnat2 declines rapidly; Nmnat2 turnover time was found to correlate with the period 
between axonal injury and the appearance of axonal blebbing (Beirowski et al., 2004). 
Depletion of Nmnat2 can induce degeneration in uninjured axons, whilst 
overexpression of Nmnat2 can delay degeneration of wild-type axons for up to 48 hr 
(Gilley and Coleman, 2010, Yan et al., 2010). Blockade of the ubiquitin-proteasome 
system has also been shown to delay degeneration following injury for up to 3 days in 
vivo (Watts et al., 2003). Since the primary function of the proteasome system is to 
regulate protein turnover, this is thought to promote axonal survival either by 
maintaining transport or by preventing degradation of survival factors. Nmnat2 
turnover has been shown to be dependent on proteosome activity (Gilley and Coleman, 
2010), further supporting the trophic withdrawal hypothesis. 
 
The final phase of axonal degeneration is the granular degeneration phase that occurs 
around 72 hr after injury, and is characterised by catastrophic, asynchronous 
fragmentation (Wang et al., 2012). Following axotomy, axonal degeneration proceeds 
anterogradely, whereas after a nerve crush, axons degenerate retrogradely (Beirowski 
et al., 2005). Notably, in WD, loss of neuromuscular transmission is recognised as an 
early event following a range of insult (Brown et al., 2015, Beirowski et al., 2005, 
Ribchester et al., 1995, Miledi and Slater, 1970, Winlow and Usherwood, 1975). The 
ability of axons to degenerate in either direction challenges the trophic withdrawal 
hypothesis. Interestingly, WldS axons only degenerate anterogradely regardless of 
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lesion type (Beirowski et al., 2005). This suggests that rather than WldS simply 
conferring a slower rate of WD, that degenerative processes may in fact be distinct, 
with blockade of WD via WldS ultimately leading to the activation of a different 
degenerative pathway. Granular degeneration is accompanied by glial influx, which 
primarily includes astrocytes, macrophages and, in the peripheral nervous system 
(PNS), Schwann cells, which facilitate the clearance of axonal debris (Wang et al., 
2012). Glial influx is thought to play a key role in facilitating regeneration attempts by 
the proximal axon (Liu et al., 2019). Following fibre tract or optic nerve crush lesion 
in the central nervous system (CNS), where macrophages are virtually excluded from 
entry, no spontaneous regeneration occurs (Horner and Gage, 2000, David and 
Ousman, 2002). In vivo tracking of macrophages has shown that macrophages enter 
crushed peripheral nerves with a proximodistal gradient that begins at the lesion site, 
and remain stationary (Bendszus and Stoll, 2003). Targeting of macrophages has been 
proposed as a way to improve peripheral nerve regeneration, however the underlying 
regulatory mechanisms of macrophage activation, polarisation and subtype 
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1.2 Dying-back pathology: an overview 
 
Motor neurons are recognised as pathological targets in neurodegenerative diseases, 
such as motor neuron diseases, however the morphology of degeneration is distinct 
from that which occurs following injury. Motor neuron disease is an umbrella term 
that encompasses a range of neuromuscular conditions where motor neurons in the 
brainstem and spinal cord are primary pathological targets (Bede and Pradat, 2019). 
Motor neuron diseases, such as ALS and SMA, are described as ‘dying-back’ 
neuropathies, due to the characteristic way in which synapses and axons withdraw 
retrogradely from the motor endplate (Cavanagh, 1964). During a die-back, the 
presynaptic terminal of the motor neuron gradually withdraws from the NMJ, and  the 
distal portion of the nerve terminal forms a bulb, known as a retraction bulb. This 
retraction leaves the motor endplate devoid of innervation (Gillingwater and 
Ribchester, 2003, Murray et al., 2008a). 
 
Neurodegenerative diseases have diverse and often unknown aetiologies, and are an 
extensive and heterogenous group of conditions. This presents challenges when 
attempting to identify and characterise common molecular factors or pathways that are 
involved in dying-back pathology. Identifying common molecular mechanisms that 
are responsible for regulating dying-back pathology is therefore difficult, with most 
groups focussing on understanding a specific disease. Our in-depth knowledge of the 
genetic underpinnings of SMA has facilitated the development of several murine 
models which can be used to study the pathogenesis and progression of dying-back 
pathology. Ultimately, this may aid in the identification of common targets that could 
prove useful in modifying the progress of degeneration in a range of different diseases. 
In Chapters 1 and 3, I will use the Smn2B/- mouse model of SMA to investigate factors 
that can alter the rate of NMJ degeneration, therefore in the following sections, I will 
summarise the genetics of SMA, animal models that are widely used, and the 
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1.2.1 Spinal Muscular Atrophy: an overview  
 
The childhood motor neuron disease, SMA, is a monogenic and devastating, 
autosomal recessive condition that is characterized by the loss of lower alpha motor 
neurons from the ventral horn of the spinal cord, proximal muscle atrophy and 
paralysis (Lunn and Wang, 2008). SMA remains the leading genetic cause of infant 
mortality, with the commonly reported incidence of SMA being between 1 in 6000 - 
10,000 live births (Lunn and Wang, 2008). More recently, a study seeking to estimate 
the worldwide incidence of SMA has suggested that incidence lies between ~1 in 3900 
and ~1 in 16,000 (Verhaart et al., 2017). 
 
SMA is caused by homozygous disruption of the telomeric survival motor neuron 1 
(SMN1) gene, located on chromosome 5q13, that ultimately disrupts the production 
of survival motor neuron (SMN) protein which is critical for motor neuron survival. 
More than 98% of patients have a homozygous disruption of SMN1 by deletion, 
rearrangement or mutation (Lefebvre et al., 1995, Hahnen et al., 1995). Full-length 
SMN protein contains 294 amino acids, and, despite its name, is expressed 
ubiquitously and is required by all cells and tissue types (Lefebvre et al., 1995, 
Giavazzi et al., 2006, Battaglia et al., 1997, Chaytow et al., 2018). Since SMN is 
ubiquitously expressed, it is unclear why motor neurons are particularly vulnerable to 
reductions. Smn is suggested to have multiple functions, with the best described being 
in pre-messenger ribonucleic (RNA) splicing (Singh and Singh, 2018, Chaytow et al., 
2018, Coady and Lorson, 2011, Workman et al., 2012). A complete lack of SMN is 
embryonically lethal, however, in humans, a paralogous ‘back-up’ gene, SMN2, exists. 
An inverted duplication in SMN1 has resulted in a centromeric copy of the gene, which 
is termed SMN2. SMN1 and SMN2 both contain 9 exons and 8 introns with differences 
at 5 bases, however, it is a critical C to T transition within exon 7 of SMN2 that disrupts 
the exon splicing enhancer site, leading to alternative splicing and skipping of exon 7 
(Singh and Singh, 2018). As a result, only around 10% of protein produced by this 
gene is full-length and functional, with the majority of SMN2 products exhibiting an 
exon 7 exclusion that results in a non-functional, truncated protein (SMNΔ7) that is 
targeted for degradation (Singh and Singh, 2018, Kolb and Kissel, 2015) (Fig. 2). 
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Consequently, in SMA, there is reduced expression of functional, full-length SMN 
protein which cannot support normal functioning of the neuromuscular system. This 
leads to motor neuron degeneration, muscular paralysis and, in severe cases, death 
before 2 years of age (Zerres and Rudnik-Schoneborn, 1995). The SMN2 gene can 
modify disease severity and patient presentation, depending on its copy number, where 
higher copy number is associated with reduced disease severity (Wirth et al., 2006b, 
Wirth et al., 2006a, Wirth et al., 2006c). In this respect, SMN2 has been described as 
a phenotypic modifier, and has been the focus of therapeutics, as a higher copy number 
leads to higher SMN levels in the body, and can extend survival (Prior et al., 2009, 
Jedrzejowska et al., 2008, Elsheikh et al., 2009). The role of SMN2 as a phenotypic 
modifier is most profoundly seen in patients that lack SMN1 yet, due to increased 
SMN2 copy number, are asymptomatic (Jedrzejowska et al., 2008, Zheleznyakova et 
al., 2011). Other phenotypic modifiers have also been described, for example, work 
by Oprea et al., has demonstrated that expression of plastin 3, an actin-binding protein 
that is important for axogenesis, can modify disease phenotype (Oprea et al., 2008). 
Thus, although SMN1 is the primary disease-causing gene, other genetic factors can 
also influence how disease manifests.  
 
Clinically, SMA is divided into different sub-types, depending on severity and onset 
of disease (Fig. 2). Type 0 is very severe with antenatal onset, and a life expectancy of 
under 6 months, whereas Type 3 and 4 are milder, with adult onset and life expectancy 
extending into adulthood. As expected, SMN2 copy number is linked to disease 
severity; more severe patients typically have fewer copies of SMN2 (Fig. 2) (Calucho 
et al., 2018, Zerres and Rudnik-Schoneborn, 1995, Kolb and Kissel, 2015, Lunn and 
Wang, 2008). Our understanding of the genetic underpinnings of SMA has accelerated 
our ability to develop effective therapies to treat this devastating disease. Therapeutic 
strategies to increase SMN protein in motor neurons have primarily focussed on 
enhancing the effectiveness of the SMN2 ‘back-up’ gene, however gene replacement 
therapy is also available for young patients. There are currently three approved 
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Despite major advances in therapeutics for SMA, complementary strategies will likely 
be required to ensure long-term, normal functioning. It is unclear whether SMN-based 
treatments confer complete rescue, therefore delayed symptoms may appear. Since 
available therapies are new and the first treated cohorts have not yet reached 
adulthood, it is unclear what other pathology may manifest as patients age. Although 
we have targeted motor neuron-related aspects of the disease, other symptoms could 
become apparent (Shababi et al., 2014, Hamilton and Gillingwater, 2013); adjunctive 
therapies will therefore likely be important in years to come. Overall, despite 
therapeutic advances in SMA, continued investigation is critical to understand 
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Figure 2: SMA is caused by a loss of SMN protein, with disease severity dependent 
on SMN2 copy number. This figure provides an overview of the genetics and prognoses in 
SMA. Complete loss of SMN is embryonically lethal, however in humans, a second gene, 
SMN2 produces around 10% functional, full-length protein. This is due to a C to T base 
transition within exon 7 of SMN2, that leads to alternative splicing and exclusion of exon 7, 
and the favoured production of a truncated protein that is non-functional and targeted for 
degradation: SMNΔ7. SMN2 is a phenotypic modifier; a higher copy number of SMN2 leads 
to more full-length SMN protein, and reduced disease severity. The different clinical 
phenotypes of SMA and associated onset, functional effect and prognoses are summarised in 
this table. (Calucho et al., 2018, Zerres and Rudnik-Schoneborn, 1995, Kolb and Kissel, 2015, 
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Table 1: Table summarising key therapies that are currently approved by the Food 
and Drug Administration (FDA) or are being tested in clinical trials for the 
treatment of SMA. Table obtained from CureSMA.org (as of 2nd September 2020, 
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1.2.2 Animal models of SMA 
 
Due to limited availability of suitable patient material, detailed analyses of cellular 
pathology, particularly across time, in SMA patients is restricted, particularly at time 
points that do not reflect the end-stage of disease (Monani and De Vivo, 2014). Much 
work has therefore been undertaken in animal models. SMA is unique to humans, as 
other species lack SMN2 (Rochette et al., 2001). Null mutations in SMN genes are 
lethal (Monani, 2005), therefore genetic modification has been undertaken in a number 
of different species to generate SMA-like models.  
 
Drosophila (Drosophila melanogaster) models of SMA are useful for genetic 
mapping, and when undertaking large-scale screens for modifiers of disease due to 
their rapid reproductive cycle, propensity to produce large numbers of progeny, 
remarkable gene and pathway conservation and ease and speed of genetic 
manipulation (McGurk et al., 2015). For example, Drosophila have been used to 
investigate a range of patient-derived SMN missense mutations and their associated 
phenotypes, demonstrating a wide range of severities and pathology that is consistent 
with phenotypes found in SMA patients (Spring et al., 2019). Zebrafish (Danio rerio) 
represent a rapidly developing and transparent vertebrate model that demonstrate 
conservation of genes implicated in neurodegenerative diseases and physiological 
processes involved in morphogenesis and maintenance of the nervous system 
(Bandmann and Burton, 2010, Becker and Rinkwitz, 2012, Xi et al., 2011). Transgenic 
zebrafish are easily and rapidly generated, as eggs are accessible and relatively easy 
to manipulate, and fish have a short generation time (Chen et al., 2016). Other work 
has also generated SMA-like models in zebrafish pharmacologically, for example the 
administration of an antisense oligonucleotides into embryos can inhibit the translation 
of target messenger RNA (mRNA). It has been shown that this can reduce Smn protein 
by over 60% and results in abnormal axonal morphology (McWhorter et al., 2003). 
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A number of transgenic mouse models with a range of severities are also available to 
study the pathophysiology of SMA (Bebee et al., 2012). Mice also have just one copy 
of the SMN gene, which poses a challenge when attempting to generate models that 
recapitulate SMA disease pathology. Complete knockout of the Smn gene (Smn-/-) is 
embryonically lethal (Schrank et al., 1997), however a number of transgenic mouse 
models have been generated. Whilst knockout of exon 2 or 7 is embryonically lethal, 
insertion of an SMN2 human transgene on this background has permitted the 
establishment of severe models of SMA. The Smn-/-;SMN2 mouse possesses 2 copies 
of the SMN2 transgene on a null murine background, and survives between 4-6 days  
(Monani et al., 2000). The additional insertion of an SMN allele without exon 7 
(SMNΔ7) onto this severe background can extend life to around 13.5 days (Le et al., 
2005) (Fig. 3). The phenotypically similar ‘Hsieh-Li’ or Taiwanese mouse, also 
possesses 2 copies of SMN2 on a null background that survives between 8-10 days 
(Hsieh-Li et al., 2000). Although invaluable, such severe models offer a limited 
timeframe to study the development and progression of SMA pathology.  
 
The more recent development of a new allele of the mouse gene, Smn2B, has led to 
the generation of the Smn2B/- mouse model, which will be used in my work. The Smn2B/- 
mouse has around 15% normal levels of Smn protein, and represents an intermediate 
mouse model of SMA (DiDonato et al., 2001, Hammond et al., 2010, Bowerman et 
al., 2012). The Smn2B allele consists of a 3 nucleotide substitution in the exon splicer 
enhancer region within exon 7 of the murine SMN gene, with the resultant model 
exhibiting reduced levels of full-length Smn protein (DiDonato et al., 2001, Hammond 
et al., 2010). Unlike in other models, no human transgenes are inserted, and rather it 
is the lack of murine Smn protein that disrupts motor neuron function and ultimately 
leads to progressive loss of lower motor neurons and skeletal muscle atrophy 
(Bowerman et al., 2012). In our hands, this model has a lifespan of around 21 days, 
with symptom onset around P10. Symptoms observed by us, and others, include 
weight loss, smaller body size, smaller ears, smaller tail and motor weakness when 
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The extended pre-symptomatic time window available in the Smn2B/- model when 
compared to other models, facilitates study of the temporal and molecular pathological 
events of a die-back that ultimately lead to motor neuron death. Not all muscles are 
equally affected in SMA; some muscles are known to be vulnerable, whilst others 
described as being more resistant to pathology (Murray et al., 2008a). This provides a 
useful tool, which I will exploit throughout this thesis, that may help us to determine 
what factors might be responsible for such differences between muscles. Overall, the 
Smn2B/- mouse model represents a useful model of a die-back, which will not only 
facilitate our understanding of motor neuron pathology in SMA, but may translate to 
other diseases where dying-back morphology is a pathological hallmark. More widely, 
this will facilitate comparison to other degenerative processes and assist us to better 
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Figure 3: Photographs showing mouse models of SMA at late-symptomatic stages. 
(A) Taiwanese mouse (top) compared to littermate control (bottom) at postnatal day 
(P) 9. SMA-like pups have a lifespan <10 days. This image was kindly provided by 
the Gillingwater group, and taken by Dr. Hannah Shorrock. (B) SmnD7 mice at P13, 
denoted by ‘D7’ (right), compared to a littermate control (left). Adapted from Le et al., 
2005. This mouse has an average lifespan of around 13.5 days. Copyright permissions 
obtained (license number can be provided on request). (C) Smn2B/- mouse (top) 
compared to littermate control (bottom). This was taken by myself at P18 in the 
Murray laboratory. Scale bar = 2cm. In our hands, this model has a lifespan of around 
21 days. Note that for Taiwanese and SmnD7 mice, date of birth is considered P1, 
whilst for the Smn2B/- line, date of birth is considered P0. In all cases, SMA-like pups 
are indicated by a black or white *. 
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1.2.3 Dying-back morphology and mechanisms in SMA 
 
The NMJ - the main focus of this thesis - is widely recognised as an early and 
significant pathological target in SMA in both human patients and animal models 
(Kariya et al., 2008, Murray et al., 2008a, Martinez-Hernandez et al., 2013, Wadman 
et al., 2012). NMJs are lost early in the disease process, with denervation in muscles 
evident prior to symptom onset (Murray et al., 2008a). Morphologically, synaptic and 
axonal degeneration in SMA proceeds by a dying-back mechanism; the presynaptic 
terminal and distal axon progressively withdraw from the post-synaptic endplate of the 
muscle in a retrograde direction without fragmentation (Murray et al., 2008a). The 
distal portion of the axon gradually retracts, and a retraction bulb forms distally; this 
leaves NMJs on skeletal muscle devoid of innervation (Kariya et al., 2008). Features 
of dying-back pathology include pre-synaptic accumulation of neurofilaments, 
endplate abnormalities and denervation, loss and shrinkage of motor neuron cell 
bodies, axonal loss in ventral roots and muscle fibre atrophy (Goulet et al., 2013, 
Tisdale and Pellizzoni, 2015).   
 
In mouse models of SMA, not all motor neuron populations are equally affected; some 
have been found to be more vulnerable to degeneration than others, even at late stages 
of disease, and are described as being selectively vulnerable (Murray et al., 2008a). 
Selective vulnerability is seen in patients and in mouse models of SMA. For example, 
in patients, the lower limb and proximal musculature have been found to be more 
affected than the upper limb and distal musculature (Dubowitz, 1999). In patients, 
whilst the intercostal muscles display significant pathology, the diaphragm and facial 
muscles are comparatively spared. In the Smn2B/- mouse, neuromuscular pathology is 
extensive in transversus abdominis (TVA) muscle, yet the rostral band of levator auris 
longus (LALr) or deep lumbrical (DL) muscles are largely spared (Murray et al., 
2008a). In other mouse models of SMA, selective vulnerability and resistance have 
also been described, although in more severe models, the pattern of susceptibility 
appears to vary (Thomson et al., 2012). This observation has been exploited to identify 
potential modifiers of motor neuron health (Kline et al., 2017, Murray et al., 2015, 
Boyd et al., 2017). It should be noted that although more variable in pattern, selective 
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vulnerability is also described in ALS, and a number of studies have similarly 
exploited intermuscular differences to investigate factors that can influence the rate of 
synaptic and axonal degeneration in ALS, to try and better understand degenerative 
mechanisms (Brockington et al., 2013, Hedlund et al., 2010, Kaplan et al., 2014). 
Recently, a cross-species comparison of transcriptional screens from SMA and ALS, 
identified candidate phenotypic modifiers, and identified alpha-synuclein as a 
common modifier of pathology in motor neuron disease (Kline et al., 2017). It is 
unclear whether selective vulnerability is a unique feature to dying-back degeneration, 
or whether intermuscular differences are present in other types of injury-induced or 
developmentally regulated degeneration. Overall, identifying intermuscular 
differences represents a powerful tool to investigate factors that can influence the rate 
of degeneration. Throughout this thesis, I identify, refer to and use intermuscular 
differences in the rate of NMJ loss as a tool to examine factors that could regulate 
synaptic stability. 
 
In SMA, molecular changes have been detected at pre-symptomatic time points, prior 
to the onset of NMJ pathology or symptoms (Murray et al., 2015). RNA sequencing 
on motor neurons from the spinal cord has identified upregulations in transcripts that 
are involved with apoptotic signalling at a pre-symptomatic time point, including 
transcripts that are associated with P53 signalling, a factor involved in apoptotic 
regulation (Murray et al., 2015). RNA sequencing has identified changes that indicate 
that dysregulation of synaptogenesis and other transcriptome abnormalities are also 
present prior to the onset of NMJ pathology  (Murray et al., 2015, Zhang et al., 2008, 
Zhang et al., 2013). Post-symptomatic transcriptional changes have also been 
described in transcripts that are involved with splicing, such as chondrolectin, in the 
SmnD7 mouse model (Baumer et al., 2009). Work in a zebrafish model of SMA has 
exploited differences in vulnerability between motor neuron pools to assess 
differences in their bioenergetic profiles. This has revealed differences in the basal 
molecular profiles between muscles that correlate with selective vulnerability in vivo 
(Boyd et al., 2017). Targeting of phosphoglycerate kinase 1 was found to modulate 
motor neuron vulnerability, where knockdown induced synaptic degeneration in wild-
type zebrafish, and pharmacological activation rescued motor axon phenotypes in the 
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SMA model (Boyd et al., 2017).  Whilst the role of apoptotic pathways in motor neuron 
death in SMA is widely appreciated, the role of pro-apoptotic pathways at the synapse 
and in the axon that influence can synaptic retraction are less clear. Further work is 
required to identify factors and pathways that can modify the rate of synaptic and 
axonal withdrawal during a die-back, which could have broader implications across a 
range of other conditions where synaptic retraction is a pathological feature. 
 
1.3 Postnatal maturation of the neuromuscular system 
In the mature, adult neuromuscular system, the NMJ is innervated by a single motor 
axon, and is therefore described as being monoinnervated. This one-to-one connection 
ensures robust neurochemical transmission; every action potential that arrives in the 
terminal of the motor neuron triggers action potentials in all of the muscle fibres that 
it innervates, facilitating coordinated muscle contraction (Shi et al., 2012, Lichtman 
and Colman, 2000). The NMJ is widely utilised experimentally to investigate synaptic 
development and function due to its large size and ease of accessibility (Sanes and 
Lichtman, 2001). At birth, the NMJ is highly polyinnervated: each NMJ receives 
multiple axonal inputs (Lichtman and Colman, 2000). The development of precise 
connectivity between the motor neuron and skeletal muscle fibre involves spatially 
defined removal of exuberant neuronal processes (Tapia et al., 2012). Across early 
postnatal development, excess synapses are removed or ‘pruned’, until just one 
connection remains, which is then strengthened and maintained throughout life 
(Lichtman and Colman, 2000, Sanes and Lichtman, 2001). Much work has attempted 
to define what determines the success of one synapse over another, with activity and 
competition thought to be key factors. Terminals compete with neighbouring synaptic 
sites for post-synaptic resources and ultimately, inactive sites are eliminated and 
withdrawn (Wyatt and Balice-Gordon, 2003). The mechanisms by which such 
selective degeneration occur remains largely unclear. In terms of morphology, synapse 
elimination has been compared to a die-back, however it is unclear whether similar 
pathways are utilised. Throughout this thesis, I examine synaptic stability across 
development: in Chapter 1, I consider whether synaptic maturity can influence the rate 
of synaptic degeneration after injury; in Chapter 2, I ask whether changes in 
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mitochondrial dynamics across development can alter synaptic stability; and in 
Chapter 3, I examine whether reductions in P53, a factor involved in apoptotic cell 
death, can delay synaptic maturation. An appreciation of the morphology and 
mechanisms of developmental synapse elimination is therefore also pertinent.  
1.3.1 Morphology and mechanisms of synapse elimination 
 
Many studies have sought to provide mechanistic insight into the process of synapse 
elimination in the CNS, in various brain regions, however, developmental synapse 
elimination has been most extensively characterised and is best understood at the 
developing rodent NMJ. This is largely due to the peripheral location of the NMJ 
which makes it accessible, but also due to its simple architecture, large size, and ease 
of functional readout in response to presynaptic axonal stimulation (muscle 
contraction) (Lee, 2020). The first anatomical descriptions of the presence of multiple 
axonal inputs in young animals date back to observations by Tello, a student of Ramon 
y Cajal (Tello, 1907). This was later functionally confirmed through intracellular 
recordings of neonatal rat muscle fibres, which revealed that in early postnatal life, 
most end-plate potentials were complex and a summation of multiple inputs, but that 
these simplified during the second week of life, to resemble that of the adult (Redfern, 
1970). Unlike in disease scenarios, during synapse elimination, only select axonal 
branches are pruned without cellular death.  
 
Several cellular mechanisms have been proposed to underlie this process, with 
competing hypotheses emerging to explain mechanisms of axonal withdrawal. The 
first is that exuberant processes degenerate by axonal fragmentation. Ultrastructural 
similarities with WD have been described in Drosophila, and this includes 
fragmentation, aberrant mitochondria, high cytoplasmic density and clumping of 
synaptic vesicles (Watts et al., 2004, Watts et al., 2003). Similar features have been 
described across the neuron, with a combination of morphological and molecular 
studies also showing that severing the dendritic tree from the cell body, results in 
subsequent fragmentation in a process that is thought to be dependent on local caspase 
activity (Williams et al., 2006, Williams and Truman, 2005, Kuo et al., 2006). Glial 
cells have also been shown to localise to severed dendrites, however their precise role 
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remains unclear (Han et al., 2011). Much of this work has been undertaken in 
Drosophila. In Wlds mice, synapse elimination proceeds normally, suggesting that 
distinct mechanisms may exist (Gillingwater et al., 2003, Parson et al., 1997, 
Gillingwater et al., 2006). 
 
A second hypothesis is that axonal branches undergo retrograde retraction, in a similar 
way as occurs during a die-back; axonal retraction involves the reabsorption of axons 
and processes into the proximal axon without fragmentation. The presence of 
retraction bulbs, that are also characteristic of dying-back pathology, and lack of 
degenerative features have supported this (Rosenthal and Taraskevich, 1977). Long-
term 2-photon imaging across the first 3 weeks of postnatal development to image 
axons in the murine neocortex, has demonstrated that pruning proceeds by retraction 
of small axon branches (Portera-Cailliau et al., 2005). It is possible that different types 
of axons may utilise different modes of pruning, depending on length (Luo and 
O'Leary, 2005). Other work has proposed that synapse elimination may proceed by a 
distinct mechanism altogether, in a processed termed ‘axosome shedding’ (Bishop et 
al., 2004). Bishop et al., 2004 suggest that as axons are eliminated, they shed 
membrane bound remnants, to expose ‘axosomes’ that are dense with synaptic 
organelles at their tips, which are then engulfed by Schwann cells.  
 
Activity-dependent competition has been proposed as a key factor regulating synaptic 
elimination at the NMJ, with only the most active inputs prevailing. This is supported 
by the finding that blocking activity can prevent synaptic elimination (Costanzo et al., 
2000). Trophic deprivation, particularly of nerve growth factor (NGF), is a well-
known model for investigating axonal pruning and the mechanisms of neuronal 
apoptosis (Maor-Nof and Yaron, 2013, Geden and Deshmukh, 2016). Trophic factors, 
such as NGF, are critical regulators of axonal maintenance and survival, with 
withdrawal of trophic support found to activate pro-apoptotic pathways (Sanes and 
Lichtman, 1999, Harrington and Ginty, 2013). It has been suggested that presynaptic 
inputs compete for muscle-derived trophic signals; indeed, a lack of trophic support 
can induce synapse elimination (Goda and Davis, 2003, Sanes and Lichtman, 1999, 
Huang and Reichardt, 2001). Recent work has implicated glutamatergic transmission 
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in influencing neuromuscular synapse elimination. Work by Personius et al., 2016 has 
shown that N-acetylaspartylglutamate that is released from the motor nerve terminal, 
is converted to glutamate which can bind and activate N-methyl-D-aspartate (NMDA) 
receptors, leading to Ca2+ influx. This group demonstrated that developmental synapse 
pruning can be delayed by reducing NMDA receptor activation or expression, or by 
reducing production of glutamate (Personius et al., 2016). Conversely, the addition of 
exogenous NMDA was shown to accelerate synapse elimination (Personius et al., 
2016). Overall, the molecular regulators of neuronal remodelling remain largely 
unclear, however due to morphological similarities, there has been much debate as to 
the extent of mechanistic overlap or divergence between different types of axonal and 
synaptic degeneration. 
 
1.4 Mechanistic commonalities and divergence in morphologically distinct 
forms of synaptic and axonal degeneration 
Despite morphological distinctions between different forms of degeneration, it 
remains unclear how degenerative pathways relate mechanistically. A diverse range 
of triggers can ultimately result in neuronal death, and this presents a challenge when 
attempting to define common degenerative mechanisms. Whilst some work supports 
the hypothesis that WD and die-back pathways share common mechanisms, other 
work indicates that distinct mechanisms exist (Gillingwater and Ribchester, 2003, 
Coleman, 2005, Conforti et al., 2014, Wang et al., 2012, Yaron and Schuldiner, 2016, 
Mi et al., 2005). Much of the debate over the extent of convergence and divergence in 
degenerative mechanisms has arisen from conflicting results in mouse models of 
disease that express WldS.  
Support for mechanistic commonality can be seen in cases where WldS is capable of 
delaying degeneration in models that exhibit a die-back. In a mouse model of 
progressive motor neuronopathy (pmn), it has been shown that the WldS gene product 
can prevent axonal degeneration, rescue motor neuron number and size, delay deficits 
in retrograde transport, attenuate symptoms and extend life span (Ferri et al., 2003). In 
myelin protein zero mice, used to model of charcot-marie-tooth disease, WldS also 
significantly delays dying-back processes (Samsam et al., 2003). This suggests that 
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there are mechanistic links between dying-back pathology and WD. Several 
mechanistic convergence points have been suggested, including: increased intra-
axonal Ca2+, impaired axonal transport from the cell body and mitochondrial failure 
(Coleman, 2005). Changes in mitochondrial dynamics have been linked to changes in 
the rate of synaptic and axonal degeneration in different physiological scenarios. 
Proteomic studies investigating synaptic stability in WldS have identified 
mitochondria as playing an important role in the progression of WD (Wishart et al., 
2007). Wishart et al., identified 8 mitochondria-localised proteins that were 
significantly altered at Wlds synapses that are thought to be important in conferring 
the delayed Wlds phenotype. In line with this, blocking the mitochondrial permeability 
pore can phenocopy protection that is conferred by Wlds (Barrientos et al., 2011). 
Other studies also support that mitochondrial changes are critical in the procession of 
axonal degeneration, including reports of enhanced levels of mitochondrial proteins at 
the NMJ during a die-back in SMA mice and altered mitochondrial morphology 
including rounding and elongation (Neve et al., 2016). Up-regulations of 
mitochondrial proteins between P10 and P26 of postnatal development have also been 
described, that correlate with accelerations in synaptic loss following insult across this 
time frame (Murray et al., 2011).  
However, in other models with dying-back pathology, WldS fails to attenuate synaptic 
and axonal loss. For example, WldS fails to delay degeneration in some mouse models 
of ALS and SMA (Kariya et al., 2009, Vande Velde et al., 2004, Fischer et al., 2005, 
Rose et al., 2008). In the superoxide dismutase 1 (SOD1) mouse model of ALS, the 
presence of WldS fails to delay disease onset, ameliorate motor neuron death, or prevent 
synaptic and axonal degeneration (Vande Velde et al., 2004). Work by Fischer et al., 
also reports that WldS presence fails to mitigate motor axon loss in SOD1 mice (Fischer 
et al., 2005). In SMNΔ7 mice, WldS does not improve the synaptic phenotype (Kariya 
et al., 2009, Rose et al., 2008). Work in WldS mutants has also demonstrated that the 
normal rate of postnatal synapse elimination is unaffected (Parson et al., 1997), again 
suggesting that distinct mechanisms exist. 
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There is evidence to suggest that the presence of dying-back pathology may delay WD, 
which could suggest that mechanisms of a die-back and WD oppose each other. For 
example, Wasted (Wst) mice carry a spontaneous mutation that abolishes the 
expression of eukaryotic translation elongation factor 1 alpha 2 (eEF1A2). Loss of this 
factor triggers dying-back neuropathy (Murray et al., 2008b). It has been shown that 
whilst loss of eEF1A2 significantly inhibits the initiation and progression of WD, it is 
required to prevent dying-back pathology at the NMJ (Murray et al., 2008b). In 
neonatal mice, synaptic and axonal degeneration in response to traumatic or hypoxic 
nerve injury is slower than in adult mice in the DL muscles (Murray et al., 2011). 
Resistance to WD gradually declines between 2-3 weeks of age until adult levels of 
vulnerability to injury are established (Murray et al., 2011). The delay in injury-
induced synaptic degeneration observed in this time window coincides with the period 
of time during which extensive remodelling and synapse elimination is ongoing, 
supporting the hypothesis that opposing mechanisms exist. Collectively, these data 
indicate that mechanisms underlying dying-back pathology in these scenarios are 
distinct from those responsible for WD, and those in other models where rates of 
degeneration can be modified by the presence of WldS. 
The debate as to whether independent cascades exist remains ongoing; it is unclear 
whether morphological distinctions in axonal degeneration also translate to 
mechanistic distinctions. A better understanding of factors that can modify the rates of 
degeneration in different physiological scenarios will help us to better categorise 
degeneration and identify therapeutics which could have applications across a range 
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1.5 Thesis aims 
 
The work contained within this thesis aims to explore factors that can influence the 
rate of degeneration under different degenerative scenarios, including following 
injury, during disease and during postnatal development. Despite distinct 
morphologies in response to various stimuli, the mechanisms of synaptic degeneration 
and how they relate to one another remain largely unknown. Understanding factors 
that can influence the rate of degeneration is of critical importance if we are to identify 




1) To expand, optimise and explore an ex vivo model of peripheral nerve injury 
to study a range of different muscles that have not previously been looked at 
in the context of WD 
2) To apply the ex vivo model to investigate the impact of underlying dying-back 
pathology on the progression of WD 
Rationale:  
Previous work has indicated that rates of WD are developmentally regulated in 
the deep lumbrical muscles of the mouse (Murray et al., 2011), however it is 
unclear if this is unique to these muscles. Expansion of an ex vivo model of 
peripheral nerve injury will permit the inclusion of other muscle preparations, 
including those that are relevant to disease. Application of this ex vivo assay will 
permit the inclusion of preparations from mouse models that exhibit different 
synaptic pathologies, thereby providing a useful tool to investigate how these 
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Hypotheses: 
1) An ex vivo model can be expanded to investigate synaptic loss following 
injury in a range of different muscles 
2) Increases in the rate of degeneration during postnatal development will be a 
common feature across different muscles 
3) Selective vulnerability of muscles is a feature of WD 





1) To analyse two independent proteomic datasets to determine whether 
mitochondrial alterations in the murine proteome are common during early 
postnatal development 
2) To investigate whether changes in mitochondrial number or complex protein 
levels correlate with differences in synaptic vulnerability during early 
postnatal development or between muscles/nerves 
Rationale:  
In mice, neonatal NMJs are significantly more resistant to nerve injury than 
those in the adult (Murray et al., 2011). Across the first 3 weeks of life, the rate 
of WD progressively increases until adult rates of degeneration are achieved 
(Murray et al., 2011). Within this developmental time frame, increases in 
mitochondrial proteins have also been reported that appear to coincide with 
accelerations in synaptic loss (Kline et al., 2019, Kim et al., 2019). 
Pharmacological manipulation of complex I has been shown to alter the rate of 
synaptic degeneration (Kline et al., 2019). It is unclear whether changes in 
mitochondrial protein expression can similarly explain differences in the 
synaptic response to injury in other muscles, either temporally or regionally. 
Understanding how mitochondrial biology changes across this transitional, 
postnatal time window in a range of muscles and nerve will help us to better 
understand factors that can influence synaptic vulnerability. 
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Hypotheses: 
1. Consistent increases in mitochondrial-associated proteins will be revealed 
through analyses of two independent proteomic screens 
2. Increases in mitochondrial content will positively correlate with patterns of 
developmental regulation that are seen following injury 
3. Increases in mitochondrial content will positively correlate with increased 
synaptic vulnerability to injury in muscles that display greater vulnerability to 
synaptic loss following nerve injury 
4. Increases in Complex I of the respiratory chain will positively correlate with 
patterns of developmental regulation that are seen following injury 
5. Increases in Complex I of the respiratory chain will positively correlate with 




1) To investigate the role of P53 in morphologically distinct types of synaptic and 
axonal degeneration 
2) To assess whether reduced levels of P53 can influence the expression of 
synaptic genes 
Rationale: 
P53 is a transcript that plays a role in cell death, however its role in synaptic 
and axonal degeneration is unclear. Upregulation of P53-associated transcripts 
in response to reduced Smn are well-documented in the literature (Murray et 
al., 2015, Baumer et al., 2009, Jangi et al., 2017, Staropoli et al., 2015, Zhang 
et al., 2008). Previous work has indicated that postnatal reductions in P53 can 
reduce NMJ loss in a mouse model of SMA, however P53 reduction failed to 
extend lifespan or improve motor function (Courtney et al., 2019). A more 
comprehensive analysis across different muscles is required to assess whether 
reductions in P53 can uniformly improve synaptic retention. Previous work has 
indicated that P53 is present at synapses (Gilman et al., 2003) and that P53 
signalling increases in the distal nerve following injury despite separation from 
the cell body (Yao et al., 2013), suggesting that P53 may play a role in synaptic 
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degeneration in WD. Application of the ex vivo model in this case will allow 
us to assess whether P53 plays a role in regulating synaptic loss following 
injury. Pro-apoptotic pathways have been implicated in synapse elimination, 
particularly in trophic withdrawal models (Maor-Nof et al., 2016). 
Investigating whether P53 reductions can delay axonal pruning in vivo will 
provide a better indication of the role of pro-apoptotic pathways. 
 
Hypotheses: 
1. Reductions in P53 will delay synaptic loss following injury in wild-type mice 
2. Reductions in P53 will delay synaptic loss in a mouse model of SMA 
3. Reductions in P53 will delay synapse elimination during normal postnatal 
development 
4. P53-related transcripts will be dysregulated in a mouse model of SMA 
5. P53 reduction will alter the expression of synaptic genes that are thought to be 
regulated by P53, including Bin1, Picalm and Mef2c 
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Materials and Methods 
 
 
1.6 Ethics statement 
 
All animal procedures were performed in accordance with UK Home Office and 
institutional guidelines.  
 
1.7 Mouse Maintenance 
 
Throughout this thesis, a number of murine models are used to investigate factors that 
can influence the rate of synaptic degeneration under different physiological 
conditions. These models are described under the relevant headings of this section, 
however a brief overview of their applications is provided here. 
 
Firstly, an ex vivo model of peripheral nerve injury was optimised using adult 
preparations from a well-characterised mouse model where synaptic loss is known to 
be slower after injury (WldS). Next, preparations from MCos1 mice - referred to as 
wild-type mice – were introduced to expand the ex vivo model to permit the inclusion 
a range of different muscles. For these experiments, I chose to examine the time frame 
of P15 to P25, as the rate of synaptic degeneration following injury progressively 
increases during this developmental time period in the deep lumbrical muscles 
(Murray et al., 2011). This time frame was also used to examine changes in 
mitochondrial proteins across development to ask whether changes in mitochondrial 
dynamics could be responsible for conferring developmental delays in synaptic 
degeneration. To study synaptic loss in a disease scenario, I utilised the Smn2B/- mouse 
model of SMA at time points P15 or P18, as these time points represent late-
symptomatic or end-stage disease respectively. I also used a P53-floxed mouse model 
to look at the role of P53 in synaptic degeneration under different scenarios. To look 
at an injury scenario, I used ex vivo preparations from P53-floxed mice at P18 and P25, 
since we would expect to observe differential and robust synaptic loss following injury 
at these points. To look at a disease scenario, I used P53-floxed Smn2B/- mice, and 
 
Materials and Methods 39 
assessed the level of synaptic innervation remaining in different muscles at disease 
end-stage (P18). Finally, to investigate synapse loss that occurs during normal 
development or when P53 is depleted, I evaluated levels of mono- or polyinnervation 
remaining at P10 or P14, since the maturation of the neuromuscular system is thought 
to occur across the first few weeks of life. These models are detailed below. 
 
1.7.1 Wlds mice – Wallerian degeneration slow model 
 
C57BL6/Wlds adult mice were group housed in individually ventilated cages under 
pathogen-free conditions with ad libitum access to food and water, on a 12:12 
light/dark cycle within animal facilities at the University of Edinburgh. These mice 
were maintained and kindly provided by Professor Richard Ribchester to assist with 
optimising the ex vivo system. 
 
 
1.7.2 MCos1 mice – wild-type mice 
 
C57BL6/J MCos1, herein referred to as wild-type mice, were group housed in 
individually ventilated cages under pathogen-free conditions, with ad libitum access 
to food and water, on a 12:12 light/dark cycle within animal facilities at the University 
of Edinburgh. Wild-type mice of either sex were sacrificed between P15 and P25, as 
this is the time frame during which developmental regulation of WD has previously 
been described (Murray et al., 2011). When lumbrical muscle preparations were 
harvested only, animals were sacrificed by cervical dislocation and death was 
confirmed by severing a major artery. When cranial/abdominal preparations were 
harvested, these animals were sacrificed by an inhalational overdose of anaesthetic 
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1.7.3 Smn2B/- mice – an intermediate mouse model of SMA 
 
C57BL/6 Smn2B/2B and Smn+/- mice were maintained in individually ventilated cages 
under pathogen-free conditions, with ad libitum access to food and water, on a 12:12 
light/dark cycle within animal facilities at the University of Edinburgh. The Smn2B/- 
mouse is an intermediate mouse model of the childhood motor neuron disease, SMA 
that exhibits dying back pathology. The Smn2B allele consists of a three-nucleotide 
substitution in the exon enhancer region within exon 7 of the murine Smn gene. The 
resultant mouse has reduced levels of full-length, endogenous SMN protein which 
leads to progressive loss of lower motor neurons (DiDonato et al., 2001; Hammond et 
al., 2010; Bowerman et al., 2012). Symptom onset is at around P10, and, in our hands, 
this model has a lifespan of around 21 days. Smn2B/- mice of either sex were sacrificed 
at P18 by inhalational overdose of anaesthetic (isofluorane) and death was confirmed 
by severing the carotid artery. 
 
1.7.4 P53-floxed mice 
 
This colony was established in the Murray Lab after kind donation by Dr. Luke Boulter 
and Dr Kevin Myant (University of Edinburgh). Mice were group housed in open 
cages, with ad libitum access to food and water, on a 12:12 light/dark cycle within 
animal facilities at the University of Edinburgh. These mice have been described in 
depth by our lab previously (Courtney et al., 2019, see co-author paper provided in 
Appendix 3 for reference). For work investigating the role of P53 in disease scenarios, 
mice were maintained in breeding pairs that were made up of an Smn2B/2B;P53fl/fl and 
Smn+/-;P53fl/fl;CAG-Cre+ mice, to produce Smn2B/-;P53fl/fl;CAG-Cre+, herein referred to 
as P53-floxed Smn2B/-, and Smn2B/+;P53fl/fl;CAG-Cre+ controls. Controls from these 
breeding pairs also produce the equivalent Cre- controls, yielding a total of 4 
experimental genotypes. P53-floxed Smn2B- mice and control littermates of either sex 
were sacrificed by rising CO2 and death was confirmed by severing the carotid artery. 
P53 lines consisting of Smn+/+;P53fl/fl;Cre+ mice and Smn2B/-;P53fl/fl;Cre+, referred to 
herein as P53-floxed wild-type or P53-floxed Smn2B/- mice were also maintained. Mice 
for ex vivo experiments were sacrificed by an inhalational overdose of anaesthetic 
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(isofluorane) and death was confirmed by severing the carotid artery, whilst those 
sacrificed for other work were sacrificed by rising CO2 and death was confirmed by 
severing the carotid artery. 
 
1.8 Genotyping  
 
1.8.1 DNA Extraction 
 
DNA was extracted from tail tips or ear notches by digestion in 500µL of lysis buffer 
composed of 0.5M EDTA, 1M Tris- HCl, 1M NaCl, 10% SDS in ddH2O and 2.5µL of 
Proteinase K (1mg/mL) for 24 hr at 55°C. DNA was precipitated using isopropanol 
and washed in duplicate with 70% ethanol. After drying, DNA was re-suspended in 
either 200µL or 50µL of ddH2O for tail tips and ear notches respectively, and could be 
nanodropped if required. DNA was stored at -20°C. 
 
An alternative method was also applied in some cases if genotyping was required more 
quickly; this could be undertaken on the same day. In these cases, DNA was extracted 
from tail tips or ear notches by digestion in 600µL or 300µL of 50mM NaOH 
respectively. These were then heated to at least 95°C for 10 minutes. DNA was 
precipitated using 1M Tris-HCl (pH 8.0). After microfuging for 6 minutes, the 
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1.8.2 PCR Protocols 
 
For identification of appropriate genotypes and maintenance of breeding pairs, four 
PCR protocols were required. The relevant primer sequences pertaining to these 
protocols are detailed in Table 2, and master mix components and temperature cycles 
are provided in Tables 3-12. For ease, a summary of the expected band sizes is 
provided in Figure 4. 
 
The Smn2B protocol was used to identify the presence or lack of the Smn2B allele. The 
Smn2B allele was identified by a band at 700bp. This protocol used an Invitrogen PCR 
Kit. 9µL of master mix (Table 3) was added to 1µL of DNA and set to a pre-
programmed temperature cycle (Table 5). The Smn+/- protocol was used to identify the 
presence or absence of the Smn null allele. The null Smn allele was identified by a 
band at 500bp, whilst the wild-type Smn allele was identified at 800bp. This protocol 
used an Invitrogen PCR Kit. 10µL of master mix (Table 5) was added to 2µL of DNA 
and set to a pre-programmed temperature cycle (Table 6). The Cre protocol was used 
to identify whether a mouse was Cre positive or Cre negative. This protocol used an 
Invitrogen PCR Kit. 10µL of master mix (Table 7) was added to 2µL of DNA and set 
to a pre-programmed temperature cycle (Table 8). The P53 protocol was used to 
identify the presence or absence of the P53-floxed allele. This protocol used a KAPA 
PCR Kit. 26.5µL of master mix (Table 9) was added to 2µL of DNA and set to a pre-
programmed temperature cycle (Table 10).  
 
For analyses of Cre-mediated recombination in P53-floxed mice, PCR was performed 
on genomic DNA extracted from tail tips (Note that visualisation of this result can be 
seen in Chapter 3, Results, Figure 3.1). This protocol used an Invitrogen PCR Kit. 9µL 
of master mix (Table 11) was added to 1µL of DNA and set to a pre-programmed 
temperature cycle (Table 12). This protocol was used to identify the presence of the 
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Table 2: PCR Primer Sequences 
 
Table 3: 2B Protocol Master Mix Components 




dNTPs (Invitrogen) 0.2 
‘2B Forward’ Primer 0.1 






Protocol Primer Sequence 
Smn2B F: 5’AACCTCCGGGTCCTCCTTCCT 
R: 5’TTTGGCAGACTTTAGCAGGGC 
Smn+/- F Common: 5’CTCCGGGATATTGGGATTG 
R Wild-type: 5’TTTCTTCTGGCTGTGCCTTT  
R Mutant: 5’GGTAACGCCAGGGTTTTCC 
Cre F Control (interleukin-2): 5’-CTAGGCCACAGAATTGAAAGATCT 
R Control (interleukin-2): 5’-GTAGGTGGAAATTCTAGCATCATC 
F Cre: 5’TTAATCCATATTGGCAGAA 
R Cre: 5’CAGGCTAAGTGCCTTCTCT 
P53-floxed F P53-wild-type: 5’-CTCAGCAGTAAGGAAGACA 
R P53-wild-type: 5’-CCATGAGACAGGGTCTTGC 
F P53-floxed: 5’-CTGTGCCCTCCGTCCTTTT 
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Table 4: 2B Protocol Temperature Cycle 
Step Number and Temperature (°C) Time 
1. 94°C 3 minutes 
2. 94°C 45 seconds 
3. 58°C 45 seconds 
4. 72°C 45 seconds 
REPEAT STEPS 2-4 35X 
5. 72°C 5 MINUTES 
6. 4°C HOLD 
 
Table 5: Smn+/- Protocol Master Mix Components 




dNTPs (Invitrogen) 0.24 
‘Forward Common’ Primer 1.60 
‘Wild Type Reverse’ Primer 1.20 
‘Mutant Reverse’ Primer 0.60 
Taq 0.05 
 
Table 6: Smn+/- Protocol Temperature Cycle 
Step Number and Temperature (°C) Time 
1. 94°C 3 minutes 
2. 94°C 30 seconds 
3. 58°C 1 minute 
4. 72°C 1 minute 
REPEAT STEPS 2-4 35X 
5. 72°C 2 MINUTES 
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Table 7: Cre Protocol Master Mix Components 




dNTPs (Invitrogen) 0.24 
‘Control Forward’ Primer 1.2 
‘Control Reverse’ Primer 1.2 
‘Cre Forward’ Primer 1.2 
‘Cre Reverse’ Primer 1.2 
Taq 0.03 
 
Table 8: Cre Protocol Temperature Cycle 
Step Number and Temperature (°C) Time 
1. 95°C 3 minutes 
2. 95°C 30 seconds 
3. 51.7°C 1 minute 
4. 72°C 1 minute 
REPEAT STEPS 2-4 35X 
5. 72°C 2 minutes 
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Table 9: P53-floxed Protocol Master Mix Components 
Reagent Volume (µL)/sample 
Water 10.9 
Buffer (KAPA) 5 
Enhancer (KAPA) 5 
dNTPs (KAPA) 0.5 
Wild-type Forward Primer 1.25 
Wild-type Reverse Primer 1.25 
P53-floxed Forward Primer  1.25 
P53-floxed Reverse Primer 1.25 
Taq (KAPA Robust2G) 0.1 
 
Table 10: P53-floxed Protocol Temperature Cycle 
Step Number and Temperature (°C) Time 
1. 94°C 2 minutes 
2. 94°C 20 seconds 
3. 65°C 15 seconds 
4. 68°C 10 seconds 
REPEAT STEPS 2-4 10x 
5. 94°C 15 seconds 
6. 60°C 15 seconds 
7. 72°C 10 seconds 
REPEAT STEPS 6-8 28X 
8. 72°C 10 minutes 
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Table 11: P53-floxed recombined allele Protocol Master Mix Components 




dNTPs (Invitrogen) 0.2 
P53-intl-fwd 1.2 
P53-intl-rev 1.2 
Taq  1.2 
 
Table 12: P53-floxed recombined allele Protocol Temperature Cycle 
Step Number and Temperature (°C) Time 
1. 94°C 30 seconds 
2. 58°C 30 seconds 
3. 72°C 50 seconds 
REPEAT STEPS 2-4 30x 
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Figure 4: Genotyping results and expected band sizes. (A) Resulting possibilities 
following the Smn2B protocol. This protocol can be used to determine if a mouse is 
Smn2B/+ or Smn+/+. Note that this protocol cannot be used to differentiate between 
Smn2B/+ and Smn2B/-, therefore an additional protocol is required as shown in B. (B) 
Resulting possibilities after following the Smn+/- protocol. This protocol can be used 
to determine if a mouse carries the null allele. (C) Resulting possibilities after 
following the Cre protocol. This protocol can be used to determine if a mouse is Cre 
positive. (D) Resulting possibilities after following the P53-floxed protocol. This 
protocol can be used to confirm the presence of a floxed allele. Note that this protocol 
cannot distinguish copy number, for which further qPCR analysis is required. Breeding 
for homozygosity was undertaken by previous members and so copy number analyses 
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1.9 qPCR 
 
Mitochondrial DNA analyses, and P53 DNA recombination analyses were undertaken 
using quantitative polymerase chain reaction (qPCR). DNA was extracted from tissues 
by conventional extraction methods (see Materials and Methods, 1.8.1 DNA 
Extraction, for details) and concentration was determined using a nanodrop. All 
samples were loaded at concentration of 10ng/µL. Primer sets were custom-made 
(Sigma) and selected based on previous work by Puente et al., 2014 and Marino et al., 
2000 (Table 13). To test primer efficacy, standard curves were generated from two-
fold dilution series of mixed sample DNA. Relative gene expression was calculated 
using the 2−ΔΔcT formula and normalised to H19 or Gapdh for mitochondrial analysis 
(see Table 13 for primer sequences). Genes used for normalisation are detailed in 




Transcriptional analysis were undertaken using quantitative reverse transcription 
(RT-qPCR). RNA from spinal cords was extracted using an RNeasy Kit (Qiagen), 
according to manufacturer’s instructions and concentration determined using a 
nanodrop. Reverse transcription (RT) was performed using the QuantiTect Reverse 
Transcription Kit (Qiagen), according to manufacturer’s instructions, and 
complementary DNA (cDNA) was used at a concentration of 10ng/µL. A CFX96 
Touch Real-Time PCR Detection System machine (Bio-Rad) was used. RT-qPCR 
analyses was undertaken using PrimePCR SYBR Green assays for mouse. Pre-
optimised primers based on descriptions by Merlo et al., 2014 were used to target 
Bin1, Mef2c and Picalm (primers available to purchase as SYBR® Green Assays 
for mouse from Bio-rad). Relative gene expression was calculated using the 
2−ΔΔcT formula and normalised to Actin, Gapdh and Ywhaz (see Table 13 for 
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Table 13: qPCR primer sets  
Target Primer Sequence 
Mitochondrial-encoded NAD2 (herein 
referred to as mtDNA) 
F: 5’ CCCATTCCACTTCTGATTACC 
R: 5’ATGATAGTAGAGTTGAGTAGCG 
H19  F: 5’GTACCCACCTGTCGTCC 
R: 5’GTCCACGAGACCAATGACTG 
P53-recombined allele F: 5′-CACAAAAACAGGTTAAACCCA 
R: 5′-GAAGACAGAAAAGGGGAGGG 
Gapdh F: 5’ CGTCCCGTAGACAAAATGGT 
R: 5’TTGATGGCAACAATCTCCAC 
Actin F: 5’CCGTCAGGCAGCTCATAGCTCTTC  
R: 5’CTGAACCCTAAGGCCAACCGT   




1.11 Tamoxifen dosing to induce P53 recombination 
 
Pups expressing the P53-floxed allele and control littermates were dosed using a 
modified oral gavage for neonates with 80mg/kg Tamoxifen (Sigma) dissolved in corn 
oil to a concentration of 20mg/mL. Note that tamoxifen treatment was initiated prior 
to P5, as this time point precedes evidence of P53 pathway activation in the spinal 
cord in Smn2B/- mice (Courtney et al., 2019). P53-floxed Smn2B/- mice and controls were 
treated at P4 and 5, and were sacrificed at P15. P53-floxed wild-type mice were treated 
for three consecutive days; for the ex vivo study, these were treated at P4, 5 and 6 and 
for the synapse elimination study, these were treated at P1, 2 and 3. Pups were 
monitored after dosing to ensure that they maintained condition, that maternal care 
was resumed, and that pups continued to thrive. If over 10% of the maximum recorded 
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1.12 Ex vivo explant preparation 
 
Deep lumbrical (DL), cranial and abdominal nerve/muscle explants were gross 
dissected as described previously (Murray et al., 2010, Murray et al., 2014, Brown et 
al., 2015) in Hepes-buffered saline composed of NaCl (137 mM), KCl (5 mM), 
CaCl2·2H2O (2 mM), MgCl2·6H2O (1 mM), glucose (5.6 mM) and Hepes (5 mM) with 
pH corrected to 7.4. Nerves (sciatic, facial or intercostal) were severed at a consistent 
point, and distal nerve portions with attached musculature were pinned to dental wax 
and suspended in oxygenated mammalian physiological saline containing: NaCl 
(120 mM), KCl (5 mM), CaCl2·2H2O (2 mM), MgCl2·6H2O (1 mM), NaH2PO4·2H2O 
(0.4 mM), NaHCO3 (23.8 mM), glucose (5.6 mM), gentamicin (50 mg/ml, Thermo 
Fisher) and kanamycin (100 mg/ml, Thermo Fisher) in a 30 mL bijou tube. The bijou 
lid was modified, with two 0.8 mm needles, one needle clipped short, above the buffer 
level, to act as a pressure valve. A length of 0.50 mm tubing (VWR) sufficient to reach 
the bottom of the receptacle was attached to the other needle to provide a constant 
supply of 95/5% O2/CO2 to equilibrate the saline, at a perfusion rate of approximately 
5 mL/min. The bathing solution was equilibrated for approximately 30 min before 
adding the sample. The receptacle containing the nerve/muscle explant was then 
incubated in a 30°C water bath for 24 hr (Fig. 5). Temperature was monitored during 
this period using a digital thermometer (Fisher Traceable Digital Thermometer with 
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Figure 5: Ex vivo rig setup. Receptacles containing mammalian physiological saline 
(see Materials and Methods, 1.12 Ex vivo explant preparation for composition), and a 
suspended tissue sample pinned to dental wax were suspended in a water bath, with 
gas supply (95/5% O2/CO2) and air vent to relieve pressure as shown. Temperature 
was monitored by digital thermometer via a probe that was secured in the bath.  
 
1.13 Non-ex vivo tissue collection  
 
For non-ex vivo morphological work, abdominal and cranial preparations were fixed 
immediately for 15 min. Muscles of interest were microdissected in 1x phosphate 
buffered saline (PBS) as described previously (Murray et al., 2010, Murray et al., 2014, 
Brown et al., 2015)  (Fig. 6), in preparation for immunostaining. Any tissue that was 
collected for protein or transcriptional analyses were snap frozen immediately, to 
reduce the chance of post-mortem changes.  
 
To assess the level of P53 reduction, heart, tibialis anterior muscle, liver, and spinal 
cords, were collected from P15 Smn2B/+ and Smn2B/- P53-floxed and control mice and 
fixed immediately for 60 min (heart), 15 min (muscle), overnight (liver) or for 4 hr 
(spinal cord). Embedding and sectioning preparation, and immunohistochemistry for 
different tissues are detailed below and were kindly provided by Victoria Zimmel: 
 
Heart: Following thorough washing with 1xPBS, hearts were equilibrated in 30% 
sucrose solution before embedding in 50% optimal cutting temperature compound 
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(OCT) and 15% sucrose in 1xPBS. Forceps were used to suspend the hearts vertically 
with the apex at the bottom of the mould, and great vessels at the top, before snap 
freezing over dry ice. Hearts were sectioned on Leica cryostat at 10µM, with sections 
collected at 160µM intervals from the middle third of the heart on Superfrost® Plus 
slides (Thermo Fisher). Slides were stored at -20°C prior to staining. In preparation 
for staining, slides were mounted onto Shandon coverplates (Thermo Fisher) in 1xPBS 
and placed in Shandon sequenza (Thermo Fisher) slide rack at room temperature.  
 
Tibialis anterior muscle: Following thorough washing with 1xPBS, tibialis anterior 
muscles were equilibrated in 30% sucrose solution before embedding in 50% OCT 
and 15% sucrose in 1xPBS over dry ice. Muscles were sectioned on Leica cryostat at 
10µm, with sections collected at 100µm intervals from the middle third of the muscle 
on Superfrost® Plus slides (Thermo Fisher). Slides were stored at -20°C prior to 
staining. In preparation for staining, slides were mounted onto Shandon coverplates 
(Thermo Fisher) in 1xPBS and placed in Shandon sequenza (Thermo Fisher) slide rack 
at room temperature.  
 
Liver: Fixed livers were embedded in paraffin wax in preparation for sectioning on a 
microtome at 8µm. Antigen retrieval was performed using citric acid buffer (10mM 
sodium citrate; 0.05% Tween 20; with pH adjusted to 6); slides were immersed in a 
staining rack in a water bath at 95-100°C for around 30 min.  The staining dish was 
removed from the water bath and allowed to cool at room temperature for around 25 
min. In preparation for staining, slides were mounted onto Shandon coverplates in 
1xPBS and placed in sequenza and washed with 1xPBS for 10 min. 
 
Spinal Cord: Spinal cords were equilibrated in 30% sucrose in 1xPBS for 24-48 hours. 
Samples were then embedded in moulds in embedding solution composed of 50% 
OCT and 15% sucrose in 1xPBS. Samples were snap frozen over dry ice. Tissue was 
sectioned longitudinally on a Leica cryostat at 20°C at 10µm thickness. Sections were 
collected at 50µm intervals on Superfrost Plus slides (Thermo Fisher). Slides were 
stored at -20°C prior to staining. In preparation for staining, slides were mounted onto 
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Shandon coverplates (Thermo Fisher) in 1xPBS and placed in Shandon sequenza 




For ex vivo tissue, after 24 hr incubation in oxygenated mammalian physiological 
saline, muscle preparations were fixed immediately in 4% paraformaldehyde (EMS) 
for 15 min. For all other tissue, muscle preparations were dissected and fixed 
immediately in 4% paraformaldehyde (EMS) for 15 min. Muscles were then washed 
in PBS. Muscles of interest were microdissected as described previously (Murray et 
al., 2010, Murray et al., 2014, Brown et al., 2015) (Fig. 6), and permeabilised in 2% 
Triton-X-100-PBS (Sigma; PBT) for 30 min on a rocking platform at room 
temperature. Blocking solution (4% bovine serum albumin [BSA]/1% PBT) was 
applied for 60 min followed by primary antibodies against synaptic vesicle protein 2 
(SV2) and neurofilament (NF) (SV2, 1:100; 2H3, 1:50 respectively, both from 
Developmental Studies Hybridoma Bank) in blocking solution, and left to incubate at 
4°C on a rocking platform for 24 hr. Preparations were then washed three times for 
5 min with PBS. Secondary antibody (anti-mouse, Alexa Fluor 488, Stratech, 1:250 in 
1×PBS) was added to each well and incubated in the dark at room temperature for a 
minimum of 4 hr. Muscles were washed three times in 1 × PBS for 5 min, and 
incubated with tetramethylrhodamine-conjugated α-bungarotoxin (TRITC-BTX; 
Thermo Fisher, 1:250) for 20 min. Muscles were washed in PBS and whole-mounted 
on glass slides with Mowiol® (Calbiochem) and cover-slipped. Slides were stored in 
the dark at 4°C. 
 
For activated caspase-3 cell staining, slides that were mounted in sequenza were 
washed with 400µL of 1xPBS and then permeabilised for 30 min with 400µL of 2% 
Triton X-100 (Sigma) in PBS. Sections were blocking with 400µL of 1% Triton X-
100, 4% BSA (Sigma) in PBS. 300µL of rabbit anti-active caspase-3 (BD Bioscience) 
primary antibody (1:200 in block) was added and slides were incubated at 4°C 
overnight. Slides were washed in triplicate with PBS, before incubation with 
secondary antibody (AlexaFluor 488 donkey anti-rabbit IgG, Life Technologies, 1:250 
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in block) in the dark for 2 hr.  Slides were washed in triplicate with PBS for 10 minutes 
each. 400µL of 4’, 6-diamidino-2-phenylindole (DAPI) (DAPI, 1:1000, in 1xPBS) was 
then added for 10 min in the dark. Following triplicate washing with PBS, slides were 
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Figure 6: Muscles of interest that were microdissected and quantified following 
fixation. (A) Deep lumbrical muscle preparation after removal of flexor digitorum 
brevis, with lumbrical muscles 1-4 highlighted by black rings. (B) Thoracoabdominal 
preparation with the superficial layer of external oblique and rectus abdominis muscles 
removed to expose the deeper muscles of interest. Superior portion of transversus 
abdominis (TVA) and triangularis sterni (TS) muscles highlighted. (C) Cranial muscle 
preparation with cranial muscles of interest highlighted. Deeper muscles – auricularis 
superior (AS) and adductor auris longus (AAL) – and superficial muscles – rostral and 
caudal bands of the levator auris longus (LALr/LALc respectively) are highlighed. (D-
E) Schematics to show the anatomical positions of muscles of interest from 
thoracoabdominal and cranial regions respectively. (F) NMJs labelled with antibodies 
against neurofilament (NF, green) and synaptic vesicle protein 2 (SV2, green), and α-
bungarotoxin (BTX, red). The yellow arrowheads highlight endplates that would be 
quantified as ‘full’, whereas the pink arrowhead indicates a vacant endplate, where 
apposition between the pre-synaptic terminal and the motor endplate has been lost (see 
Materials and Methods, 1.17 Quantification and statistical analyses for further detail 
of categorisation). 
 
1.15 Quantitative fluorescent western blotting 
 
Levels of Complex I-V in muscle and Complex I, IV and V in nerve were determined 
by quantitative fluorescent western blotting, following protocols as described 
previously (Huang et al., 2019). Muscles were collected bilaterally and pooled from 2 
animals to ensure adequate protein yield, and included: LALr/LALc/AS combination 
of cranial muscles; AAL cranial muscle; TVA/TS combination of thoracoabdominal 
muscles. Nerves were collected bilaterally and pooled from 2 animals, and included 
sciatic/tibial nerve and intercostal nerves (x15 intercostal nerves in total). Brain 
(halved along the longitudinal fissure) with cerebellum removed, and spinal cord 
(halved along the midline) were also harvested. Spinal cord was removed via 
application of needle pressure applied from the rostral end (note that results relating to 
central tissue can be found in Appendix 4). All tissue were snap-frozen on dry ice prior 
to extraction. In brief, tissue was thawed and homogenised in ice-cold PBS with 
 
Materials and Methods 58 
Dounce homogeniser (VWR) and extracted in RIPA lysis and extraction buffer 
(ThermoFisher) with 1% Halt protease inhibitor cocktail (ThermoFisher).  Protein 
concentration was determined by micro-BCA assay (Pierce Biosystems). Samples 
were diluted to load 30µg of protein in 10µL of deionised water and 5µL of NuPage® 
LDS Sample buffer (4X) (Invitrogen) and run on a NuPAGE™ Novex™ 4-12% Bis-
Tris protein gel (Invitrogen) before transfer to a PVDF membrane using an iBlot2® 
transfer system (ThermoFisher).  
 
To determine total protein concentration as a loading control, membranes were 
incubated in 5mL of REVERT fluorescent total protein stain (Licor) for 5 minutes and 
washed twice with REVERT was solution (Licor). Total protein stain was scanned 
whilst still wet using an Odyssey imaging system (Licor) with Image Studio Lite 
software (Licor). The membrane was then blocked with Odyssey blocking buffer 
(Licor) for 30 minutes at room temperature, before overnight incubation with primary 
antibody of Total OXPHOS (1:1000) (Abcam) in 5mL Odyssey blocking buffer at 
4°C. This OXPHOS cocktail contains 5 mouse antibodies, one against each CI subunit 
NDUFB8, CII-30kDa, CIII-Core protein 2, CIV subunit 1, and CV alpha subunit as a 
premixed cocktail. These subunits have the benefit in that they are labile when the 
complex is not assembled. Membranes were incubated in secondary solution 
containing IRDye 680RD donkey anti-mouse IgG (H + L) antibody (Licor) at 1:5000 
in Odyssey blocking buffer for 1 hr at room temperature. Membranes were dried and 
stored at 4°C prior to imaging and analysis. For measurement and analysis, Image 
Studio Lite software was used to analyse intensities of area-constant total protein 
banding against background. Quantification of bands was undertaken on the 700nm 
channel, and normalised to total protein. Readouts were exported to Microsoft Excel 
for normalisation. All statistical analyses and graph generation was performed on 
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1.16 DAVID Analysis 
 
Proteomic datasets were obtained from that of Kline et al., 2019 and Kim et al., 2019, 
however all analyses presented here were undertaken by myself. Note that I am a co-
author on the Kline et al., 2019 paper, which is provided in Appendix 2 for reference. 
Proteins exhibiting a consistent up-regulation in muscle from P12 to P24, regardless 
of magnitude of change, were submitted as a gene list and converted to Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) identifications using the 
DAVID 6.7 Mus musculus database. For a more in depth description of using DAVID 
bioinformatic resources for gene list analyses and manipulation, readers are directed 
to Huang et al., 2009 (Huang da et al., 2009). In brief, converted gene lists were 
analysed using the Functional Annotation Clustering tool, in DAVID Bioinformatics 
Resources (Version 6.7) to produce a list of functional annotations. Functional 
annotations are ranked by an enrichment score. An enrichment score of >1.3 in 
DAVID is equivalent to p < 0.05, which is considered to be statistically significant. 
 
1.17 Quantification and Statistical Analyses 
 
Quantification of NMJ occupancy or maturity status was undertaken by fluorescent 
microscopy at ×40 magnification. The investigator was blinded to the age, genotype 
and treatment of muscles. A minimum of two (deep lumbrical, TS) or three (LALr, 
LALc, AS, AAL, TVA) fields of view and 50 NMJs were sampled per muscle (average 
of 118 motor endplates per muscle). Fields of view were chosen at random from across 
the entire muscle using bungarotoxin staining only, to ensure a fair representation of 
the entire muscle and to reduce the chance of bias for innervated areas. Previously 
optimised criteria for NMJ quantification were applied to quantify the percentage of 
fully occupied endplates (Murray et al., 2013, Murray et al., 2015, Murray et al., 2011, 
Murray et al., 2008a, Thomson et al., 2012, Sleigh et al., 2014a, Sleigh et al., 2014b, 
Brown et al., 2015, Comley et al., 2016, Kline et al., 2017, Courtney et al., 2019, 
Osman et al., 2019). In brief, fully occupied endplates were defined as complete 
apposition between the pre-synaptic terminal and the motor endplate (see Fig. 6F for 
examples). This has been expressed as a percentage of the total number of endplates 
 
Materials and Methods 60 
quantified for each muscle, with the remainder of endplates displaying synaptic 
withdrawal, appearing either only partially occupied (where only part of the ACh 
receptor cluster is covered by a pre-synaptic terminal) or vacant (where no pre-
synaptic staining is evident at the ACh receptor cluster). An example of the occupancy 
criteria implemented to categorise NMJs can be seen in Fig. 6F. For NMJ maturation, 
the number of axonal inputs to the motor endplate were quantified, and expressed as a 
percentage of the total number of endplates included for analysis.  
 
Quantification of activated caspase-3 (AC3) positive cells was undertaken blind to 
genotype on a Leica DMi8 fluorescent microscope with LAS X software at x40 
magnification, and images were stitched together to create a whole section image in 
Adobe Photoshop. The absolute number of AC3 positive cells were counted and 
averaged from a minimum of three slides to give the mean number of cells per section, 
per replicate. Quantification of AC3 staining in different tissues were undertaken and 
provided by lab members: Victoria Zimmel (heart/liver), Mohammad Omar Khan 
(muscle), and Dr. Alison Thomson (spinal cord). 
 
All analyses were collated into Microsoft Excel before exporting to GraphPad Prism 8 
software for statistical analysis with n numbers referring to the number of muscles or 
biological replicates analysed. Statistical tests are detailed in the legend of the relevant 
graphs to which they refer. Data were tested for normality using a Shapiro–Wilk test. 
Data that were normally distributed were tested using one-way analysis of variance 
(ANOVA) with post-hoc Tukey correction, or two-way ANOVA with post-hoc Sidak 
correction or unpaired t-test with post-hoc Welch correction. In groups that were not 
normally distributed, Kruskal–Wallis tests with Dunn’s post-hoc or, when one group 
has been normalised to 1, a one-sample t-test with comparison to a hypothetical value 
of 1 were applied. All data are presented as mean values ± standard error of the mean 
(SEM). Differences were considered significant when p < 0.05. 
 
Micrographs are projections of Z-image stacks collected on a Nikon A1R FLIM 
confocal microscope and were adjusted for overall image brightness and contrast only 
using ImageJ (downloadable from https://imagej.nih.gov/ij/) and 
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Adobe Photoshop CS6 software (licence purchased 
from https://www.adobe.com/uk/products/).
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 : Expansion and exploration of an ex vivo model of 
Wallerian degeneration 
 
1.18 Chapter overview and principle findings 
 
In this chapter, I aimed to expand, optimise and explore an ex vivo model of peripheral 
nerve injury in a range of different muscles that have not been looked at in this context 
previously. Here, I examined the level of synaptic loss across time in different muscles, 






• Ex vivo modelling of peripheral nerve injury is possible in a range of muscles 
• Synaptic loss increases with age in the cranial muscles 
• Differences in the level of synaptic loss following injury does not correlate 
with synaptic maturity 
• Synaptic loss is minimal in the thoracoabdominal muscles following injury 
• Patterns of synaptic vulnerability are distinct from those that occur in a die-
back 
• WD is Smn-independent 
• The presence of a die-back can accelerate synaptic loss following injury 
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1.19 Introduction 
 
Motor neurons are vulnerable to degeneration following physical or chemical injury 
and in a range of neurodegenerative diseases. Damaged axons and synapses degenerate 
in morphologically distinct ways depending on the nature of the original trauma. 
Following injury, spontaneous and rapid fragmentation occurs along the length of the 
injured axon in a characteristic process known as Wallerian degeneration (WD) 
(Waller, 1851, Beirowski et al., 2004, Beirowski et al., 2005, Conforti et al., 2014). In 
WD, the cytoskeleton is disassembled and granular degeneration proceeds distal to the 
injury site (reviewed by Wang et al., 2001). This is morphologically distinct from 
degeneration that occurs during peripheral neuropathies, such as ALS and SMA. In 
some forms of motor neuron disease, axons retrogradely retract away from the synaptic 
region and are described as ‘dying-back’ (Cavanagh, 1964). An example of dying-
back pathology can be seen in the childhood motor neuron disease, SMA, where a lack 
of survival motor neuron (SMN) protein leads to the progressive loss of lower motor 
neurons (Lefebvre et al., 1995, Rodrigues et al., 1995). Despite morphological 
distinctions between WD and dying-back pathology, the degree of mechanistic 
divergence remains unclear. Understanding the degree to which morphologies also 
relate to different mechanisms would provide a powerful tool to better categorise 
different types of neurodegeneration and will potentially facilitate the identification of 
novel therapeutic targets. 
 
Attempts to decipher the mechanisms of synaptic and axonal degeneration have been 
facilitated by model systems in which the degenerative rate is altered.  For example, 
the discovery of the Wallerian Degeneration slow (Wlds) mutation, so called for its 
ability to delay axonal and synaptic degeneration, has been instrumental in developing 
our understanding of the mechanisms of WD (Lunn et al., 1989, Ribchester et al., 
1995, Mack et al., 2001, Wang et al., 2001, Gillingwater et al., 2004, Gillingwater et 
al., 2002, Gillingwater et al., 2006, Coleman and Freeman, 2010). Wlds confers tenfold 
delays in the rate of WD following axotomy in mice (Coleman, 2005); expression of 
Wlds is sufficient to protect the structural integrity of wild-type axons for up to two 
weeks in vivo (Mack et al., 2001). Indeed, the fortuitous discovery of Wlds mutant 
 
Chapter 1: Expansion and exploration of an ex vivo model of Wallerian degeneration 64 
mouse, has been pivotal to much work that has sought to elucidate the mechanisms of 
WD (Lunn et al., 1989) (see General Introduction 1.1.2 for more detail on Wlds). In 
brief, pathways that regulate WD are thought to be activated by the loss of axonal, 
labile nicotinamide mononucleotide adenylyl-transferase 2 (NMNAT2), a 
nicotinamide adenine dinucleotide (NAD)-synthesising enzyme. Following injury, 
levels of axonal NMNAT2 decline within a few hours when transport or synthesis are 
impaired (Gilley and Coleman, 2010). Endogenous NMNAT2 has been reported to 
prevent spontaneous degeneration of healthy axons, and it is thought that Wlds may 
therefore substitute for NMNAT2 loss after axon injury (Gilley and Coleman, 2010). 
Similar delays in the rate of WD have also been reported when Sterile Alpha and TIR 
motif-containing 1 (Sarm1), is knocked out. In both Drosophila and mice, Sarm1 
knockout also confers protection that phenocopies Wlds (Osterloh et al., 2012), and 
appears to either operate independently or downstream of NMNAT2 (Gilley et al., 
2015). These models have been invaluable in developing our understanding of the 
putative mechanisms of WD. 
 
Recent work has revealed that rates of axonal and synaptic degeneration also can be 
influenced by postnatal age. Significant differences in the response of neonatal versus 
adult mice to peripheral nerve injury and hypoxic insult have been reported (Murray 
et al., 2011). In young adult mice (P25), tibial nerve lesion results in a loss of motor 
nerve terminals within the deep lumbrical (DL) muscles, with just 3% of motor 
endplates remaining innervated after 24 hr (Murray et al., 2011). In contrast, in mice 
aged less than 2 weeks of age, the rate of degeneration is much slower, with 86% of 
endplates remaining innervated after 24 hr (Murray et al., 2011). Synaptic loss in 
response to injury therefore appears to be regulated during postnatal development in 
the DL muscles. Neonatal, murine NMJs also remain structurally intact following 
exposure to an ex vivo model of hypoxia reperfusion injury, with over 99% of 
endplates remaining fully occupied in P2 murine TVA, compared with just 4% in adult 
mice (Murray et al., 2011). 
 
Differential rates of degeneration have been reported between different motor neurons 
pools in humans and in mouse models of motor neuron disease (Bowerman et al., 
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2012). This difference in relative vulnerability has been used as a tool to identify 
transcripts and pathways which can modify the rate of degeneration (Hedlund et al., 
2010, Brockington et al., 2013, Kaplan et al., 2014, Comley et al., 2015, Murray et al., 
2015, Kline et al., 2017, Boyd et al., 2017). Properties that are intrinsic to the motor 
neuron may therefore regulate the rate of axon degeneration. Understanding the 
properties of different groups of motor neurons should better inform us of the 
mechanisms of axon degeneration.  
 
Due to the limited numbers of muscle that have been studied in detail, it remains 
unclear whether there is any variability in the rate of synaptic loss that occurs 
following injury in different muscles. Similarly, it remains unclear whether 
developmental resistance to injury is unique to DL preparations. Investigating synaptic 
degeneration following injury in different muscles in vivo presents challenges; for 
example, the precise and reproducible nerve injury required is difficult in nerves like 
the facial nerve that are not as easily accessible as the sciatic nerve. Furthermore, some 
muscles, such as the abdominal and thoracic muscles, are innervated by multiple spinal 
nerves, meaning consistent and complete denervation is experimentally challenging. 
Determining how different pools of motor neurons respond to injury and how this 
response changes during postnatal development would provide a useful tool to 
investigate the factors that regulate WD, and how this relates to other types of axonal 
and synaptic degeneration. 
 
Here, we optimised and expanded an ex vivo assay to assess the level of synaptic 
degeneration in cranial and thoracoabdominal musculature following nerve injury. 
This was achieved by using an ex vivo model of axon injury, where the nerve is 
transected, and the distal portion along with the musculature that it innervates are 
removed and maintained in oxygenated solutions for 24 hr. Cranial muscle/facial 
nerve and abdominal muscle/intercostal nerve preparations were introduced from 
different postnatal time points. These muscles have not previously been maintained in 
this way, and so this system was optimised to permit their inclusion. The ex vivo setup 
was established within our laboratory and optimised using sciatic nerve/deep lumbrical 
muscle preparations from Wlds mice to confirm that the system could reproduce results 
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described in the literature (Brown et al., 2015, Kline et al., 2019). I then optimised this 
system for ex vivo maintenance of a range of other muscles, which involved precise 
dissection and the resolution of issues including bacterial infection and contamination. 
Antibiotics were introduced to prevent bacterial growth, and were found to have no 
effect on the level of synaptic loss following injury in the cranial muscles. For the first 
time, a range of cranial and thoracoabdominal muscles were maintained. It was found 
that there is a developmental delay in synaptic withdrawal following injury in all 
cranial muscles. Interestingly, some muscles (such as adductor auris longus; AAL) 
showing significantly greater loss than other muscles of the same age (such as levator 
auris longus; LAL). Furthermore, synaptic degeneration was consistently and 
dramatically reduced in the thoracoabdominal muscles compared to the cranial 
muscles. Together these data suggest that factors intrinsic to the muscle/motor neuron 
affect the degree of synaptic degeneration following injury. It was shown that 
increased monoinnervation – used as an indicator of maturational status of the muscle 
– did not correlate increased levels of synaptic loss, although differences in the level 
of mono- and polyinnervation were seen across different muscles. Comparison of the 
degree of synaptic loss following injury with the degree of synaptic loss in a mouse 
model of SMA, revealed strikingly different patterns. This suggests that the factors 
which affect the rate of synaptic degeneration following injury are not the same as 
those which affect the vulnerability of motor neurons to SMA. Finally, by exposing 
muscles from the mouse model of SMA to the ex vivo model of nerve injury, it was 
shown that the presence of SMA-induced synaptic pathology significantly increases 
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1.20 Results  
 
1.20.1 Preliminary ex vivo assay optimisation 
 
An ex vivo model of peripheral nerve injury has previously been used to investigate 
levels of innervation and synaptic function in the DL muscles following tibial nerve 
injury in Wlds and wild-type mice (Brown et al., 2015, Gillingwater et al., 2002, Mack 
et al., 2001, Kline et al., 2019, Murray et al., 2011). Here, the aim was to setup and 
optimise a new ex vivo system that would facilitate the expansion of ex vivo modelling 
into muscles that have not previously been characterised following peripheral nerve 
injury. Levels of synaptic loss following sciatic nerve injury are well-characterised in 
Wlds DL muscles; for example, Brown et al., 2015, reported that after 24 hr ex vivo at 
32°C, the majority of synapses remained functional and around 54% of motor 
endplates remained innervated (Brown et al., 2015). Preliminary work to test the 
system therefore firstly involved maintaining DL nerve/muscle preparations from 
adult Wlds mice at 32°C for 24 hr and quantifying the level of innervation remaining. 
Preparations maintained ex vivo in the ‘new setup’ were compared to equivalent 
preparations that were maintained in a ‘pre-optimised setup’ that has been utilised 
extensively in previous work by Professor Richard Ribchester. Access to the pre-
optimised setup to prepare equivalent preparations was kindly provided by Professor 
Richard Ribchester. This comparison aimed to replicate previous findings to validate 
the new ex vivo setup (Brown et al., 2015).  For ex vivo preparation techniques see 
Materials and Methods, 1.12 Ex vivo explant preparation. 
 
However, initial trials with the new setup yielded problems. Most notably, there was 
a distinct, and unexpected, loss of muscle fibre integrity, with preparations often 
disintegrating within the receptacle. Muscles also had a globular appearance and 
texture, with immunohistochemistry (when possible) revealing a lack of innervation 
that was not consistent with previous work in Wlds DL muscles. Initially, it was 
hypothesised that muscle breakdown could be due to the presence of 
paraformaldehyde fixative residue on equipment or tools. As tools had also used in 
fixed tissue dissection, it was possible that contamination had occurred. To address 
this, new tools were purchased, and separate space and equipment was designated for 
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non-fix work. Pinning tension on the muscle was also reduced to ensure that muscles 
remained in a natural position. These measures did not improve the outcome, and it 
was concluded that there must be other factors influencing assay viability. An odour 
was also identified from specimens, therefore it was next hypothesised that bacterial 
contamination might be compromising the system. Indeed, the introduction of the 
antibiotics gentamicin and kanamycin (50 mg/ml, and 100 mg/ml, respectively) into 
the physiological buffer resolved all integrity issues. From this point, antibiotics were 
included in the oxygenated solution.  
 
After Wlds sciatic nerve/DL muscle preparations were maintained for 24 hrs at 32°C, 
DL muscles in the pre-optimised setup remained 89.72±2.67% innervated, whilst DL 
muscles in the new setup remained 84.54±3.57% innervated (Fig. 1.1). No significant 
differences in innervation were therefore seen between setups, indicating that these 
were comparable (Unpaired t-test; p > 0.25).  
 
To further validate this as an ex vivo model of nerve injury, sciatic nerve/DL muscle 
preparations were maintained from adult wild-type mice. For this work, a maintenance 
temperature of 30°C was selected for wild-type experiments, which was expected to 
produce robust degeneration in adult preparations. Previous publications show that the 
majority of endplates are denervated in wild-type murine DL muscles after 24 hr ex 
vivo (Brown et al., 2015). Previous work has also reported that the rate of synapse loss 
is impacted by developmental age (Kline et al., 2019, Murray et al., 2011). I was able 
to replicate this finding in wild-type murine DL muscles at P15 versus adult (6-7 weeks 
old) (Fig. 1.2). As expected, reduced levels of synaptic loss were seen in younger 
animals following nerve injury in the DL muscles, with the percentage of fully 
occupied endplates found to be 77.68 ± 10.85% at P15 compared to 1.08 ± 1.08% in 
adult mice (Fig. 1.2).  
 
To assess whether antibiotics can influence synaptic degeneration, the percentage of 
fully occupied endplates were quantified following the inclusion of gentamicin and 
kanamycin in the oxygenated mammalian physiological saline after ex vivo 
maintenance of cranial muscle preparations at 30°C for 24 hr. Antibiotics had no 
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significant influence on the levels of innervation in any cranial muscle (Two-way 
ANOVA with Sidak correction; p > 0.2). I conclude that the presence of antibiotics 
has no significant effect on synaptic loss in response to injury (Fig. 1.3).  
 
Overall, I have optimised the ex vivo system of nerve injury, and it was evident that 

















Figure 1.1: Following optimisation of a new ex vivo system, adult WldS DL 
muscle/nerve explants can be maintained at 32°C as expected, with high levels of 
innervation remaining after 24 hr. (A-B) Micrographs with higher magnification 
insets from one plane of focus obtained by standard fluorescent microscopy to show 
innervation remaining in DL muscles of Wlds mice after measures to reduce the 
possibility of fixative contamination and excessive tension, and after antibiotic 
introduction in the new setup (A) and preoptimised setup (B). NMJs are labelled with 
antibodies against neurofilament (NF, green) and synaptic vesicle protein 2 (SV2, 
green), and α-bungarotoxin (BTX, red). Black scale bar: 100μm, white scale bar: 
20μm. (C) Quantification of the percentage of fully occupied endplates remaining in 
the DL muscles following ex vivo nerve injury and maintenance at 32°C. There is no 
significant difference in the percentage of fully occupied endplates between setups. Ns 
= not significant, p > 0.25; Unpaired t-test with Welch’s correction. Pre-optimised, n 
= 11 and new setup, n = 10 muscles. Error bars represent mean ± SEM. 
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Figure 1.2: Developmental regulation is present in the DL muscles of wild-type mice 
following injury and ex vivo at 30°C for 24 hr. The percentage of fully occupied 
endplates in DL muscles at P15 and in adults (6-7 weeks old) were quantified, where 
age refers to the age of the animal at the time of dissection. Note that developmental 
regulation of synapse loss is evident, with significantly less fully occupied endplates 
seen in adult mice following injury. ***p < 0.001; Unpaired t-test with Welch’s 
correction. N = 6, 3 muscles at P15 and adult time points respectively. Error bars 
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Figure 1.3: The introduction of antibiotics has no effect on the level of synapse loss 
in response to ex vivo injury at P15 in wild-type cranial muscles when maintained 
at 30°C for 24 hr. Quantification of the percentage of fully occupied endplates 
remaining with and without antibiotics in a range of cranial muscles (levator auris 
longus rostral/caudal band [LALr/c], auricularis superior [AS] and abductor auris 
longus [AAL]). Note that there is no significant difference in the percentage of fully 
occupied endplates remaining after ex vivo nerve injury in preparations suspended in 
oxygenated solution with or without antibiotics in any muscle. Ns = not significant, p 
> 0.2; Two-way ANOVA with Sidak correction. N = 4 muscles in all cases. Error bars 
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1.20.2 Synaptic loss following injury is developmentally regulated and non-
uniform in the cranial muscles of the mouse 
 
It remains unclear whether developmental regulation of synaptic loss in response to 
injury is unique to the DL muscles or whether developmentally regulated delays in 
synaptic withdrawal also occurs in other muscle preparations. Rates of synaptic 
withdrawal following injury were therefore examined during the critical time window 
of P15–P25, using an ex vivo model of nerve injury (see Materials and Methods, 1.12 
Ex vivo explant preparation for details). Nerve-muscle preparations comprising facial 
nerve (CN VII) branches innervating the cranial musculature (comprising rostral and 
caudal bands of levator auris longus [LALr/LALc, respectively], abductor auris longus 
[AAL] and auricularis superior [AS]) were isolated and maintained in oxygenated 
physiological solution at 30°C for 24 hr. It was hypothesised that synapse loss would 
be slower in younger mice, and that the level of synaptic loss would differ between 
different muscles. This was tested this by analysing the percentage of fully occupied 
endplates following 24 hr exposure to the ex vivo model of nerve injury at different 
postnatal ages. 
 
The percentage of fully innervated or ‘occupied’ endplates remaining in 
immunostained muscles from P15–P25 mice, 24 hr after ex vivo nerve injury were 
quantified (Fig. 1.4 to 1.5). Note that all ages refer to the age at dissection. The data 
show that postnatal age affected the degree of synapse loss in all preparations analysed 
(Fig. 1.4 to 1.5). For example, at P15, the LALr remained highly innervated, with 
77.05 ± 7.05% (mean ± SEM) of endplates covered by motor nerve terminals. As 
expected, levels of innervation 24 hr after injury declined with age to 58.75 ± 6.06% 
innervation in preparations from mice aged P18, to 13.81 ± 10.4% aged P21, and 7.53 
± 2.84% aged P24/5. The LALc and AS muscles followed similar patterns. However, 
significantly more denervated endplates in AAL were seen from the outset, with only 
23.56 ± 3.85% innervation remaining at P15. This declined with mouse age to 21.02 
± 4.96% at P18, whereas less than 1.3% innervation remained at P21 and P24/5 (Fig. 
1.5). As both AAL and LAL are homogeneously fast twitch muscles, and AS 
predominantly slow twitch, these differences cannot be attributed to fibre type. This 
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data suggests that there are other intrinsic properties of nerve or muscle that influence 




Figure 1.4: Levels of synaptic loss following injury are developmentally regulated 
and non‐uniform in cranial muscles of the mouse. (A) Confocal micrographs 
showing NMJs labelled with antibodies against NF (green) and SV2 (green), and BTX 
(red) from cranial muscles (levator auris longus rostral/caudal band [LALr/c], abductor 
auris longus [AAL], auricularis superior [AS]) that have been maintained ex vivo at 
30°C for 24 hr. Postnatal age refers to the age of the animal at the time of dissection. 
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Figure 1.5: Quantification of the percentage of fully innervated NMJs remaining 
after injury and ex vivo maintenance at 30°C for 24 hr. (A) Quantification of the 
percentage of fully innervated motor endplates in cranial muscle bands between P15 
and P24/5. Note that the percentage of fully occupied endplates decreases as postnatal 
age increases, supporting the finding that the response to injury is developmentally 
regulated. (B) Quantification of the percentage of fully occupied endplates in cranial 
muscles grouped by postnatal age at the time of ex vivo nerve injury. Note that there 
is a significant reduction in the percentage of fully occupied endplates in the AAL at 
both P15 and P18 time points in comparison to all other muscles. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001; one-way ANOVA with Tukey’s correction. All 
comparisons where no statistical result is shown were not significantly different. N = 
10 at P15 and P24/5; n = 18/6 for the LALr/all other muscles at P18; and n = 4/5 at 
P21 for the AAL/all other muscles. Error bars represent mean ± SEM. 
 
1.20.3 Levels of synaptic loss are uniformly reduced following injury in the 
thoracoabdominal muscles of the mouse 
 
Data thus far suggest that the rate of synaptic loss is slower in younger animals in a 
range of muscles. However, differences between the rates of synaptic withdrawal 
observed in the AAL at different time points, led us to ask whether there would be 
similar differences within thoracoabdominal musculature. To investigate the response 
to injury in these muscles, TVA and TS muscles were examined 24 hr after ex vivo 
nerve injury using the same protocol as for cranial muscles. In contrast to cranial 
preparations, both the TVA and TS showed high levels of NMJ innervation across all 
time points analysed (Fig. 1.6). There was no significant difference in the percentage 
of fully occupied endplates at any time point; in all cases, the muscle remained over 
77% innervated (one-way ANOVA with Tukey correction, p ≥ 0.09) (Fig 1.6). 
 
Taken together, the data indicate that there are properties intrinsic to the muscle, and/or 
motor neuron, that can influence the extent of synaptic withdrawal in response to 
injury during the postnatal period. In this case, there must be properties that are 
intrinsic to the throacoabominal muscles (and/or nerves that serve these muscles) that 
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are responsible for conferring significant and remarkable delays to synaptic 
withdrawal. The thoracoabdominal ex vivo preparation therefore represents an 
intriguing model system to further discern the factors and mechanisms that that govern 
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Figure 1.6: Minimal synaptic loss is observed following injury across all time points 
analysed in thoracoabdominal musculature. (A) Confocal micrographs showing 
NMJs labelled with antibodies against neurofilament (NF, green) and synaptic vesicle 
protein 2 (SV2, green), and α-bungarotoxin (BTX, red) from transversus abdominis 
[TVA] and triangularis sterni (TS) muscles which have been maintained ex vivo at 
30°C for 24 hr. Postnatal age refers to the age of the animal at the time of dissection. 
Note that the majority of endplates remain fully occupied at all ages examined. Scale 
bar: 20μm. (B) Quantification of the percentage of fully innervated motor endplates 
after ex vivo nerve injury in the TVA and TS at P15, P18, P21, and P24/5. The 
percentage of fully occupied endplates remains high across all time points and there is 
no significant difference within muscles at any time point. Ns = not significant, p ≥ 
0.09; one-way ANOVA with Tukey’s correction. TVA, n = 6, 18, 4, and 6 muscles, at 
P15, 18, 21, and 24/5, respectively, and n = 6, 6, 6, and 4 in the TS at P15, 18, 21, and 
24/5, respectively. Error bars represent mean ± SEM. 
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1.20.4 Synaptic loss following injury is minimal in the thoracoabdominal 
muscles at 32°C 
 
Thoracoabdominal musculature/intercostal nerve preparations showed resistance to 
WD across all time points analysed. However, the extent of this resistance remained 
unclear. Previous work by Brown et al., 2015 has shown that after 24 hr exposure at 
32°C, the majority of endplates lack innervation in the hindlimb muscles of wild-type 
(WT) animals (Brown et al., 2015). Based on previous findings that have shown the 
rate of WD to be temperature-dependent (Tsao et al., 1999), it was hypothesised that 
raising the temperature would lead to robust synapse loss. To further test the response 
of the thoracoabdominal explants, the ex vivo temperature was therefore raised to 
32°C.  
 
Remarkably, it was found that raising the temperature had no effect on the level of 
synaptic innervation remaining in the thoracoabdominal musculature (Fig 1.7) 
(Unpaired t-test with Welch’s correction, p > 0.15 and p > 0.25 for TVA and TS 
respectively). At 30°C, 87.66 ± 6.03% and 89.98 ± 5.06% of endplates remained fully 
innervated, and at 32°C, 97.75 ± 1.46% and 97.10 ± 1.72% of endplates remained fully 
innervated after 24 hr in the TVA and TS muscles respectively (Fig. 1.7). The 
thoracoabdominal muscles therefore demonstrate a remarkable resistance to WD. 
These muscles therefore represent intriguing candidates to further investigate factors 
capable of conferring this comparative protection and regulating axonal and synaptic 
degeneration. 
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Figure 1.7: Minimal synaptic loss is observed following injury and ex vivo at 30 or 
32°C in the thoracoabdominal muscles of wild-type mice at P25. Quantification of 
the percentage of fully innervated motor endplates after ex vivo nerve injury and 
maintenance at 30 or 32°C in the transversus abdominis [TVA] and triangularis sterni 
[TS] muscles, where P25 refers to the age of the animal at the time of dissection. Note 
that an increase in temperature has no significant effect on the percentage of fully 
occupied endplates in either muscle. Ns = not significant, p > 0.15 for TVA and p > 
0.25 for TS; unpaired t-test with Welch’s correction. At 30°C in TVA, n= 6; for all 
other groups n=4 muscles. Error bars represent mean ± SEM. 
 
1.20.5 An increase in synaptic maturation does not correlate with synaptic 
vulnerability to injury 
 
It is clear that some muscles exhibit significantly more synaptic loss than others in 
response to injury. In general, increases in age lead to progressively more synaptic loss 
following injury across this time window. Increased synaptic loss therefore appears to 
temporally correlate with the maturation of the neuromuscular system which occurs 
across the first 2-3 weeks of life. During this time, extensive remodelling occurs as 
neuromuscular junctions shift from being predominantly polyinnervated structures, to 
a mature monoinnervated neuromuscular system that prevails into adulthood. This 
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raises the question as to whether differences in maturational rates might contribute to 
the differential responses to injury. It was hypothesised that muscles that reach 
maturity at an earlier time point would be more vulnerable to synaptic loss following 
injury. If this is true, muscles that demonstrate more profound synaptic loss after 
injury, such as the AAL, would be expected to mature at an earlier timepoint in 
development. It follows that the AAL would be predicted to exhibit higher levels of 
monoinnervation at P10 than the other cranial muscles. In line with this, it would also 
be expected that muscles with comparable resistance after injury, such as the TVA/TS, 
would have higher degrees of polyinnervation. 
 
Contrary to this however, in wild-type mice at P10, it was found that muscles that 
exhibit extensive synapse loss in response to injury, such as the AAL, had significantly 
lower levels of monoinnervation than muscles that are comparatively resistant, like the 
TVA. To exemplify, AAL was 49.18 ± 2.67% monoinnervated, whilst the TVA was 
82.94 ± 2.65% monoinnervated (Fig. 1.8). Significant differences were also seen in 
levels of monoinnervation between LALr and LALc, and between LALc and AS, 
despite these muscles exhibiting similar profiles in response to injury (Fig 1.8). This 
suggests that increased maturity does not explain incidences of increased synaptic loss 
following injury. In fact, there is a trend towards the opposite, with muscles that are 
more mature appearing to exhibit less synaptic loss following injury. 
 
Overall, despite significant intermuscular differences in the level of polyinnervation 
across muscles at P10, it is concluded that increased NMJ maturity does not correlate 
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Figure 1.8: Neuromuscular junction maturity in wild-type mice varies between 
different muscles at P10, but does not correlate with synaptic vulnerability to injury. 
Note that here, NMJ maturity is defined by the number of axonal inputs to motor 
endplates, where 1 input (monoinnervation), represents mature NMJs (See Materials 
and Methods, 1.17 Quantification and statistical analysis for details). (A) Confocal 
micrograph showing example NMJs to exemplify criteria for input quantification. 
NMJs are labelled with antibodies against neurofilament (NF, green) and synaptic 
vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, red). The blue arrowhead 
highlights an input that would be considered ‘monoinnervated’, whereas the yellow 
arrowhead indicates multiple inputs (in this case, 2) that would be considered 
‘polyinnervated’. Scale bar: 20μm. (B) Confocal micrographs showing innervation of 
AAL, LALr and TVA in wild-type animals at P10. Again, NMJs are labelled with 
antibodies against neurofilament (NF, green) and synaptic vesicle protein 2 (SV2, 
green), and α-bungarotoxin (BTX, red). Scale bar: 20 µm. (C) Quantification of the 
percentage of motor endplates with 1, 2 or more than 3 axonal inputs in a range of 
wild-type muscles at P10. Statistics refers to the single input (monoinnervation) group 
only. It is important to bear in mind that NMJs of the AAL have already been shown 
to be more vulnerable to injury than those of LALr or TVA at younger age points (See 
Chapter 1, Results, Figure 1.5). Note that there are significant differences in NMJ 
maturity across different muscles. Statistics refer to endplates receiving 1 input only 
where **p = 0.005, ***p < 0.001 ****p < 0.0001. All comparisons where no statistical 
result is shown were not significantly different. Two-way ANOVA with Sidak 









Chapter 1: Expansion and exploration of an ex vivo model of Wallerian degeneration 84 
1.20.6 Patterns of differential synaptic stability in Wallerian degeneration contrast 
with patterns of vulnerability in a mouse model of Spinal Muscular Atrophy 
 
Variability in the levels of synaptic degeneration between different muscles, has 
previously been reported in mouse models of motor neuron disease. For instance, in 
the Smn2B/− mouse model of SMA, the TVA muscle is highly vulnerable and displays 
high levels of synaptic loss, whereas the LALr and AAL muscles are relatively spared, 
with little synaptic loss even at late stages of disease (Murray et al., 2015). To 
investigate how synaptic stability differs between disease and injury, levels of 
innervation remaining in muscles from end-stage (P18) Smn2B/− mice in vivo were 
compared with levels of innervation remaining in homologous muscles from wild-type 
animals after ex vivo nerve injury. This provided insight into how synaptic responses 
differ following these distinct insults. 
 
In line with previous work undertaken by Murray et al., 2015, here the LALr and AAL 
of Smn2B/− mice were largely spared from dying-back neuropathy in vivo, with over 
98% of motor endplates remaining fully innervated at P18 (Fig. 1.9 and 1.10). 
Contrasting this, 24 hr after ex vivo nerve injury in P18 wild-type mice, the LALr was 
47.23 ± 2.58% innervated and the AAL only 21.02 ± 4.96% innervated (Fig. 1.10). 
These cranial muscles therefore appear to be more vulnerable to injury than in an SMA 
mouse model (Mann–Whitney U-test, p ≤ 0.0007). Also in line with descriptions by 
Murray et al., in the Smn2B/− model, the TVA is vulnerable to dying-back pathology in 
vivo, with 62.11 ± 3.78% innervation remaining at P18, compared with 99.54 ± 0.29% 
innervated in wild-type age-matched mice 24 hr after ex vivo nerve injury (Fig. 1.10). 
This suggests that the TVA exhibits less extensive synaptic loss following injury than 
in an SMA mouse model (Mann-Whitney U test, p = 0.0002). Thus, the factors 
responsible for determining relative synaptic stability following both nerve injury and 
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Figure 1.9 : Confocal micrographs that show differences in synaptic loss in response 
injury or disease conditions. NMJs are labelled with antibodies against neurofilament 
(NF, green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, 
red) showing innervation of abductor auris longus (AAL), levator auris longus rostral 
band (LALr), and transversus abdominis (TVA) following ex vivo nerve injury in wild-
type (WT) animals at P18 (Nerve injury/WT group) and under disease conditions from 
Smn2B/− mice at P18 (Smn2B/- group). Nerve/muscle explants from the ‘nerve injury’ 
group were maintained ex vivo at 30°C for 24 hr. Scale bar: 20μm.  
 
 
Figure 1.10: Quantification of the percentage of fully innervated NMJs remaining 
in injury or disease conditions. Quantification of the percentage of fully innervated 
motor endplates in the AAL, LALr, and TVA after ex vivo nerve injury in WT vs. 
Smn2B/− mice reveals opposing patterns of synaptic loss. In the Smn2B/−  mouse, the 
LALr and AAL cranial muscles are spared from degeneration in comparison to the 
TVA muscle. Following ex vivo nerve injury, LALr and AAL show high levels of 
synapse loss, whereas the TVA appears preserved. Ns = not significant, ***p < 0.001; 
Mann–Whitney U-test. Note that for the AAL, n = 9, 6; for the LALr, n = 8, 6; and for 
the TVA, n = 10, 6 muscles for Smn2B/− and nerve injury/WT groups, respectively. 
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1.20.7 Reduced Smn levels do not influence the incidence of synaptic withdrawal 
following injury in the LALr cranial muscle of the mouse 
 
Previous work in Smn-independent motor neuron diseases, like ALS, have indicated 
that Smn could be a disease modifier. For example, SOD1 mutant mice with genetic 
reductions in Smn display a more severe phenotype, whilst overexpression of Smn has 
been shown to ameliorate the ALS phenotype (Turner et al., 2009, Turner et al., 2014), 
suggesting SMN can modify synaptic stability. I therefore asked whether reductions 
in SMN levels could influence synaptic loss after injury. To address this, cranial 
nerve/muscle preparations were isolated and maintained from wild-type mice and from 
Smn2B/− mice. In Smn2B/- mice, cranial muscles are classified as selectively resistant, in 
that even at end-stage of disease, there is no synapse loss evident (Fig. 1.11). 
Therefore, these muscles have reduced Smn levels but no resultant synaptic loss. 
Levels of denervation in the LALr were compared under three conditions: LALr from 
wild-type after ex vivo nerve injury; LALr from Smn2B/−; and LALr from Smn2B/− after 
ex vivo nerve injury. 
 
In this disease-resistant muscle, as described above, minimal denervation was found 
in vivo in Smn2B/− mice, with 98.28 ± 0.79% of endplates remaining fully occupied. In 
wild-type mice, as expected, ex vivo nerve injury induced extensive denervation, with 
47.12 ± 4.08% of endplates remaining fully occupied. In muscles from Smn2B/− mice 
subject to ex vivo nerve injury, it was found that the level of synaptic loss was 
comparable to wild-type levels, where 58.55 ± 3.53% of endplates remaining fully 
occupied (Kruskal-Wallis with Dunn’s correction, p = 0.031; Fig. 1.11). It was 
concluded that in the LALr, where synapse loss due to Smn deficiency is minimal, the 
synaptic loss caused by nerve injury is not altered. As Smn levels are reduced in this 
model, despite the lack of NMJ pathology, it follows that Smn levels do not affect 
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Figure 1.11: Reduced SMN levels have no effect on the level of synaptic 
degeneration following injury in the LALr cranial muscle of the mouse. (A) 
Confocal micrographs showing NMJs labelled with antibodies against neurofilament 
(NF, green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, 
red) from levator auris longus rostral band [LALr] in wild-type animals after ex vivo 
nerve injury (nerve injury/WT), in Smn2B/− mice and in Smn2B/− mice after ex vivo nerve 
injury (nerve injury/ Smn2B/−). In nerve injury/WT and nerve injury/ Smn2B/− conditions, 
LALr muscles were maintained ex vivo at 30°C for 24 hr. Scale bar: 20μm. (B) 
Quantification of the percentage of fully occupied endplates in LALr in nerve 
injury/WT, Smn2B/− , and nerve injury/Smn2B/− conditions. The percentage of fully 
occupied endplates after nerve injury in Smn2B/− mice is not significantly different than 
after nerve injury in wild-type animals. *p < 0.05, ***p < 0.001, ns = not significant. 
For all comparisons with the Smn2B/− group, Kruskal–Wallis with Dunn’s correction 
was used to account for non-normally distributed data; otherwise, a one-way ANOVA 
with Tukey’s correction was used. Note that n = 6, 8, 6 for the nerve 
injury/WT, Smn2B/− and nerve injury/ Smn2B/− groups, respectively. Error 
bars: mean ± SEM. 
 
1.20.8 The presence of dying-back pathology increases the level of synaptic loss 
following injury in the TVA muscle of the mouse 
 
Previous work has shown that dying-back pathology can delay WD (Murray et al., 
2008b). Therefore, to investigate the relationship between synaptic loss that occurs in 
injury versus disease, I also investigated whether there was any alteration in the level 
of synaptic loss following injury in the presence of dying-back pathology. The TVA 
muscle of the Smn2B/− mouse model exhibits high levels of synaptic pathology, 
including denervation, pre-synaptic swelling, and post-synaptic shrinkage at end-
stages of disease (P18). Levels of denervation in the TVA were compared under three 
conditions at P18: TVA from wild-type after ex vivo nerve injury; TVA from Smn2B/−; 
and TVA from Smn2B/−  after ex vivo nerve injury.  
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It was found that ex vivo nerve injury of the TVA muscle from Smn2B/− mice resulted 
in a significant reduction in the percentage of fully occupied endplates, to 29.22 ± 
6.23% in comparison with wild-type TVA with ex vivo nerve injury (99.54 ± 0.29% 
of endplates fully innervated, Kruskal–Wallis with Dunn’s correction, p < 0.0001) and 
to Smn2B/−  in vivo (61.45 ± 3.98% of endplates fully innervated, Kruskal-Wallis with 
Dunn’s correction, p = 0.0001) in isolation (Fig. 1.12). Overall, as it has already been 
established that Smn reduction alone is not sufficient to increase levels of synaptic 
loss, it follows that the increase in synapse loss observed here is induced by the 
presence of disease-induced synaptic pathology.  
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Figure 1.12: Presence of synaptic pathology in the Smn2B/− mouse significantly 
amplifies the level of synaptic loss induced by injury in the TVA muscle. (A) 
Confocal micrographs showing NMJs labelled with antibodies against neurofilament 
(NF, green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, 
red) from transversus abdominis (TVA) at P18 in wild-type animals after ex vivo nerve 
injury (nerve injury/WT), in the Smn2B/− mice, and in Smn2B/− after ex vivo nerve injury 
(nerve injury/Smn2B/−) conditions, respectively. In ex vivo conditions, TVA muscles 
were maintained ex vivo at 30°C for 24 hr. P18 refers to the postnatal age of the animal 
at the time of dissection. Scale bar: 20μm. (B) Quantification of the percentage of fully 
occupied endplates in the TVA in nerve injury/WT, Smn2B/−, and nerve injury/Smn2B/− 
conditions. The percentage of fully occupied endplates following injury in Smn2B/− 
mice was significantly increased in comparison with either wild-type injury or Smn2B/− 
conditions in isolation. *p < 0.05, ***p = 0.0001, ****p < 0.0001. For all comparisons 
with the nerve injury/WT group, Kruskal–Wallis with Dunn’s correction was used to 
account for non-normally distributed data, otherwise a one-way ANOVA with Tukey’s 
correction was used. Note that n = 6, 10, 6 muscles for the nerve injury/WT, Smn2B/−, 
and nerve injury/Smn2B/− groups, respectively. Error bars: mean ± SEM. 
 
1.20.9 Journal of Anatomy Publication Declaration 
 
Some work presented within this chapter has been published as a paper in the Journal 
of Anatomy entitled: The rate of Wallerian degeneration following injury is influenced 
by postnatal maturity, motor unit specific properties and the presence of underlying 
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1.21 Discussion 
 
1.21.1 Overview of Results 
 
Here, an ex vivo assay has been optimised and applied to investigate rates of synaptic 
withdrawal following traumatic nerve injury in a range of muscles that have not been 
examined in this context previously. Optimisation of an ex vivo assay demonstrated a 
capacity for this model of peripheral nerve injury to be expanded to a range of muscles 
that have not been examined previously. Applying this model found that increasing 
postnatal age led to a progressive decline in the level of innervation remaining 
following injury in the cranial muscles, suggesting that synaptic stability is 
developmentally regulated in these muscles. It has also been shown that levels of 
synaptic loss are non-uniform in the cranial muscles, with a significant increase in the 
rate of synaptic withdrawal in response to injury in the AAL at younger ages when 
compared with other cranial muscles. Remarkably high levels of innervation persisted 
in the thoracoabdominal muscles after injury across P15–P25, and this preservation 
remained evident even at 32°C. Results suggest that muscle and/or motor neuron 
intrinsic properties can affect synaptic stability following injury. Analyses of NMJ 
maturational status did not reveal a correlation between increased maturity and 
increased synaptic loss following injury, although there was a trend towards muscles 
with less mature NMJs being more susceptible to synaptic loss. Furthering this, 
comparison of the patterns of relative synaptic stability following injury to the patterns 
of synaptic vulnerability in a mouse model of SMA suggests that the factors which 
affect synaptic stability following injury are distinct from those in peripheral 
neuropathies such as SMA. By exposing a muscle from a mouse model of SMA that 
is resistant to dying-back pathology to the ex vivo nerve injury assay, it was found that 
synaptic loss in response to injury is SMN-independent. Furthermore, exposure of a 
muscle with ongoing dying-back pathology to the assay has demonstrated that the 
presence of dying-back pathology accelerates the rate of synaptic loss in response to 
injury. Overall, I have provided and characterised a model system of peripheral nerve 
injury in a range of different muscles that will facilitate the investigation of factors that 
can alter rates of synaptic degeneration temporally and regionally. I have also provided 
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an indication of downstream, mechanistic convergence in degenerative mechanisms 
in injury and disease scenarios; this could ultimately aid in the identification of 
common targets to slow synaptic degeneration under different physiological 
conditions. 
 
1.21.2 Synaptic stability following injury is governed by properties that are 
intrinsic to the muscle and/or motor neuron 
 
This work suggests that synaptic withdrawal in response to injury is influenced by 
developmental age in a range of muscles that can now be maintained ex vivo. Across 
all four cranial muscles analysed, there was a marked increase in the incidence of 
denervated endplates with increasing postnatal age. These findings are in line with 
previous work that has shown that following either peripheral nerve injury or hypoxic 
insult, resistance is gradually lost across the first few weeks of life as the muscle 
transitions to adult levels of vulnerability (Murray et al., 2011). Furthermore, some 
muscles, like the AAL, reach adult levels of degeneration at an earlier time point, 
whereas others, such as the TVA, remain comparatively stable following injury, even 
at P25 (Murray et al., 2011). This suggests that postnatal maturity as well as properties 
specific to the muscle and/or motor neuron, are capable of regulating synaptic 
degeneration following injury. The expansion of the ex vivo model of peripheral nerve 
injury to allow the inclusion of a range of different muscles that respond differently 
will provide an opportunity to discern mechanisms and regulators of synaptic 
degeneration in injury and disease. 
 
Various genetic mutations have been shown to alter the rate of WD in animal models, 
and have increased our understanding of the mechanisms of WD. As mentioned 
previously, this includes Wlds and SARM1 knockout, both of which can delay axonal 
and synaptic degeneration significantly after injury (Lunn et al., 1989; Ribchester et 
al., 1995; Mack et al., 2001; Wang et al., 2001; Gillingwater et al., 2002, 2004, 2006; 
Coleman, 2005; Coleman and Freeman, 2010; Gilley and Coleman, 2010; Osterloh et 
al., 2012; Di Stefano et al., 2015; Gilley et al., 2015). Work presented here highlights 
the presence of differential responses both at different ages and between different 
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muscles. It is interesting to note that subcellular, compartmental differences have also 
been reported in the response to injury within the central nervous system, suggesting 
that differential responses to injury may also feature centrally (Sajadi et al., 2004). 
Such differences in degenerative rates can help us to discern the factors that might 
govern the rate of synaptic degeneration and identify novel targets aiming to slow 
neurodegeneration.  
 
Differences in synaptic vulnerability in motor neuron disease have been exploited to 
investigate the underlying factors that may be responsible making motor neurons 
vulnerable in motor neuron disease. Transcriptional profiling of differentially 
vulnerable motor neurons has helped identify transcripts and pathways which can 
modify the rate of degeneration (Hedlund et al., 2010; Brockington et al., 2013; Kaplan 
et al., 2014; Comley et al., 2015; Murray et al., 2015; Boyd et al., 2017; Kline et al., 
2017).  Work by Hedlund et al., 2010 in rats has highlighted that there are 
transcriptome level differences in populations of motor neurons that are generally 
spared in conditions like ALS and SMA (Hedlund et al., 2010). Similar findings have 
also been shown in mouse model of SMA, where comparative gene expression 
profiling of vulnerable and resistant populations of motor neurons has found that a 
modified bioenergetic profile, particularly relating to mitochondrial biogenesis (which 
will be discussed further in Chapter 2), can modulate motor neuron vulnerability (Boyd 
et al., 2017). Through cross-species comparisons, the Murray laboratory has also 
highlighted that differential gene expression can commonly modify neurodegenerative 
phenotypes (Kline et al., 2017). In this work, alpha-synuclein and stathmin 1 were 
identified as phenotypic modifiers of pathology in motor neuron diseases. Importantly, 
when levels of alpha-synuclein or stathmin 1 were increased, disease severity was 
reduced and NMJ pathology ameliorated (Kline et al., 2017; Villalon et al., 2019). 
Overall, it is clear that identifying factors that can modify the rate of synaptic and 
axonal degeneration is invaluable in the search for targets that can modify the rate of 
neurodegeneration. This emphasises the value of the expanded ex vivo model as a tool 
to identify and investigate factors that can modify the rate of synaptic and axonal 
degeneration. Any factor that can alter the degenerative rate represents an opportunity 
to study the mechanisms of degeneration in both disease and injury.  
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Here it has been shown that muscle and/or motor neuron-specific properties are 
another factor that can influence the rate of synaptic loss, with responses varying 
between muscles. This is unlikely to be attributed to muscle fibre type. For example, 
both LAL and AAL are predominantly fast twitch muscles, but they display a marked 
difference in synaptic stability following injury (Erzen et al., 2000; Murray et al., 
2008a, 2010a, 2010b). Intermuscular differences in maturational status do exist, as 
evidenced by differences in the level of mono- and polyinnervation across different 
muscles, however it remains unclear whether differences in NMJ maturity could be 
directly responsible for determining susceptibility to synaptic loss following injury. In 
wild-type rats and in Wlds mice, the rate of synaptic loss has been shown to be 
dependent on nerve stump length, with failure of neuromuscular transmission 
occurring more rapidly when nerve stump length is shorter (Slater, 1966; Ribchester 
et al., 1995). However, the differences reported here cannot be attributed to differences 
in nerve stump length, as stump length is the same for all of the cranial muscles.  
 
A promising avenue which may explain the differing synaptic stability following 
injury in different muscles at different postnatal ages, is differences in mitochondrial 
bioenergetics. In a recent study, profiling of the nerve and muscle proteome in tibial 
nerve/lumbrical muscles between P12 and P24, highlighted a consistent up-regulation 
in proteins involved with mitochondrial bioenergetics in both muscle and nerve. 
Interestingly, similar profiles have been observed in the tibialis anterior muscle, and 
during postnatal development of the heart (Puente et al., 2014; Kim et al., 2019). 
Importantly, in our previous work it was also shown that inhibition of complex I of the 
mitochondrial respiratory chain could slow axon degeneration, whereas 
pharmacological activation of oxidative phosphorylation accelerated synaptic 
degeneration (Kline et al., 2019). It will be important to investigate mitochondrial 
bioenergetics in the range of ages and muscles investigated in this study, to determine 
whether this can explain the differences in synaptic stability observed. This will help 
identify factors responsible for conferring rate differences and will provide insight into 
the mechanisms of synaptic degeneration. This may further aid in the identification of 
targets to manipulate the rate of degeneration. The role of mitochondria in influencing 
the rate of synaptic loss following injury will be considered in Chapter 2. 
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1.21.3  To what extent do mechanistic commonalities exist between synaptic 
withdrawal in injury and dying-back neuropathy? 
 
Following traumatic injury in the Smn2B/− mouse model of SMA, I assessed the 
influence on the level of synaptic loss. Selective vulnerability is a known feature in 
this disease model, therefore both die-back-resistant (LALr) and die-back-vulnerable 
(TVA) muscles were studied (Murray et al., 2015). As synaptic withdrawal after injury 
was amplified in the presence of a die-back, it is concluded that the presence of dying-
back pathology can increase synaptic loss in following injury. 
 
Initially, these results are perhaps surprising based on previous work where the 
presence of dying-back pathology has reduced synaptic loss and axon fragmentation 
following nerve injury. For example, Wasted (Wst) is a spontaneous, autosomal 
recessive mutation in which the gene encoding translation factor eEF1A2 is deleted 
(Shultz et al., 1982). Wst mice display a dying-back neuromuscular phenotype and 
have a lifespan of around 30 days (Shultz et al., 1982, Newbery et al., 2005, Murray 
et al., 2008b). It has been found that whilst loss of translation elongation factor 
eEF1A2 causes dying-back pathology at the NMJ, loss of this factor can also delay the 
initiation and progression of WD following axotomy of the tibial nerve (Murray et al., 
2008b). This is in contrast to my findings where the presence of a die-back neuropathy 
accelerated WD. Therefore, although differing requirements for eEF1A2 expression 
may represent a mechanistic distinction between injury-induced degeneration and 
dying-back pathology, work presented here suggests that there may be convergence in 
degenerative pathways further downstream. 
 
Commonalities between WD and dying-back neuropathies have been reported in 
animal models of motor neuron disease.  For example, WldS has been found to be 
protective in some motor neuron disease and peripheral neuropathy models, 
suggesting that there may be some convergence between degenerative mechanisms. 
Similarly, in mice with progressive motor neuronopathy, WldS expression also delays 
dying-back pathology (Ferri et al., 2003). It is worth noting that protection conferred 
by Wlds during dying-back neuropathy is not universal. Work in SOD/WldS mice, a 
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mouse model of ALS, has shown that this levels of motor axon loss remain unaffected, 
although modest delays in NMJ degeneration and prolonged survival were reported 
(Fischer et al., 2005). Similarly, work undertaken by Velde et al., has also evidenced 
that WldS cannot slow disease onset, motor neuron death, axonal degeneration or 
reduce synapse loss in a mouse model of ALS (Vande Velde et al., 2004). In mouse 
models of SMA, the WldS gene did not alter the onset or progression of disease 
phenotype (Rose et al., 2008, Kariya et al., 2009). Delays in neurodegeneration have 
been reported in a number of other diseases however, including animal models of 
Parkinson’s and demyelinating diseases that possess the WldS mutation (Sajadi et al., 
2004, Conforti et al., 2014).  
 
Several similarities have also been highlighted at the cellular level between WD and 
dying-back pathology, including poor axonal transport, mitochondrial dysfunction, 
and an increase in intra-axonal calcium (reviewed by Coleman, 2005; Conforti et al., 
2014). Our recent proteomic work in mice has also identified alterations in 
mitochondrial bioenergetics that coincide with delays in the change in level of synaptic 
loss in response to injury during postnatal development in the hindlimb (Kline et al., 
2019, see Appendix 2 for co-author paper). Furthermore, we demonstrated that 
Complex I inhibition could delay WD, and pharmacological activation of oxidative 
phosphorylation accelerated WD (Kline et al., 2019). Targeting bioenergetic pathways 
by enhancing mitochondrial bioenergetics has also been found to rescue motor axon 
defects in a model of SMA (Boyd et al., 2017). Alterations in mitochondrial dynamics 
may therefore represent a promising, and perhaps uniting factor in WD and dying-back 
neuropathy. The role of mitochondria will be considered in Chapter 2. 
 
Overall, the ex vivo system optimised and described here will provide a valuable model 
to aid in the identification of factors that are capable of influencing the rate of 
neurodegeneration under different physiological conditions. Anything that can alter 
the rate of degeneration can inform of mechanism, therefore the range of muscles now 
available for study and characterised in terms of WD present intriguing opportunities 
to further study the mechanisms and regulators of synaptic degeneration. Ultimately 
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this could aid in the identification of targets that are common across multiple diseases, 
and that may slow degeneration under different physiological conditions. 
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1.22 Chapter overview and principle findings 
 
This chapter aimed to examine changes in mitochondrial proteins and number during 
early postnatal development, where rates of synaptic degeneration following injury 
progressively accelerate. Here, I analysed two independent proteomic screens and 
highlighted key changes in mitochondrial proteins across the first few weeks of life. I 
then examined mitochondrial protein levels in a range of other muscles and nerve to 
determine if similar patterns of changes in mitochondrial proteins could be observed. 
Overall, I sought to investigate whether changes in mitochondrial proteins or number 
correlated with accelerations in the rate of synaptic degeneration across development, 





• Analyses of two independent proteomic screens reveal that mitochondrial 
proteins increase across postnatal development. 
• These increases in mitochondrial proteins can be accounted for by an increase 
in mitochondrial number in nerve, but not in muscle. 
• Expanding analysis to include a range of nerves and muscle reveals changes in 
mitochondrial complex protein levels do not correlate with the rate of synaptic 
degeneration during postnatal development. 
• Comparison of muscles with differential rates of synaptic degeneration reveals 
that the rate of degeneration does not correlate with changes in mitochondrial 
number in either muscle or nerve. 
• Comparison of nerves with differential rates of synaptic degeneration reveals 
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1.23  Introduction 
 
As discussed and expanded upon in Chapter 1, previous work has demonstrated that 
there are age-dependent accelerations in the rate of synaptic withdrawal in the deep 
lumbrical muscles following traumatic injury of the sciatic nerve (Murray et al., 2011). 
To better understand what factors might be responsible for determining the rate of 
synaptic withdrawal, in a recent paper where I am a co-author, we recently profiled 
proteomic changes during postnatal developmental in sciatic nerve and DL muscles 
from P12 to P24 (Kline et al., 2019) (see Appendix 2). In this paper, a tandem mass-
tagging proteomic approach was used and protein changes were identified in both 
muscle and nerve that correlated with accelerations in synaptic degeneration across 
this early developmental period (Kline et al., 2019). Previously, using network-based 
software and functional annotation of upregulated clusters in DAVID, we identified 
consistent increases in proteins pertaining to mitochondria, oxidation/reduction and 
the electron transport chain across this time period. Using pathway analysis software, 
specific enrichments and convergence on components pertaining to complexes I and 
IV were identified (Kline et al., 2019).  
 
The hypothesis that mitochondrial changes are therefore responsible for accelerations 
in axon degeneration was further supported through pharmacological manipulation of 
oxidative phosphorylation. Pharmacological inhibition of complex I (CI) through the 
application of rotenone was found to be axoprotective to dorsal root ganglion (DRG) 
neurons in culture following axon injury, whilst up-regulation of basal oxidative 
phosphorylation through the application of 5-Aminoimidazole-4-carboxamide 
ribotide (AICAR) was found to accelerate synaptic degeneration (Kline et al., 2019). 
It therefore appears that an increase in mitochondrial proteins correlates with the 
acceleration in the rate of synaptic degeneration in the DL muscles during postnatal 
development. If mitochondrial changes are responsible for the acceleration in synaptic 
degeneration, then these changes should be consistent and robust, and present in other 
nerves and muscles. This therefore provides a platform from which I now ask whether 
changes in mitochondrial proteins correlate with alterations in synaptic stability in 
other muscles or nerves following injury.  
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Structurally, mitochondria are composed of a matrix that is surrounded by an inner 
and outer mitochondrial membrane that are separated by an intermembrane space. The 
outer membrane separates the mitochondrion from the cytosol. The inner 
mitochondrial membrane is folded to form cristae, which is where the electron 
transport chain (ETC) is housed. The ETC is essential for cellular respiration and the 
production of ATP, the energy currency of the cell. The ETC is composed of a series 
of multi-subunit complexes, complexes I-IV and ATP synthase (herein referred to as 
complex V), and mobile, electron transporters that are responsible for accepting and 
transferring electrons. The assembled components and supercomplexes are the basis 
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Figure 2.1: Schematic of the mammalian electron transport chain (ETC) on the 
inner mitochondrial membrane. In the presence of NADH. H+ or FADH2, energy 
substrates arising as products from the metabolism of glucose, electrons are transferred 
through a series of enzyme complexes, complex I-IV (CI-IV). To provide a simplified 
overview, CI (NADH dehydrogenase) and CII (succinate dehydrogenase), accept 
electrons from NADH or FADH respectively. Both CI and CII transfer electrons onto 
Coenzyme Q (ubiquinone, labelled here as Q). Electrons are then passed onto CIII 
(ubiquinol cytochrome c reductase), then cytochrome c (labelled here as Cyt C). 
Complex IV (cytochrome c oxidase) is the final enzyme in the series, where the final 
electron receptor, oxygen, is reduced to water. As electrons are transferred, protons 
are extruded from the cell, thereby establishing an electrochemical gradient. This 
gradient is then used by ATP synthase (often referred to as Complex V), to generate 
energy in the form of ATP. This overall process is referred to as oxidative 
phosphorylation, since it culminates in the phosphorylation of ADP to ATP. Note that 
the membrane-bound enzymes are complex and composed of multiple subunits; this 
schematic does not show this supramolecular complexity. Schematic reproduced from 
Benard et al., 2011, with copyright permissions (license number can be provided on 
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The transfer of electrons through the ETC is not 100% efficient; some electrons are 
transferred to O2, thereby generating reactive oxygen species (ROS). Endogenous ROS 
are mainly produced by mitochondria, and are an inevitable by-product of oxygen 
metabolism. ROS can include: superoxide anions (O2•-), hydrogen peroxide (H2O2), 
and hydroxyl radicals (OH•). At low concentrations, ROS are thought to play key 
signalling roles in proliferation, hypoxia adaptation and cell fate determination (Sena 
and Chandel, 2012). However, excessive production of ROS can have harmful and 
irreversible effects on lipids, proteins and nuclear acids. It is well recognised that 
elevated intracellular ROS can lead to oxidative stress that results in DNA damage and 
even cell death (Cross et al., 1987, Vendemiale et al., 1999, Simon et al., 2000a). ROS 
overproduction has also been linked as being both causative and a consequence of 
disease, for example mitochondrial defects and ROS have been implicated in axon 
degeneration, including in WD (Barrientos et al., 2011, Villegas et al., 2014, 
O'Donnell et al., 2013, Park et al., 2013, Calixto et al., 2012).  In our previous work, 
inhibition of CI, which is known to be a major ROS producer (Brand, 2010, Zhao et 
al., 2019, Kowaltowski et al., 2009), prevented axotomy-induced elevations in ROS 
and was shown to be axoprotective (Kline et al., 2019). Mitochondrial depolarisation 
in the absence of physical injury can similarly induce axonal death through WD 
pathways (Loreto et al., 2020). In work by Press and Milbrandt, the application of 
antioxidants was shown to confer axonal protection from rotenone-induced axonal 
degeneration (Press and Milbrandt, 2008). Other work has also suggested that 
anitoxidants may prove therapeutically useful to counteract oxidative damage and 
toxicity in disease scenarios (Sherer et al., 2003, Testa et al., 2005). This further 
supports the hypothesis that ROS-mediated damage plays a key role in determining 
the neuronal response to injury and implicates mitochondrial dysfunction as a key 
factor in determining axonal and synaptic health. 
 
Additionally, there is a growing body of evidence that implicates mitochondria as 
playing a role in axonal and synaptic degeneration. Proteomic profiling have 
highlighted mitochondrial dysfunction as an important factor in regulating synaptic 
stability and vulnerability in the pathogenesis of neurodegenerative diseases (Llavero 
Hurtado et al., 2017, Luiro et al., 2006, Graham et al., 2017). This is particularly true 
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of diseases where the synapse is an early pathological target, such as Parkinson’s 
disease (Ferrer et al., 2012), Alzheimer’s disease (Lee et al., 2012, Du et al., 2010), 
and Batten disease (Luiro et al., 2006). In mouse models of SMA, mitochondrial 
dysfunction has been implicated as playing a role in disease pathogenesis, with both 
structural and functional defects having been described prior to symptom onset (Miller 
et al., 2016). In mutant SOD1 mice, widely used as a mouse model of ALS, protein 
aggregation, enhanced oxidative stress and excitotoxicity have been implicated in the 
process of motor neuron degeneration (Martin et al., 2007). Structural defects in 
mitochondria have also been described in ALS patients in skeletal muscle, liver and 
spinal motor neurons (Menzies et al., 2002), with markers of oxidative stress and ROS 
damage also reportedly elevated (Beal, 2002). Considering the abundance of evidence 
implicating mitochondrial dysfunction in disease, it is unsurprising that mitochondria 
are thought to play a fundamental role in axonal and synaptic degeneration under 
pathophysiological conditions.  
 
 
There is increasing evidence that implicates mitochondrial changes as an important 
aspect of normal development. In rats, it has been shown that whilst mitochondria are 
arranged individually and parallel to the muscle fibre at birth, by 2 months of age, 
these form a highly connected, and grid-like network that facilitates rapid energy 
distribution (Bakeeva et al., 1981, Glancy et al., 2015). Proteomic work by Kim et al., 
has profiled proteomic changes in developing tibialis anterior muscle that are thought 
to be important for the formation of this mature mitochondrial network (Kim et al., 
2019). Kim et al., highlight an upregulation of proteins that are associated with 
mitochondrial bioenergesis and oxidative phosphorylation across development. 
Across P1-P42 of postnatal development, Kim at al., not only demonstrate 
morphological changes in the orientation of muscle mitochondrial network 
configuration, but also detail changes in mitochondrial-associated protein expression. 
This group profile changes in cytochrome c oxidase, complex IV (CIV), subunits, 
assembly factors, mitophagy-associated proteins and antioxidants to ultimately 
conclude that proteins involved in mitochondrial biogenesis and oxidative 
phosphorylation are upregulated throughout muscle development. Cytochrome c 
oxidase (CIV) plays a pivotal role in mitochondrial energetics; work by Larsen et al., 
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has previously highlighted that CIV shows a strong association with oxidative capacity 
in human skeletal muscle (Larsen et al., 2012). CIV is also the last enzyme in the 
respiratory chain, and is therefore considered as a major regulation site for oxidative 
phosphorylation (Li et al., 2006). In the Kim et al., study, developmentally-regulated 
transitions in mitochondrial biology are discussed in the context of the establishment 
of a mature mitochondrial network; alterations in mitochondria are suggested to 
represent a metabolic shift towards mitochondria that are specialised to meet postnatal, 
cellular energy demands. Although this work clearly recognises that the mitochondrial 
proteome is dynamic during development, it remains unclear how this relates to 
alterations in synaptic stability. Focussing on the postnatal time frame where 
developmental regulation is a feature (in this dataset this refers to P1-P21), and 
drawing comparisons to the Kline et al., dataset, will therefore provide better insight 
into the role of mitochondria across this critical and transitional time period. 
 
Other work has also implicated mitochondria as playing an important role in postnatal 
development. In 2015, Puente et al., undertook a temporal analysis to better understand 
factors that can regulate the loss of regenerative capacity in cardiomyocytes 
postnatally in mice (Puente et al., 2014). This work focused on the first week of life, 
where there is a shift from a hypoxic, embryonic environment where cardiomyocytes 
primarily utilise anaerobic glycolysis as their energy source, to the mature, adult state 
where cardiomyocytes primarily utilise oxygen-dependent mitochondrial oxidative 
phosphorylation as their energy source. Within this early time frame, there are marked 
increases in ROS, oxidative DNA damage and DNA damage response markers (Puente 
et al., 2014). Postnatal hypoxemia, ROS scavenging and inhibition of DNA damage 
response were also shown to prolong the proliferative period of cardiomyocytes 
(Puente et al., 2014). Across the first two weeks of development, mitochondrial 
number – indicated by increased mitochondrial DNA (mtDNA) copy number – and 
complexity were shown to significantly and linearly increase across time. Levels of 
mtDNA have previously been used as a biomarker of mitochondrial content (Malik 
and Czajka, 2013, Puente et al., 2014, Quiros et al., 2017). Such changes in 
mitochondrial biology, and the associated increase in ROS production during this time 
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frame, indicate an important role for mitochondria in postnatal development however, 
it remains unclear if similar temporal shifts are also seen in neural tissue. 
 
Overall, a major question that emerges is whether changes in mitochondrial protein 
expression can also explain differences in the synaptic response to injury in other 
muscles, either temporally or regionally. In our previous work, proteomic analyses 
were limited to CI and IV, therefore a more comprehensive analyses of the Kline et 
al., proteomic dataset would provide insight into how mitochondrial proteins change 
during this transitional period. A range of proteins originally profiled by Kim et al., 
will be examined in the Kline et al., dataset, and considered in the context of synaptic 
stability after injury. Note that synaptic withdrawal responses were described in 
Chapter 1, and for ease of referral are summarised in Table 14. Kim et al., originally 
consider an extended postnatal time period, however this is not specific to the 
transitional time window in which synaptic stability is altered. To facilitate 
comparison and begin to look for correlations with rates of synaptic loss, here, I will 
only time points up to and including P24 were considered. Notably, both the Kline et 
al., and Kim et al., proteomic screens are limited in that they only looked at one muscle, 
therefore comparing and expanding upon this to investigate patterns of change in 
mitochondrial proteins in other muscles at a range of different time points, will provide 
an indication of whether temporal and regional differences in mitochondria might 
influence the rate of synaptic withdrawal following injury.  
 
In this chapter, I subjected proteomic datasets to new analyses and highlight increases 
in mitochondrial protein abundance across the first 3 weeks of life that correlate with 
accelerations in synaptic degeneration following injury across early postnatal 
development. I found that increases in mitochondrial proteins correlated with an 
increase in mtDNA in muscle but not in nerve, suggesting that increased mitochondrial 
number could account for the increase in mitochondrial proteins in muscle. To 
determine if changes in mitochondria could explain the alterations in the rates of 
synaptic degeneration, I analysed mitochondrial complex protein levels and mtDNA 
content in cranial and thoracoabdominal musculature, and in sciatic and intercostal 
nerves across the time period of P12 to P24. In contrast with findings from the 
proteomic analysis, I found that changes in mitochondrial complex protein levels or 
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mitochondrial number were not consistent with previous reports, and therefore could 
not account for regional or temporal changes in the rate of synaptic degeneration. 
However, interestingly, in nerve increases in complex I did correlate with differential 
rates of synaptic degeneration. Overall, despite initially promising indications from 
proteomics that mitochondrial changes could be responsible for accelerations in 
synaptic degeneration in muscle, this pattern is not substantiated, suggesting that other 
factors must be involved in regulating the degenerative rate.  
 
Table 14: Summary table showing the rates of synaptic withdrawal at postnatal days 
15 and 24 in a range of different muscles following ex vivo nerve injury and 
maintenance at 30°C in muscle. Note that • denotes muscles served by the facial 
nerve, whilst * denotes those served by intercostal nerves. 
 
Muscle P15 P24 
AAL • Fast Fast 
LALr • Slow Fast 
LALc • Slow Fast 
AS • Slow Fast 
TVA * Slow Slow 
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1.24 Results  
 
1.24.1 Proteomic comparisons highlight changes in mitochondrial proteins that 
coincide with developmental regulation 
 
Raw proteomic data gathered from our previous work in deep lumbrical muscles 
(Kline et al., 201), and a raw proteomic dataset made available by Kim et al., in tibialis 
anterior muscle (Kim et al., 2019), were subjected to new analysis with the aim of 
undertaking a comprehensive analysis of the changes in mitochondrial proteins 
occurring during postnatal development. Note that whilst these datasets were collected 
as part of other studies, the analyses and comparisons presented here have been 
undertaken by myself. In both studies, isolated and pooled regions of nerve or muscle 
were digested and extracted from each age point, and a tandem mass tagging approach 
was implemented. Here, I performed functional clustering of up-regulated proteins in 
both data sets using open source DAVID software. This revealed a significant overlap 
in the most highly enriched functional clusters in both Kline et al., and Kim et al., 
datasets, with mitochondria emerging as the most significantly enriched cluster, with 
scores of 152.52 and 33.93 respectively (Fig. 2.2). Notably, the majority of functional 
clusters that were identified in these analyses pertained to aspects of mitochondrial 
function. Note that a DAVID score of >1.3 is equivalent to p < 0.05, and so all of the 
clusters listed are significantly enriched. 
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Figure 2.2: Top 10 most significantly enriched functional clusters identified by 
DAVID analysis across the postnatal time periods analysed from two independent 
proteomic screens. Note that in deep lumbrical muscles (A) and in tibialis anterior 
muscle (B), analysis of proteins consistently upregulated across P12-24 or P1-42 
respectively, reveals an enrichment of processes relating to mitochondria and oxidative 
phosphorylation. Note the many commonalities between independent screens. 
Functional annotations are ranked by a DAVID enrichment score, where a score of 
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Our previous work primarily focussed on characterising and validating changes in CI 
levels and activity across P12 to P24 (Kline et al., 2019, Appendix 2). Here, I expanded 
this analysis to include subunits from different complexes to gain a broader overview 
of ETC activity within this time frame. This included profiling five different subunits 
across P12-P24: CI subunit NDUFB8 (NADH: Ubiquinone oxidoreductase subunit 
B8), an accessory subunit of CI; complex II (CII) subunit SDHB (Succinate 
dehydrogenase complex iron sulfur subunit B), an iron-sulfur protein subunit of CII; 
complex III (CIII) subunit UQCRC2L (Ubiquinol-cytochrome c reductase core protein 
2), a key assembly component of CIII;  CIV subunit COX II, the second subunit of 
CIV; and complex V (CV) subunit ATP5A (ATP synthase F1 subunit alpha), a 
component of the catalytic core of mitochondrial membrane ATP synthase. Here, these 
subunits have also been profiled in the Kim et al., dataset across P1 to P21. In line with 
previous work, it was hypothesised that increases in CI subunit expression would be 
seen in both datasets. Since it has previously been shown that oxidative activity 
increases across the postnatal period, it was also hypothesised that other complex 
subunits would also be upregulated across these time periods. Consistent with these 
hypotheses, it was found that CI subunit expression increased with age in both cases 
(Fig. 2.3), as did expression of all other complex subunits across P12-P24 and P1-P21 
in the Kline et al., and Kim et al., datasets respectively. Notably, CI showed the 
strongest correlation when both datasets are considered. Since CI is recognised as a 
major ROS producer (Giachin et al., 2016, Telford et al., 2009), it is hypothesised that 
increases in CI will be a key and common factor in determining the synaptic response 
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Figure 2.3: Relative fold change of oxidative phosphorylation (OXPHOS)-related 
subunits in developing muscles across early postnatal development. Changes of 
individual OXPHOS subunit proteins are shown across postnatal development of the 
deep lumbrical muscles relative to P12 (A) or tibialis anterior muscle relative to P1 
(B). (A) Line graph showing expression fold change in subunits of CI-V of the 
electron transport chain from P12-P24 in the deep lumbrical muscles. Note that 
increases are seen across time in all subunits. N = 5 mice, with 20 muscles per 
timepoint, with timepoints including P12, P15, P18, P21 and P24 (raw data available: 
Kline et al., 2019) (B) Line graph showing expression fold change in subunits of CI-
V of the electron transport chain from P1-P21 in tibialis anterior muscle. Note that 
increases are seen across time in all subunits, although this is most pronounced in CI. 
N = 4 mice, with 3-5 pooled tissues, with timepoints P1, P7, P14 and P21 (raw data 
available: Kim et al., 2019). 
 
Kim et al have previously described upregulations of cytochrome c oxidase subunits 
(CIV) between P1 and P42 (Kim et al., 2019). I therefore examined subunits identified 
by Kim et al., within our own dataset, and re-examined data provided by Kim to focus 
on the time period of P1 to P21, the period of postnatal development when synaptic 
stability is altered. It was hypothesised that there would be progressive increases in 
cytochrome c oxidase subunit protein levels between P12 and P24 in our dataset. 
Consistent upregulations in cytochrome c oxidase subunit protein levels were seen in 
both datasets. 13 common subunit proteins were identified (Fig. 2.4). Of these, 10 
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proteins were consistently upregulated across time (Fig. 2.3). Three notable and 
common exceptions were seen, that can be attributed to developmentally regulated 
isoform switches that occur. Cox4 has two isoforms: isoform 1 (Cox4i1), which 
increases with age, and isoform 2 (Cox4i2) which decreases. In early development, 
Cox6a also undergoes an isoform switch from isoform 1 (liver isoform) to isoform 2 
(heart isoform). The third exception is seen in Cox7a, which also has heart (Cox7a1) 
and liver (Cox7a2) isoforms. Heart isoforms are seen to increase across time, whilst 
the liver isoform declines (Fig. 2.4). Such isoform switches are important for 
regulation of a number of regulatory processes including enzyme activity and energy 
production (Malek et al., 2018). Overall, comparable patterns are seen in both datasets, 
with progressive increases in cytochrome c oxidase subunits being evident. This 
provides further support for the hypothesis that changes in the mitochondrial proteome 
during postnatal development are important in determining and influencing synaptic 
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Figure 2.4: Relative fold change of cytochrome c oxidase proteins in developing 
muscles across early postnatal development. Changes of individual cytochrome c 
oxidase subunit proteins are shown across postnatal development of the deep lumbrical 
muscles relative to P12 (A) and tibialis anterior muscle relative to P1 (B). For deep 
lumbrical muscles, n = 5 mice, with 20 muscles per timepoint, with timepoints 
including P12, P15, P18, P21 and P24 (raw data available: Kline et al., 2019); for 
tibialis anterior muscles n = 4 mice, with 3-5 pooled tissues, with timepoints P1, P7, 
P14 and P21 (raw data available: Kim et al., 2019). Note that many similar increases 
are seen in cytochrome c oxidase protein changes between different muscles. 
 
Previous work has shown that following axonal injury, ROS levels rise rapidly 
(O'Donnell et al., 2013). I was interested in whether factors that act to counteract ROS, 
including antioxidants and flavoproteins, were also upregulated across this time frame. 
I therefore mapped profiles of antioxidants and flavoproteins up to and including P24 
(Fig. 2.5 and Fig. 2.6 respectively). Analyses of major antioxidant-related proteins 
revealed upregulations in three common, major antioxidants in both datasets: SOD2, 
GSTk1 and mitochondrial GPX (Fig. 2.5). Common decreases were seen in Catalase 
and IDH2. In addition, proteomic analyses of flavoproteins revealed consistent 
increases across time (Fig. 2.6). Flavoproteins are mainly localised to mitochondria, 
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Figure 2.5: Relative fold change of major antioxidant-related proteins in developing 
muscle across early postnatal development. Changes of major antioxidant proteins 
are shown across postnatal development in the deep lumbrical muscles relative to P12 
(A) and tibialis anterior muscle relative to P1 (B). For deep lumbrical muscles, n = 5 
mice, with 20 muscles per timepoint, with timepoints including P12, P15, P18, P21 
and P24 (raw data available: Kline et al., 2019); for tibialis anterior muscles n = 4 
mice, with 3-5 pooled tissues, with timepoints P1, P7, P14 and P21 (raw data available, 
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Figure 2.6: Relative fold change of flavoproteins in developing muscles across early 
postnatal development. Changes in individual flavoprotein proteins are shown across 
postnatal development of the deep lumbrical muscles relative to P12 (A) and tibialis 
anterior muscle relative to P1 (B). Note that flavoproteins levels generally increase 
across the first three weeks of life, and always increase by P24 (A) or P21 (B) relative 
to the earliest time point. For deep lumbrical muscles, n = 5 mice, with 20 muscles per 
timepoint, with timepoints including P12, P15, P18, P21 and P24 (raw data available: 
Kline et al., 2019); for tibialis anterior muscles n = 4 mice, with 3-5 pooled tissues, 
with timepoints P1, P7, P14 and P21 (raw data available: Kim et al., 2019). 
 
These comparisons were also undertaken in sciatic nerve, using the Kline et al., raw 
dataset. Note that nerve data was not gathered in the Kim et al., study, therefore this is 
not included here. In nerve, although there are fluctuations during development, 
overall there are similar upregulations in proteins as described in muscle. For example, 
for cytochrome c oxidase subunit analysis, there are similar increases in the majority 
of proteins if the general trend from P12 to P24 is considered (Fig. 2.7, A). Cox6a2 
and Cox7a1 show the most profound increases, which is consistent with isoform 
switching that is seen in muscle. Similar upregulations are also seen in the major 
antioxidants SOD2, GSTk1 and GPX in nerve. IDH2 is similarly decreased in nerve 
as it is in muscle, however catalase levels are seen to increase in nerve (Fig. 2.7, B). 
When considered generally, flavoprotein levels increase from P12 to P24 in nerve, 
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despite greater oscillations observed at intermediate time points (Fig. 2.7, C). Finally, 
oxidative phosphorylation (OXPHOS) subunits also follow a similar trend, with 
general increases from P12 compared to P24, despite intermediate time point 
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Figure 2.7: Relative fold changes of mitochondrial-associated proteins in sciatic 
nerve across early postnatal development. All changes are expressed relative to P12. 
(A) Relative fold change of cytochrome c oxidase subunit proteins in developing 
nerve. (B) Relative fold change of major antioxidant-related proteins in developing 
sciatic nerve. (C) Relative fold change of flavoproteins in developing sciatic nerve. 
Note that at P24, there are consistently higher levels of flavoproteins compared to P12, 
despite intermediate oscillations. (D) Relative fold change in individual oxidative 
phosphorylation (OXPHOS) subunit proteins across postnatal development in the 
sciatic nerve. Changes in different subunits of CI-V of the electron transport chain are 
shown from P12-P24. CIV subunit is not detected in nerve in this proteomic screen. 
Note that increases are seen from P12 to P24 in all subunits, despite intermediate time 
point oscillations. N = 5 mice, with 10 nerves per timepoint, with timepoints including 
P12, P15, P18, P21 and P24 (raw data available: Kline et al., 2019). 
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Overall, there appear to be consistent upregulations in mitochondrial-associated 
proteins across time in the deep lumbrical and tibialis anterior muscles and in sciatic 
nerve across independent proteomic screens, which coincide temporally with the 
acceleration in the rate of axon degeneration following injury. There appear to be 
global changes in mitochondrial proteins that are not restricted to a specific subset of 
proteins. This provides strong rationale to hypothesise that alterations in the 
mitochondrial proteome during postnatal development may influence the rate of 
synaptic loss following injury in other muscles. It remains unclear whether such 
alterations in mitochondrial protein level are a result of an increase in the total mass 
of mitochondria, i.e. a change in mitochondrial number, or due to increased 
mitochondrial activity. An assessment of mitochondrial content in subsequent analyses 





Chapter 2: Role of mitochondria in regulating postnatal delays in Wallerian degeneration 120 
1.24.2 Increases in mitochondrial content in nerve, but not muscle, can explain 
increases in protein expression and direct the rate of synaptic loss 
following injury 
 
To provide insight into whether proteomic changes could be due to increases in 
mitochondrial number, mtDNA – a biomarker of mitochondrial content – was assessed 
by qPCR. Recent work by Puente et al., has used mtDNA copy number as an indicator 
of mitochondrial content, with temporal correlations seen between mtDNA and the 
shift from glycolytic to mitochondrial, oxidative phosphorylation during early 
postnatal development (Puente et al., 2014). To firstly validate the use of mtDNA as 
an indicator of mitochondrial content, I used qPCR to compare mtDNA levels between 
a slow- (type I) oxidative and fast- (type II) twitch glycolytic muscle, since it is known 
that these have different numbers of mitochondria (Picard et al., 2012). Slow-twitch 
muscles like soleus, would be expected to have higher numbers of mitochondria than 
fast-twitch muscles like gastrocnemius. In line with this, it was found that mtDNA 
levels were significantly higher in soleus than in gastrocnemius, suggesting a positive 
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Figure 2.8: Quantification of mtDNA levels as determined by qPCR and 2-∆∆CT 
method in soleus and gastrocnemius at P25 in wild-type mice. Note that, as expected, 
mtDNA is significantly higher in soleus, a slow-twitch muscle, than in gastrocnemius, 
a fast-twitch muscle. This suggests that mtDNA can be used to indicate mitochondrial 
number. This shows relative normalised quantity of mtDNA as determined by 2-∆∆CT 
method. Data is normalised to H19 and expressed relative to soleus. ** p = 0.0095; 
One-sample t-test. In both groups, n = 3 biological replicates. Error bars represent 
mean ± SEM. 
 
Next, this qPCR approach was used to ask whether mitochondrial content changed 
from P15 to P24 in sciatic/tibial nerve, and whether increases in mtDNA might 
therefore explain observed increases in mitochondrial protein expression. In 
sciatic/tibial nerve, the relative quantity of mtDNA was seen to increase significantly 
with age, increasing by 0.67 fold from P15 to P24 (One sample t-test, p = 0.0058) (Fig. 
2.9). In nerve, differences in mitochondrial content correlate with protein expression 
changes over time, suggesting that increases in mitochondrial number could be 
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Figure 2.9: Quantification of mtDNA levels as determined by qPCR and 2-∆∆CT 
method in sciatic/tibial nerve at P15 and P24 in wild-type mice. For ease of 
interpretation, preparations that have been found to degenerate faster following injury 
are represented by pink bars, whilst those that are comparatively slower are 
represented by green bars. Data is expressed normalised to H19, and expressed relative 
to P15. Note that a significant increase in relative quantity of mtDNA is detected in 
sciatic/tibial nerve from P15 to P24. ** p = 0.0058; one sample t-test. N = 3 biological 
replicates. Error bars represent mean ± SEM. 
 
However, when changes in mitochondrial content was examined from P15 to P24 in 
LALr/c/AS pooled muscles, it was found that there were no significant changes in 
mtDNA levels (One sample t-test; p > 0.98) (Fig. 2.10). This suggests that 
developmental regulation of synaptic withdrawal following injury cannot be attributed 
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Figure 2.10: Quantification of mtDNA levels as determined by qPCR and 2-∆∆CT 
method at P15 and P24 in LALr/c/AS pooled muscles from wild-type mice. For ease 
of interpretation, preparations that have been found to degenerate faster following 
injury are represented by pink bars, whilst those that are comparatively slower are 
represented by green bars. Data is expressed normalised to H19, and relative to P15. 
Note that no significant changes in mtDNA are detected. Ns = not significant, p > 0.98; 
one sample t-test. At both time points, n = 3 biological replicates. Error bars represent 
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1.24.3 Changes in mitochondrial proteins and content do not correlate with 
differences in vulnerability across development in other muscles 
 
If mitochondrial changes account for the developmentally regulated alterations in the 
rate of synaptic degeneration, then it follows that similar changes in mitochondrial 
proteins would be seen in other nerves and muscles. To expand analysis of 
mitochondrial proteins into other muscles, quantitative fluorescent western blotting 
was applied to quantify levels of CI protein in the cranial and thoracoabdominal 
musculature, and in sciatic/tibial and intercostal nerves. To provide an overview of this 
transitional period, three time points were analysed: P15, P19 and P24. It was 
hypothesised that, since the cranial muscles follow a similar developmental profile as 
the DL in response to injury (See Chapter 1, Results, 1.20.2), that there would be 
similar increases in CI protein levels with increasing age. Since the thoracoabdominal 
muscles show minimal synaptic loss in response to injury within this timeframe (See 
Chapter 1, Results, 1.20.3), it was hypothesised that protein levels in this group would 
remain constant. Overall, it was predicted that higher levels of CI, would correlate with 
greater vulnerability to synaptic loss.  
 
An antibody cocktail was used that targets subunits from each complex within the 
respiratory chain, thereby providing a better overview of ETC activity within this time 
frame. These subunits were: CI subunit NDUFB8 (NADH: Ubiquinone 
oxidoreductase subunit B8), an accessory subunit of CI; CII subunit SDHB (Succinate 
dehydrogenase complex iron sulfur subunit B), an iron-sulfur protein subunit of CII; 
CIII subunit UQCRC2L (Ubiquinol-cytochrome c reductase core protein 2), a key 
assembly component of CIII;  CIV subunit COX II, the second subunit of CIV; and 
CV subunit ATP5A (ATP synthase F1 subunit alpha), a component of the catalytic 
core of mitochondrial membrane ATP synthase. Note that protein extracted from 
muscles were grouped in ways that reflected differential ex vivo responses, as have 
been described in Chapter 1 (see Table 14 for summary): the LALr/c/AS were grouped 
together, AAL was considered on its own, and TVA/TS were grouped together.  
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It was found that regardless of which muscle group is selected (LALr/c/AS; AAL or 
TVA/TS), CI protein levels fail to correlate with patterns of synaptic stability 
following injury; CI protein levels do not increase between P15 and P24 in any case 
(Fig. 2.11, Fig 2.12 and Fig. 2.13) (Two-way ANOVA with Sidak correction, p > 
0.06). Moreover, no convincing trends towards an increase were identified in any of 
the other complex subunits analysed. If anything, trends towards a decrease were more 
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Figure 2.11: Analysis of respiratory chain complex subunit protein levels across 
P15-24 fails to reveal any significant increases across time in pooled LALr/c/AS 
muscles from wild-type mice. (A) Western blot result using antibodies against 
Complex I, II, III, IV and V subunits on muscle from P15, P19 and P24 mice, with 
total protein staining used as a loading control. (B) Quantification of western blot 
against different complex subunits. Data is expressed normalised to loading control 
and relative to levels at P15. Note that no increases in protein levels are seen across 
time. Ns = not significant, p > 0.15, * p = 0.027; two-way ANOVA with Sidak 
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Figure 2.12: Analysis of respiratory chain complex subunit protein levels across 
P15-24 fails to reveal any significant increases across time in AAL from wild-type 
mice. (A) Western blot result using antibodies against Complex I, II, III, IV and V 
subunits on muscle from P15, P19 and P24 mice, with total protein staining used as a 
loading control. (B) Quantification of western blot against different complex subunits. 
Data is expressed normalised to loading control and relative to levels at P15. Note that 
no increases in protein levels are seen across time. Ns = not significant, p > 0.22; two-
way ANOVA with Sidak correction. For each time point, n=3 biological replicates. 
Error bars represent mean ± SEM. 
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Figure 2.13: Analysis of respiratory chain complex subunit protein levels across 
P15-24 fails to reveal significant increases in complex I levels across time in pooled 
TVA/TS muscles from wild-type mice. There is also a lack of convincing increases in 
other complexes. (A) Western blot result using antibodies against Complex I, II, III, 
IV and V subunits on muscle from P15, P19 and P24 mice, with total protein staining 
used as a loading control. (B) Quantification of western blot against different complex 
subunits. Data is expressed normalised to loading control and relative to levels at P15. 
Note that no increase in CI is seen, and that the majority of other complex subunit 
proteins also fail to show increases. Ns = not significant, p > 0.06, * p = 0.024; two-
way ANOVA with Sidak correction. For each time point, n=3 biological replicates. 
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Figure 2.14: Analysis of respiratory chain complex subunit protein levels across 
P15-24 fails to reveal significant increases in either sciatic/tibial nerve or intercostal 
nerve from wild-type mice. (A) Western blot result using antibodies against Complex 
I, II, III, IV and V subunits on muscle from P15, P19 and P24 mice in sciatic/tibial 
nerve (left) and intercostal nerve (right), with total protein staining used as a loading 
control. Note that in both nerves only CI, III and IV bands are detected (B) 
Quantification of western blot against different complex subunits in sciatic/tibial 
nerve. Data is expressed normalised to loading control and relative to levels at P15. 
Note that no increases in protein levels are seen across time. Ns = not significant, p > 
0.31; two-way ANOVA with Sidak correction. Error bars represent mean ± SEM. (C) 
Quantification of western blot against different complex subunits in intercostal nerve. 
Data is expressed normalised to loading control and relative to levels at P15. Note that 
no increases in protein levels are seen across time. Ns = not significant, p > 0.23; two-
way ANOVA with Sidak correction. In all cases, n=3 biological replicates. Error bars 
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1.24.4 Changes in mitochondrial proteins and DNA do not correlate with 
differences in vulnerability between different muscles 
 
It was next important to determine whether mitochondrial changes could contribute to 
muscle-specific differences. When considering the results contained within this 
section, it is important to keep in mind the injury-response profiles that have been 
described in Chapter 1. To briefly summarise, the LALr, LALc and AS cranial muscles 
have a characteristic profile of developmental regulation, with increased synaptic loss 
occurring with age. The AAL shares a similar profile, but is significantly more affected 
at earlier time points than the other cranial muscles, suggesting it is more vulnerable 
to loss earlier in development. Meanwhile, the abdominal muscles show comparatively 
slower rates of synaptic loss across all time points. Here, it was hypothesised that 
muscles that are more vulnerable to synaptic loss following injury would have higher 
levels of CI.  
 
Firstly, using western blotting, regional differences in CI-V protein levels were 
analysed at P15, P19 and P24. Since it was found in Chapter 1, that the AAL was 
significantly more denervated following injury at P15 than any of the other muscles, 
it was anticipated that CI levels would be higher in the AAL at this time point. 
However, this was not the case: it was found that CI levels were not higher in the AAL 
at any age, and even showed significantly reduced levels compared to the TVA/TS at 
P15 and P19 (Fig. 2.15). In general, when other complexes are considered, the AAL 
fails to show a convincing trend towards an increase at any age. Although CII is higher 
in the AAL at P19 and P24 when compared to the TVA/TS, at P15, no difference in 
protein levels are detected despite differences in the synaptic response to injury. Thus, 
although developmental changes are present, these do not correlate with patterns of 
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Figure 2.15: Analysis of respiratory chain complex subunit protein levels across 
different muscles from wild-type mice fails to reveal increases that are consistent 
with patterns of synaptic vulnerability in response to injury. (A) Western blot result 
using antibodies against Complex I, II, III, IV and V subunits on pooled 
LALr/LALc/AS muscle, AAL muscle and pooled TVA/TS muscle from P15, P19 and 
P24 mice, with total protein staining used as a loading control. (B) Quantification of 
western blot against different complex subunits in pooled LALr/LALc/AS muscle, 
AAL muscle and pooled TVA/TS muscle. Data is expressed normalised to loading 
control and relative to levels in LALr/LALc/AS. Note that with the exception of CII, 
no significant increases in protein levels are seen in more vulnerable muscles. CII does 
show increases at P19 and P24, however since differences in vulnerability are already 
prevalent in this muscle at P15 (see Chapter 1, Results, 1.20.2 for profiling), 
differences do not appear to be consistent with alterations in synaptic stability. Ns = 
not significant, p > 0.07, * p < 0.05; Kruskal Wallis with Dunn’s correction. In all 
cases, n=3 biological replicates. Error bars represent mean ± SEM.  
 
Next, it was asked whether increases in CI protein levels correlated with differences 
in the response to injury in nerve. It was hypothesised that CI levels would be higher 
in the sciatic/tibial nerve, since the muscles served by this nerve exhibit greater 
synaptic loss than those served by the intercostal nerve. At all timepoints, there were 
significantly higher CI protein levels in the sciatic/tibial nerve than the intercostal 
nerve, with the sciatic/tibial nerve found to have up to 5X relative fluorescence 
intensity (One sample t-test; p < 0.02) (Fig. 2.16). Contrasting this, in CIII and V, there 
was a consistent trend towards an increase in protein levels in the intercostal nerve 
when compared to the sciatic/tibial nerve (Fig. 2.16).  
 
Overall, in nerve, there are clear and significant differences in CI protein levels that 
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Figure 2.16: Analysis of respiratory chain complex subunit protein levels in 
sciatic/tibial and intercostal nerves from wild-type mice reveals increases in CI 
protein level that correlate with increases in the rate of synaptic withdrawal after 
injury. (A) Western blot result using antibodies against Complex I, II, III, IV and V 
subunits on sciatic/tibial nerve (S), and intercostal nerve (I) from P15, P19 and P24 
wild-type mice, with total protein staining used as a loading control. Note that in both 
nerves only CI, III and IV bands are detected. (B) Quantification of western blot 
against different complex subunits in sciatic/tibial nerve versus intercostal nerve at 
P15, 19 and P24. Data is expressed normalised to loading control and relative to levels 
in sciatic/tibial nerve. Note that whilst increases in CI are seen at P19 and P24 in the 
sciatic/tibial nerve, this difference is also seen at P15, when similar synaptic responses 
to injury are observed. This suggests that although differences are present, these do 
not explain developmentally-regulated alterations to synaptic stability following 
injury. Ns = not significant, p > 0.13, * p < 0.02, ** p < 0.005, *** p = 0.0001; One-
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The final part of this work was to determine whether regional differences in 
mitochondrial number correlated with patterns of synaptic stability following injury in 
nerve or muscle. Comparison of mtDNA levels in intercostal nerve versus sciatic/tibial 
nerve revealed no significant differences at P24 (One sample t-test; p > 0.98). Altered 
mtDNA levels in nerve therefore do not correlate explain differential rates of 
degeneration following injury (Fig. 2.17). For ease of interpretation preparations that 
have been found to degenerate more rapidly following injury are represented by pink 
bars, whilst those that are comparatively slower are represented by green bars. 
 
In muscle, no significant difference was detected in mtDNA levels between the 
LALr/c/AS and the AAL at P15 (Fig. 2.18, A). Note that the LALr/c/AS muscles show 
significantly less synaptic loss following injury than the AAL at P15 (refer to Chapter 
1, Results 1.20.2, or Table 14 for summary). This suggests that altered mitochondrial 
number does not correlate with differential rates of degeneration following injury 
across different muscles. At P24, the TVA/TS has minimal synaptic loss following 
injury, whilst the LALr/c/AS muscles exhibit profound synaptic loss (Fig. 2.18, B). 
When considered in isolation, increases in mtDNA content initially appear to correlate 
with reduced synaptic stability; the more vulnerable muscle group (LALr/c/AS) has 
higher mtDNA at P24. However, when taken together with the P15 data, this 
correlation is not consistent, and therefore remains unconvincing. Overall, although 
global differences in mtDNA levels are detected, these do not correlate with patterns 
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Figure 2.17:  Quantification of mtDNA levels as determined by qPCR and 2-∆∆CT 
method in nerve at P24 in wild-type mice. For ease of interpretation, preparations that 
have been found to degenerate faster following injury are represented by pink bars, 
whilst those that are comparatively slower are represented by green bars. Here, the 
relative quantity of mtDNA in intercostal nerve versus sciatic/tibial nerve at P24 has 
been quantified. Note that no significant difference is detected between different 
nerves at P24. Data is expressed normalised to Gapdh, and expressed relative to 
sciatic/tibial nerve. ns = not significant, p > 0.98; one sample t-test. n = 3 biological 
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Figure 2.18: Comparison of regional differences in relative quantity of mtDNA as 
assessed by qPCR and 2-∆∆CT method in different muscles in wild-type mice. For ease 
of interpretation, preparations that have been found to degenerate faster following 
injury are represented by pink bars, whilst those that are comparatively slower are 
represented by green bars. (A) Relative normalised quantity of mtDNA in 
LALr/LALc/AS pooled muscles versus AAL at P15. Data is expressed normalised to 
H19, and relative to LALr/LALc/AS. Note that no significant changes in mtDNA are 
detected. Ns = not significant, p > 0.22; one sample t-test. (B) Relative normalised 
quantity of mtDNA in pooled TVA/TS muscles versus pooled LALr/LALc/AS 
muscles at P24. Data is expressed normalised to H19, and relative to LALr/LALc/AS. 
Note that mtDNA levels are significantly reduced in the TVA/TS compared to the 
LALr/c/AS at P24. * p = 0.01; one sample t-test. At P15, n = 4 and at P24, n = 3 
biological replicates. Error bars represent mean ± SEM. 
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1.25 Discussion 
 
1.25.1 Overview of results 
 
Here, analyses of two independent proteomic datasets revealed increases in 
mitochondrial proteins that correlate with accelerations in synaptic degeneration 
following injury across early postnatal development. I found that these increases could 
be attributed to increases in mitochondrial number in nerve, but not in muscle.  
However, changes in mitochondrial complex protein levels failed to correlate with 
accelerations in the rate of synaptic degeneration across development in a range of 
other muscles and nerve. Differential rates of synaptic degeneration also failed to 
correlate with changes in mitochondrial number in either muscle or nerve, although 
changes in complex I in nerve did correlate with patterns of selective vulnerability. 
Overall, although there are global changes to the mitochondrial proteome during early 
postnatal development, changes in mitochondrial proteins fail to correlate with 
accelerations in rates of synaptic degeneration following injury across this time 
window. There is some evidence however to support that changes in complex I in 
nerve could underlie intermuscular differences in the rate of synaptic degeneration 
following injury.    
 
1.25.2 Accelerations in synaptic degeneration cannot be attributed to changes in 
mitochondrial proteins in muscle across early postnatal development 
 
I initially demonstrated a strong and promising correlation between increases in 
mitochondrial proteins and accelerations in the rate of synaptic degeneration following 
injury across early postnatal development. All five mitochondrial complexes, as well 
as other key mitochondrial-associated proteins, consistently increased in deep 
lumbrical and tibialis anterior muscles. In previous work in both scenarios of health 
and disease, mitochondrial alterations have been associated with altered synaptic 
stability (Llavero Hurtado et al., 2017, Luiro et al., 2006, Graham et al., 2017, Kline 
et al., 2019, Kim et al., 2019). Early proteomic studies investigating synaptic stability 
in WldS identified mitochondria as playing an important role in conferring the delayed 
WldS phenotype (Wishart et al., 2007). This is further supported by studies showing 
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that inhibition of the mitochondrial permeability pore can phenocopy protection that 
is conferred by WldS expression (Barrientos et al., 2011). In drosophila models, and in 
WldS mice, it has been proposed that WldS can prevent axon degeneration by increasing 
mitochondrial motility and by enhancing the capacity of mitochondrial calcium 
buffering. This buffering prevents elevations in calcium that are thought to trigger 
axon degeneration, and has been considered as a mechanism of WD suppression 
(Avery et al., 2012). Mitochondrial dysfunction is also recognised as a common feature 
in many neurodegenerative disorders where synapses are early pathological targets 
(Llavero Hurtado et al., 2017, Luiro et al., 2006, Graham et al., 2017). In mouse models 
of SMA, structural and functional defects in mitochondria have been described pre-
symptomatically (Miller et al., 2016). Increased levels of mitochondrial proteins, and 
altered mitochondrial morphology have been described at the NMJ during a die-back 
in SMA mice (Neve et al., 2016). In a mouse model of ALS, accumulations of 
mitochondria have been reported in motor neurons, along with higher levels of ROS 
than their wild-type counterparts, further supporting a role for mitochondrial 
dysfunction in the process of motor neuron degeneration (Martin et al., 2007). 
Structural defects in mitochondria have been described in ALS patients in skeletal 
muscle, liver and spinal motor neurons (Menzies et al., 2002), with markers of 
oxidative stress and ROS damage also reportedly elevated (Beal, 2002). Based on our 
proteomic work and work by others, the hypothesis that mitochondrial changes could 
be responsible for determining synaptic stability in the context of postnatal 
development was therefore well-founded. 
 
However, when I expanded these analyses to assess mitochondrial complex protein 
levels and number in a range of other muscles, this was not substantiated. I found that 
changes in mitochondrial complex I-V protein levels failed to correlate with 
accelerations in the rate of synaptic degeneration across development in LALr/c/AS, 
AAL or TVA/TS muscles. I therefore considered what could explain such disparity in 
other muscles. Firstly, I considered whether the technique applied was sensitive 
enough to detect alterations in mitochondrial proteins. However, since changes in 
complex I protein levels are evident in work undertaken by Kline et al., where similar 
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methods are implemented, it is unlikely that technique sensitivity is masking changes 
(Kline et al., 2019).  
 
Perhaps disparity could instead be due to differences in the developmental profile of 
different muscles. Postnatal changes in mitochondrial content have been described 
previously, with previous work indicating that metabolic remodelling in cardiac tissue 
occurs during early postnatal life and is triggered by the transition from a hypoxic 
environment in utero, to an oxygen-rich postnatal environment (Puente et al., 2014, 
Neary et al., 2014). Across the first week of life, Puente et al., describe a transition 
from glycolytic metabolism to aerobic metabolism, with ROS, oxidative DNA damage 
and DNA damage response markers all increasing within this time frame (Puente et 
al., 2014). It is possible that different tissues undergo metabolic remodelling at 
different rates or at different developmental time points. Further work to characterise 
mitochondrial maturation across a range of muscles at earlier time points (<P12), may 
provide insight into whether maturation of mitochondrial networks occurs at an earlier 
time point in development. Interestingly, I also demonstrated a lack of correlation 
between increases in mitochondrial complex proteins, number or activity in spinal cord 
and brain across P12 to P24, providing further evidence that published patterns of 
mitochondrial increases across this window do not bear out in other tissues (see 
Appendix 4, Figures A1 and A2). A more comprehensive temporal characterisation of 
mitochondrial changes in a range of different muscles would help us to better 
understand the impact of postnatal, metabolic shifts on synaptic vulnerability. 
 
It is important to note that not all aspects of mitochondrial biology were considered. 
Additional assessment of changes in mitochondrial morphology and/or activity in 
early postnatal development in a range of muscles would also help to further strengthen 
the conclusion that mitochondria are not responsible for altering rates of synaptic 
degeneration during early postnatal development. Mitochondrial morphology could be 
assessed by electron microscopy, whilst activity could be assessed through enzyme-
linked immunosorbant assay (ELISA) assay, or by assessing the effect of CI stimulants 
of inhibitors, such as AICAR or rotenone, on the level of synaptic loss after injury. If 
the conclusion that mitochondrial changes are not responsible for determining 
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developmental delays in WD is corroborated, then additional proteomic profiling and 
pathway analysis could be performed in muscles like the LALr and TVA, to identify 
other changes or differences in the proteome that could explain the differences in the 
rate of WD across this transitional developmental window. Following this, we could 
undertake a proteomic comparison of these outputs with the DL proteomic with the 
aim of identifying intermuscular commonalities that might be responsible for altering 
synaptic stability. 
 
1.25.3 Postnatal accelerations across time and selective vulnerability are 
regulated by distinct factors 
 
These data suggest that mitochondrial changes in nerve correlate with differential 
vulnerability. In Chapter 1, I demonstrated that muscles served by the intercostal nerve 
(TVA/TS) show a remarkable and consistent resistance to WD across the 
developmental time window of P12 to P24, whilst muscles served by the sciatic/tibial 
nerve (DL) show progressive acceleration in synaptic degeneration across the same 
time window (Murray et al., 2011). When I examined levels of mitochondrial proteins 
across time in either sciatic/tibial nerve or intercostal nerve, no significant increases in 
complex I protein levels were seen. However, CI levels were significantly higher in 
the sciatic/tibial nerve when compared to the intercostal nerve directly at different time 
points, indicating that differences in the rate of synaptic degeneration in different 
muscles can be attributed to increases in CI protein levels. Notably, differences were 
not present in muscle, suggesting that changes in nerve may be more important in 
determining degenerative rate. These findings suggest that different factors may be 
responsible for determining synaptic vulnerability in the contexts of development 
versus selective vulnerability. 
 
These data suggest that intermuscular differences in synaptic vulnerability to injury 
can be explained by an increase in CI protein levels. Whilst CI changes in nerve at the 
protein level do correlate with accelerations in synaptic degeneration, we did not detect 
an increase in mtDNA, suggesting that increases in CI are unlikely to be due to 
increases in mitochondrial number.  It is possible that increases in protein level are 
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rather due to increased mitochondrial activity. This could be assessed in future by 
ELISA, or by pharmacologically manipulating CI activity. Previous work has 
demonstrated that the CI inhibitor, rotenone, is axoprotective in dorsal root ganglion 
primary cultures (Kline et al., 2019). We have also previously utilised AICAR to 
pharmacologically upregulate oxidative phosphorylation in an ex vivo scenario, where 
AICAR accelerated the rate of NMJ degeneration in the DL muscles (Kline et al., 
2019). AICAR is capable of upregulating oxidative metabolism through acting as an 
agonist of adenosine monophosphate kinase (Golubitzky et al., 2011, Jager et al., 
2007). Testing the effect of CI inhibition or upregulation in a range of different 
muscles would help to reveal whether altered CI activity is responsible for conferring 
intermuscular differences in the rate of synaptic degeneration. 
 
Across postnatal development, I did not find any correlation between mitochondrial 
complex protein levels or number and accelerated rates of synaptic degeneration. The 
factors that are responsible for determining postnatal vulnerability may therefore be 
distinct from those which regulate selective vulnerability. Further work is required to 
determine the extent of divergence, as well as identifying what other factors might be 
involved however returning to proteomic outputs may provide some insight. In both 
proteomic screens, we identified carbon metabolism as a common and significantly 
upregulated functional cluster. One-carbon metabolism, mediated by folate cofactor, 
supports many physiological processes that include nucleotide biosynthesis, DNA 
methylation, and redox defence (Ducker and Rabinowitz, 2017). These processes are 
critical components of cell and tissue homeostasis. Although the importance of folate 
metabolism is well-recognised in embryonic development, very little is known about 
the regulation of one-carbon metabolism in muscle during postnatal development, 
therefore profiling changes over early postnatal development may reveal whether 
alterations correlate with accelerations in synaptic degeneration, 
 
Proteomic data also suggest that proteins involved with ROS neutralisation increase 
across postnatal development in muscle. ROS, oxidative DNA damage and DNA 
damage response markers have all been shown to increase across early postnatal 
development following the transition from a hypoxic in utero environment, to an 
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oxygen-rich postnatal environment (Puente et al., 2014). Increases in ROS induce cell 
cycle arrest of postnatal cardiomyocytes, which can be delayed by pharmacological 
inhibition of the DNA damage response pathway or ROS scavenging (Puente et al., 
2014). Could alterations in ROS handling be responsible for delays in WD during 
postnatal development?  Mouse models have been created to investigate the effect of 
altering endogenous levels of mitochondrial oxidative stress by modulating the 
function of superoxide dismutase 2 (SOD2). SOD2 is a key component of the 
antioxidant defence system against superoxide radicals (Birben et al., 2012). SOD2 is 
localised to the inner mitochondrial matrix, specifically at sites of superoxide 
production from the ETC. When oxygen diffuses into mitochondria, it can be 
converted to superoxide as a by-product of oxidative phosphorylation. SOD2 converts 
superoxides into hydrogen peroxide which can then diffuse from mitochondria to be 
further detoxified by enzymes like gluthathione perioxidase or catalase. Work in 
animal models has demonstrated that the severity of neurodegeneration due to loss of 
Sod2 can be modulated in a dose-dependent manner with antioxidants that prevent 
oxidative damage (Melov et al., 1998, Melov et al., 2001, Hinerfeld et al., 2004). 
Dosing of N-acetylcysteine (NAC), a ROS scavenger, in vivo or ex vivo, could provide 
insight into the importance of ROS neutralisation across early postnatal 
developmental. NAC is a derivative of the natural amino acid cysteine, which is a 
substrate of glutathione (GSH), also known as the “master antioxidant” (Teskey et al., 
2018). NAC acts by supporting antioxidant synthesis under conditions where demands 
increase, such as in conditions of oxidative stress. GSH levels increase with age and 
in disease states (Teskey et al., 2018, Ballatori et al., 2009), thus we would hypothesise 
that NAC dosing would increase antioxidant capacity, and exert neuroprotective 
effects. ROS scavengers have been shown to delay WD and axon pathology associated 
with neurodegenerative disorders (Wagner et al., 1998, Calixto et al., 2012, Lopez-
Erauskin et al., 2011). Resveratrol, a compound thought to have antioxidant effects, 
has been shown to delay axonal degeneration in vitro and following nerve crush in 
vivo (Calliari et al., 2014). Investigating whether administration of antioxidants in vivo 
or ex vivo can alter the rate of synaptic degeneration in the context of postnatal 
development would provide insight into the role of antioxidant mechanisms across this 
time frame. 
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Flavoproteins are also critical components of ROS neutralisation, which I have shown 
increase across development, however the role of flavoproteins remains unclear in the 
context of peripheral nerve injury. Flavin adenine dinucleotide (FAD) and flavin 
mononucleotide (FMN) are redox cofactors that are required for the activity of over 
100 human enzymes, with inactivity having been linked to neurodegenerative disease 
(Lienhart et al., 2013). For example, mutations in the flavoprotein D-amino acid 
oxidase have been linked to familial cases of ALS, with a pathogenic role for D-serine 
accumulation being postulated to reduce motor neuron survival (Mitchell et al., 2010). 
Flavoproteins appear capable of influencing neuronal survival in disease, therefore it 
would be interesting to determine if they can influence rates of synaptic degeneration 
in other contexts. Considering the importance of ROS neutralisation, this represents 
an interesting candidate for further work in determining the factors that can regulate 
synaptic stability.  
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 : The role of P53 in morphologically distinct types of 
degeneration 
 
1.26 Chapter overview and principle findings 
 
This chapter aimed to examine the role of P53 in synaptic degeneration; specifically, 
I examined whether reductions in P53 could reduce levels of synaptic loss following 
injury, during disease, or during developmental synaptic elimination. Applying an ex 
vivo model of peripheral nerve injury to tissue from a mouse model with reduced levels 
of P53, I examined whether P53 reduction could reduce synaptic loss following injury. 
In a mouse model of SMA with reduced levels of P53, I then assessed whether P53 
reduction could reduce synaptic loss in the context of a die-back. In a mouse model 
with reduced P53, I investigated whether P53 reductions could delay synaptic 
elimination during development. In P53-reduced SMA and wild-type mice, I also 
examined the impact of P53 reduction on the expression of synaptic genes that are 





• Cre-LoxP mediated recombination of P53 causes measurable changes in P53-
dependant processes 
• P53 reduction has no effect on the level of synaptic loss following injury 
• P53 reduction has no effect on the level of synaptic loss in a mouse model of 
SMA 
• P53 reduction has no effect on polyinnervation levels in young mice  
• The expression of the synaptic genes Bin1, Mef2c and Picalm are unaffected 
by reduced levels of SMN or P53 
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1.27 Introduction 
 
Neuronal dysfunction, and ultimately cell death, is a characteristic of many 
neurodegenerative diseases. Despite growing appreciation of distinct morphologies of 
synaptic degeneration in response to various stimuli, the mechanisms of neuronal 
degeneration remain largely unknown. Understanding factors that can influence the 
rate of degeneration will provide mechanistic insight which is of critical importance if 
we are to identify and develop therapies to target neurodegeneration in different 
contexts. The P53 signalling pathway, due to its role in inducing and regulating 
apoptotic cell death, is one such factor that has emerged as an intriguing candidate 
(Fridman and Lowe, 2003, Aubrey et al., 2018).  
 
The TP53 gene is well-recognised for its role as a tumour suppresser within the body, 
and mutations have been extensively linked to tumour development in cancers 
(Eliyahu et al., 1989, Finlay et al., 1989, Aubrey et al., 2018, Vogelstein et al., 2000). 
In response to a variety of signals, including DNA damage and cell stress, the P53 
signalling pathway is activated and plays a key role in cell cycle control, DNA repair 
and apoptosis (Eizenberg et al., 1996, Vousden, 2000, Elmore, 2007, Li and Yuan, 
2008, Williams and Schumacher, 2016). P53 acts to integrate multiple stress signals, 
and plays a fundamental, and conserved, role in promoting apoptosis (Fridman and 
Lowe, 2003, Brodsky et al., 2000, Jin et al., 2000, Ollmann et al., 2000).  The ability 
of P53 to promote cell death has led to much interest in whether P53 also plays a role 
in pro-apoptotic pathways that ultimately result in synaptic and axonal degeneration.  
 
It is widely accepted that P53 acts as a nuclear transcription factor that induces the 
production of pro-apoptotic proteins in the cell body, however there is also evidence 
to support that P53 acts locally at the synapse (Gilman et al., 2003, Gilman and 
Mattson, 2002). Injury models represent intriguing candidates to study the role of P53, 
as communication between the cell body and distal axon is disrupted. Microarray 
analysis of expression changes in the distal nerve stump across the first 28 days after 
sciatic nerve injury in rats have highlighted upregulations in P53 signalling, indicating 
a local role for P53 in synaptic degeneration (Yao et al., 2013). P53 has been identified 
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in synaptosomes of cortical neurons in vivo, with P53 levels and activity seen to 
increase following DNA damage (Gilman et al., 2003). Synaptosomes from P53 
knockout mice, and those from mice treated with the P53 inhibitor, pifithrin-α, display 
increased resistance to oxidative and excitotoxic injury, with the mitochondrial 
membrane potential being preserved and ROS production decreased (Gilman et al., 
2003). Mitochondria that have been isolated from synaptosomes of P53 knockout mice 
also show greater resistance to oxidative and excitotoxic injury in response to 
pharmacologically-induced DNA damage in hippocampal neuron cultures (Gilman et 
al., 2003). 
 
The ability of P53 to influence the transcription of pro- and anti-apoptotic transcripts 
has implicated P53 in regulating compartmental degeneration in neurons, such as 
during development, where select synapses and axonal branches are ‘pruned’ or 
eliminated, whilst the motor neuron persists (Maor-Nof et al., 2016). Trophic 
deprivation is a well-known model for investigating axonal pruning and the 
mechanisms of neuronal apoptosis (Maor-Nof and Yaron, 2013, Geden and 
Deshmukh, 2016). Apoptotic pathways and proteins, including P53, have been 
strongly implicated in axonal degeneration in response to trophic deprivation (Kaplan 
and Miller, 2000, Aloyz et al., 1998, Maor-Nof and Yaron, 2013). Trophic factors, 
such as NGF, are critical regulators of axonal maintenance and survival, with 
withdrawal of trophic support found to activate pro-apoptotic pathways (Sanes and 
Lichtman, 1999, Harrington and Ginty, 2013). Increases in P53 phosphorylation have 
been seen following trophic withdrawal, which has been shown to induce synaptic 
elimination (Maor-Nof et al., 2016). Phosphorylated and activated P53 act as a 
transcription factor for a number of pro-apoptotic transcripts including Bax, Bak and 
Pmaip. These can increase permeability of the mitochondrial membrane, leading to 
the release of pro-apoptotic factors and the activation of ‘executioner’ caspases, 
including caspase-3 (Schuler and Green, 2001). In line with this, in vivo, knockout of 
caspase-3 has been shown to delay developmental pruning in retinocollicular axons, 
but also leads to severe developmental defects, highlighting a crucial role for apoptotic 
machinery at synapses during development (Simon et al., 2012, Shan et al., 2018). 
Previous, in vitro work has demonstrated that genetic deletion of caspase-3 is 
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protective against axon degeneration that is induced by trophic factor withdrawal, 
however does not protect against injury-induced WD (Simon et al., 2012). Synaptic 
function may also be influenced by P53, with P53 shown to regulate genes involved 
with regulating synaptic function including BIN1, MEF2C and PICALM, in a model 
of Alzheimer’s disease, and suggested to play a key role in maintaining synaptic 
function (Merlo et al., 2014).  
 
P53 is also implicated in synaptic degeneration in disease scenarios. An upregulation 
of P53-associated transcripts in response to reduced Smn is well-documented in the 
literature (Murray et al., 2015, Baumer et al., 2009, Jangi et al., 2017, Staropoli et al., 
2015, Zhang et al., 2008). Recent transcriptional profiling in SMA mice has identified 
pre-symptomatic upregulations of transcripts that are associated with P53 signalling 
(Murray et al., 2015, Simon et al., 2017). In work by Murray et al., 2015, RNAseq 
analysis and functional clustering in an SMA mouse model identified an upregulation 
of downstream, P53-targeted transcripts including Fas, CDKN1a and PMAIP1, that 
preceded NMJ loss and symptom onset (Murray et al., 2015). Gene expression 
profiling in SMA mice has also highlighted upregulations of P53 transcriptional targets 
in vulnerable – but not resistant – SMA motor neurons, suggesting that P53 may 
influence synaptic vulnerability and contribute to selective vulnerability (Murray et 
al., 2015). Similar upregulations in P53 have been reported in mice in which SMN 
deficiency is induced postnatally using antisense oligonucleotides (Jangi et al., 2017). 
Gene expression profiling undertaken Simon et al., agreed with these findings, 
highlighting specific upregulations of P53 transcriptional targets in vulnerable 
populations of motor neurons (Simon et al., 2017). Simon et al., also demonstrated that 
pharmacological or genetic inhibition of the P53 pathway could rescue vulnerable 
motor neurons from degeneration in a mouse model of SMA (Simon et al., 2017). 
However, in severe mouse models of SMA, and in ALS mouse models, despite 
elevations in P53 being reported in both patient post-mortem tissue and experimental 
models, P53 knockout does not reduce motor neurons loss, indicating P53-independent 
mechanisms also exist (Simic et al., 2000, Culmsee and Mattson, 2005). More 
recently, in a paper that I was a co-author on, P53 knockout was shown to reduce NMJ 
loss in the Smn2B/- mouse model of SMA, suggesting that axonal and synaptic 
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degeneration in this context is P53-dependent (Courtney et al., 2019) (see co-author 
paper in Appendix 3 for reference). 
 
Unlike other studies that have focused on P53 and its pro-apoptotic role, studies such 
as that by Merlo et al., 2014, have investigated the role of P53 as a neuroprotective 
agent. Rather than promoting cell death, Merlo et al., present evidence in a model of 
Alzheimer’s disease to support that P53 may instead contribute to a protective stress 
response that is critical to neuronal systems, including synaptic function (Merlo et al., 
2014). Merlo et al., identify a group of susceptibility genes that are regulated by P53 
that are involved in controlling synaptic function. This group suggest that regulation 
of synaptic genes can prevent neurodegeneration, with genetic manipulation of P53 
target genes shown to be capable of modifying tau neurotoxicity in a Drosophila model 
(Merlo et al., 2014). Taken together, there is much evidence that highlights P53 as a 
potential target to modify the progress of synaptic degeneration. 
 
Overall, whilst the role of P53 in apoptosis is widely appreciated, the role of P53 at 
the synapse and in the axon remains unclear. Although P53 has been implicated at 
early stages of neuronal death, with local actions suggested to contribute to 
dysfunction and degeneration of synapses, further work is required to understand how 
P53 is involved in different neurodegenerative contexts. Here, I aimed to investigate 
the role of P53 in axonal and synaptic degeneration, asking whether reductions in P53 
can reduce synaptic loss under conditions of injury, during a die-back or during 
synapse elimination that occurs as part of normal development. In P53-reduced SMA 
and wild-type mice, I also sought to examine the impact of P53 reduction on the 
expression of synaptic genes that are thought to be regulated by P53. Overall, my data 
indicate a lack of association with P53 in all of the contexts examined, with no 
reductions in synaptic loss seen in injury or during a die-back, and normal levels of 
polyinnervation observed during development. In conditions where P53 or SMN 
protein is reduced, I also report no significant impact on the expression of synaptic 
genes. Collectively, data presented in this thesis supports that synaptic and axonal 
degeneration in these scenarios is not impacted by reductions in P53. 
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1.28 Results 
 
1.28.1 Tamoxifen treatment leads to recombination in P53-floxed mice 
 
To confirm cre-mediated recombination had taken place in P53-floxed mice, PCR 
reaction was undertaken on genomic DNA to probe for the presence of the recombined 
allele (Fig. 3.1). The recombined allele was only detected in P53-floxed mice that had 
been treated with tamoxifen, as demonstrated by the presence of a band at 612bp (Fig. 
3.1, B). qPCR was then performed on DNA from treated mice at age of sacrifice to 
determine the relative quantities of P53, to indicate the extent of P53 reduction. 
 
Following treatment with tamoxifen over two (Fig. 3.1, C) or three (Fig. 3.1, D and E) 
days, and at different time points, significant reductions in P53 levels were confirmed 
(Unpaired t-test with Welch correction, p < 0.018 in all cases). Postnatal induction of 
P53 recombination in floxed (Cre+) mice resulted on average in 2.3 fold reductions in 
P53 quantity, which is consistent with previous descriptions by our group (Courtney 
et al., 2019) (Fig. 3.1, C-E). In Smn2B/- mice, this level of reduction can return numbers 
of activated caspase-3 (AC3) positive cells – indicative of ongoing apoptosis – to 
baseline levels in heart, muscle, liver and spinal cord (Fig. 3.2). Thus, although 
postnatal, Cre-LoxP-mediated recombination of P53 does not lead to complete 
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Figure 3.1: P53 recombination occurs after tamoxifen treatment in P53-floxed mice 
only. (A) Structure of the P53-floxed allele adapted from Marino et al., 2000 (Marino 
et al., 2000). (B) Agarose gel imaged by UV illuminator showing PCR result. After 
tamoxifen dosing for 2-3 consecutive days, P53 recombination occurs and a band is 
detected in animals that express the floxed allele (P53fl/fl) and have been treated. Lanes 
1-5 contain DNA from P53fl/fl animals that have been treated with tamoxifen; Lanes 6-
8 contain DNA from littermate controls (P53+/+) that do not possess the floxed allele 
and have been treated with tamoxifen; Lanes 9 and 10 contain DNA from untreated 
controls with and without the floxed allele respectively, that have not been treated with 
tamoxifen. Lane 11 was loaded with sample that was devoid of DNA. Lane 12 contains 
a 100bp DNA ladder. The P53fl/fl allele is identified by a band at 612bp (primers IF and 
10R shown in (A) by PCR in treated P53fl/fl animals only, referred to here as Cre+, 
confirming recombination. Note that this band is only detected in animals that both 
express the floxed allele and have been treated with tamoxifen. (C-E) Relative 
quantities of P53 in P53-floxed mice shown relative to control as determined by qPCR. 
These data show that expression of P53 following tamoxifen treatment is significantly 
reduced after treatment at either P4 and P5 (C), P4, P5 and P6 (D) or P1, P2 and P3 
(E); in all cases, P53 expression is significantly downregulated at the time of sacrifice 
(p < 0.001, p < 0.01, and p < 0.018 respectively, Unpaired t-test with Welch’s 
correction). Black bars represent P53+/+ control treated animals, whilst white bars 



















Chapter 3: The role of P53 in morphologically distinct types of degeneration 153 
Figure 3.2: P53 reduction induced by postnatal tamoxifen treatment over two days 
is sufficient to return levels of activated caspase 3 (AC3) positive cells to baseline 
values in a number of tissues in P53-floxed Smn2B/- mice. (A) Micrographs from P15 
Smn2B/-;P53+/+ and Smn2B/-;P53-/- heart sections showing immunostaining of 
cardiomyocyte nuclei with DAPI (blue) and activated caspase-3 (AC3) (green) to 
indicate apoptotic cells. Examples of AC3 positive cells are indicated by white arrows. 
Scale bar: 50μm. (B) Comparison of the mean number of AC3 positive stained cells 
per section in different tissues at P15 in Smn2B/+;P53+/+, Smn2B/+;P53-/-, Smn2B/-;P53+/+, 
and Smn2B/-;P53-/- mice. Note that in heart, tibialis anterior muscle, and in the ventral 
horn of the thoracic spinal cord, there are significant reductions in the number of AC3 
positive cells in Smn2B/-;P53-/- mice, indicating that the induced reduction of P53 is 
sufficient to return apoptotic levels to baseline. This trend is also seen in liver. ns = 
not significant, p = 0.052; **, p < 0.007; ****, p < 0.0001; One-way ANOVA with 
Tukey correction. N (heart) = 4,6,3,3; n (muscle) = 4,4,3,3; n (liver) = 3,4,4,4 and n 
(spinal cord) = 3,3,3,3 for Smn2B/+;P53+/+, Smn2B/-;P53+/+, Smn2B/+;P53-/-, and Smn2B/-; 
P53-/- groups respectively. All comparisons where no statistical result is shown were 
not significantly different. Error bars represent mean ± SEM. I acknowledge Victoria 
Zimmel, Mohammad Omar Khan, Dr. Alison Thomson and Dr. Laura Comley for their 
assistance with this work. 
 
1.28.2 P53 reduction has no effect on levels of NMJ loss following injury 
 
Previous work has indicated that P53 signalling progressively increases in the distal 
nerve following injury, suggesting that P53 may play a role in synaptic degeneration 
in WD (Yao et al., 2013). Here, I aimed to investigate the role of P53 in WD using an 
ex vivo model of peripheral nerve injury with reduced P53 levels. It was hypothesised 
that P53 reduction would reduce synaptic loss following injury, consistent with P53 
playing a local role in synaptic degeneration during WD. 
 
To test this, the ex vivo model of nerve injury described in Chapter 1 was utilised. 
Following the induction of P53 recombination through tamoxifen treatment at P4, 5 
and 6, cranial nerve/muscle preparations from P53-floxed wild-type mice and 
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littermate controls were collected. These preparations were maintained in oxygenated 
physiological saline at 30ºC for 24 hr as described previously (see Chapter 1). This 
therefore generated a model of peripheral nerve injury with reduced levels of P53. As 
demonstrated in Chapter 1, rates of WD are age-dependent. At P25, minimal 
innervation would be expected to remain in any of the cranial muscles following injury 
in wild-type animals. If P53 signalling is involved in the mechanisms of synaptic 
degeneration following injury, then P53 reduction would be expected to reduce NMJ 
loss following injury. 
 
At P25, it was found that P53 reduction had no significant influence on the level of 
synaptic loss following injury (Two-way ANOVA with Sidak correction, p > 0.30). 
For example, in the LALr, when P53 levels are normal, there is just 8.32 ± 3.14% fully 
innervated endplates remaining, which is comparable to the 9.77 ± 5.40% remaining 
when P53 levels were reduced (Fig. 3.3). 
 
It is possible that P53 could only exhibit marginal affects at the synapse, which would 
be more apparent when synaptic degeneration is slower. I therefore expanded this 
analysis to assess the impact of P53 loss on the level of innervation remaining at P18. 
At the younger time point of P18, rates of synaptic loss are lower, with over 34% 
innervation remaining in the LALr, LALc and AS muscles (see Chapter 1, Results 
1.20.2). However, at P18, P53 reduction was found to have no significant influence on 
the level of synaptic loss following injury (Two-way ANOVA with Sidak correction, 
p > 0.15). For example, in the LALr, when P53 levels are normal, there is 34.99 ± 
6.73% fully innervated NMJs remaining after injury, which is comparable to P53-
reduced conditions, where the percentage of fully innervated endplates is 32.29 ± 
11.68% (Fig. 3.3). 
 
Overall, the loss of P53 had no significant effect on the level of synaptic loss at two 
age points, indicating P53-independence. 
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Figure 3.3: Synaptic loss following injury is not affected by reduced P53 levels in 
the cranial muscles. (A)  NMJs labelled with antibodies against neurofilament (NF, 
green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, red) 
from the LALr of control and P53-floxed mice at P18 after ex vivo maintenance at 
30ºC for 24 hr. Scale bar: 20μm. (B) Quantification of the percentage of fully occupied 
endplates in a range of cranial muscles from wild-type animals at P25 under conditions 
of normal versus reduced P53 (P53+ and P53- respectively). Note that there is no 
significant difference between these groups. (C) Quantification of the percentage of 
fully occupied endplates in a range of cranial muscles from wild-type animals at P18 
under conditions of normal versus reduced P53 (P53+ and P53- respectively). Note 
that there is no significant difference between these groups. In both (B) and (C), 
controls with normal levels of P53 are represented by black bars, whilst those with 
reduced P53 are represented by white bars. Ns = not significant, p > 0.99 in all cases; 
two-way ANOVA with Sidak correction. Note that at P25, n = 4 and 6 for the P53+ 
group and P53- group respectively. At P18, n = 6, 5, 6, 6 muscles for the P53+ group 
and 6, 5, 6, 6 muscles for the P53- group for the LALr, LALc, AS and AAL 
respectively. Error bars represent mean ± SEM. 
 
1.28.3 P53 reduction has no effect on levels of NMJ loss in an SMA mouse 
model 
 
Previously, we demonstrated that postnatal reductions in P53 can result in a significant 
reduction in NMJ loss in the TVA muscle of Smn2B/- mice at P15 (Courtney et al., 2019, 
see Appendix 3). Here, I aimed to undertake a more comprehensive analysis to assess 
whether reductions in P53 can promote similar improvements in neuromuscular 
pathology in other muscles. Firstly, analysis of the TVA muscle from P53-floxed 
Smn2B/- mice was undertaken to ensure that I could replicate previous findings in this 
muscle.  
 
Contrasting previous work, however, there was no significant improvement in NMJ 
retention in the TVA (Fig. 3.4). Since this finding was in contrast to previous results, 
quantification was performed by 3 independent researchers and all found no difference 
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in the percentage of fully innervated NMJs remaining at P15 between P53-floxed 
Smn2B/- mice and Smn2B/- littermate controls. For assistance with this validation, I 
acknowledge Victoria Zimmel and Dr. Laura Comley. I suggest that this inconsistency 
could be due to high variability in innervation across this muscle, which could have 
resulted in inadvertent selection for areas with high innervation. To ensure a fair 
representation of the muscle and reduce the chance of selection bias for innervated 
areas, bungarotoxin staining was used to select >100 motor endplates per muscle for 
analysis, with selected fields of view distributed across the entire muscle (detailed in 
Materials and Methods, 1.17 Quantification and Statistical Analyses).  
 
To provide a comprehensive overview of the effect of P53 reduction on synaptic loss 
in this model, the percentage of full, partial and vacant endplates were also quantified 
in the triangularis sterni (TS) and external oblique (EO) muscles at P15 from Smn2B/- 
mice following cre-mediated P53 recombination through tamoxifen induction at P4 
and 5. Note that consistent with previous work, tamoxifen treatment was initiated prior 
to P5, as this time point precedes evidence of P53 pathway activation in the spinal 
cord (Courtney et al., 2019). 
 
In the TS and EO, the Smn2B/- P53+/+ control group, referred to as 2B/- P53+, remained 
97.98 ± 0.84% and 93.41 ± 3.41% innervated respectively, and the Smn2B/- P53-/- 
experimental group, referred to as 2B/- P53-, remained 94.62 ± 3.09% and 91.38 ± 
2.76% innervated respectively (Figures 3.5 and 3.6 respectively). Concurrent with 
findings in the TVA, no significant improvements in neuromuscular innervation were 
observed in Smn2B/- mice when P53 was reduced in either TS (Fig. 3.5) or EO muscles 
(Fig. 3.6) (Two-way ANOVA with Sidak correction, p > 0.23 in both cases). P53 
reduction had no significant effect on the percentage of vacant endplates, which, for 
ease of visualisation, are also displayed on an extended axis (Fig. 3.5, C and Fig. 3.6, 
C) (One-way ANOVA with Tukey correction, p > 0.1). I did note a trend towards an 
increase in the percentage of fully occupied endplates in Smn2B/-P53-/- mice when 
compared to Smn2B/-P53+/+ mice, however this was not statistically significant (Two-
way ANOVA with Sidak correction, p > 0.45 and p > 0.55 for TS and EO 
respectively).  
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Overall, I conclude that P53 reduction does not significantly reduce levels of NMJ loss 
in Smn2B/- mice. 
 
 
Figure 3.4: P53 reduction has no significant effect on the level of NMJ innervation 
remaining in transversus abdominis (TVA) muscle from a SMA mouse model. 
Quantification of the percentage of full, partial and vacant endplates in the TVA 
muscle at P15 from Smn2B/- mice. Note that there is no significant difference between 
2B/- P53+ and 2B/- P53- groups. For assistance with validation, I acknowledge 
Victoria Zimmel and Dr. Laura Comley. Ns = not significant, p > 0.81 in all cases; 
Two-way ANOVA with Sidak correction. N = 8, 4 muscles for the 2B/- P53+ and 2B/- 
P53- groups respectively. Error bars represent mean ± SEM.  
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Figure 3.5: P53 reduction has no significant effect on the level of NMJ innervation 
remaining in triangularis sterni (TS) muscle from a SMA mouse model. (A) 
Confocal micrographs showing NMJs labelled with antibodies against neurofilament 
(NF, green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, 
red) from the TS of Smn2B/+ and Smn2B/- mice with normal and reduced levels of P53 at 
P15. Scale bar: 20μm. (B) Quantification of the percentage of full, partial and vacant 
endplates in the TS muscle at P15 from Smn2B/+ and Smn2B/- mice with normal and 
reduced levels of P53. Statistical significance applies to the ‘full’ category only. * p = 
0.012, ** p = 0.0049; Two-way ANOVA with Sidak correction. All comparisons 
where no statistical result is shown were not significantly different. (C) Graph with 
extended axis to display quantification of the percentage of vacant endplates only in 
the TS muscle at P15 from Smn2B/+ and Smn2B/- mice with normal and reduced levels of 
P53. Again, note that P53 reduction had no significant effect on levels of endplate 
vacancy. Ns, p > 0.1; One-way AVOVA with Tukey correction. N = 4,5,5,5 muscles 
in 2B/+ P53+, 2B+ P53-, 2B/- P53+ and 2B/- P53- groups respectively. Error bars 
represent mean ± SEM. 
 
 







Chapter 3: The role of P53 in morphologically distinct types of degeneration 162 
Figure 3.6: P53 reduction has no significant effect on the level of NMJ innervation 
remaining in external oblique (EO) muscle from a SMA mouse model. (A) Confocal 
micrographs showing NMJs labelled with antibodies against neurofilament (NF, 
green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, red) 
from the EO of Smn2B/- mice with normal and reduced levels of P53 at P15. Scale 
bar: 20μm. (B) Quantification of the percentage of full, partial and vacant endplates in 
the EO muscle from Smn2B/+ and Smn2B/- mice with normal and reduced levels of P53 
at P15. **/* represents statistical analyses from full/partial categories respectively. * 
p = 0.035, ** p = 0.0036. All comparisons where no statistical result is shown were 
not significantly different. (C) Graph with extended axis to display quantification of 
the percentage of vacant endplates only in the EO muscle at P15 from Smn2B/+ and 
Smn2B/- mice with normal and reduced levels of P53. Again, note that P53 reduction 
had no significant effect on levels of endplate vacancy. Ns, p > 0.3; One-way AVOVA 
with Tukey correction. N = 6 biological replicates in all groups. Error bars represent 
mean ± SEM. 
 
1.28.4 P53 reduction has no effect on rates of synapse elimination 
 
Thus far, I have established that NMJ degeneration that occurs following injury or 
during a die-back are not affected by reductions in P53. It is well-known that across 
first few weeks of development in mice, synapses also degenerate as part of the normal 
development, in a process known as synapse elimination. Here, I aimed to investigate 
whether reductions in P53 could alter rates of synapse elimination. To address this, 
P53 recombination was induced in P53-floxed wild-type mice by treatment with 
tamoxifen at P1, 2 and 3. I hypothesised that reduced P53 levels would delay synaptic 
pruning, consistent with P53 playing a role in synaptic remodelling.  
 
To assess whether P53 reduction could delay the withdrawal of synapses, I first 
analysed the level of monoinnervation remaining in two muscles at P14. By P14, the 
majority of endplates (over 94% in both muscles) had reached adult maturity, and 
therefore only exhibited one axonal input. P53 reduction had no significant effect on 
levels of monoinnervation at P14 in either the LALr or AS (Fig. 3.7) (Two-way 
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ANOVA with Sidak correction, p > 0.4).  In the LALr, when P53 levels were normal, 
98.16 ± 0.61% of endplates were monoinnervated, which was comparable to 98.94 ± 
0.47% monoinnervation when P53 was reduced. At P14, in P53+ mice, the majority 
of endplates are monoinnervated (>96%), suggesting that at this time point, the 
developmental period of synapse elimination is almost complete. I therefore also 
investigated synaptic maturity at a younger timepoint where higher levels of 
polyinnervation were expected. At P10, in P53+ mice, monoinnervation levels varied 
across different muscles, but did not exceed 83%. 
 
As discussed in Chapter 1, the temporal profile of synapse elimination varies across 
different muscles. For example, the TVA is over 82% monoinnervated at P10, whilst 
AAL is under 50% monoinnervated. To provide a more comprehensive analysis and 
examine whether intermuscular differences exist in P53 dependency, I examined a 
range of muscles at P10. It was found that P53 reduction had no significant effect on 
levels of the percentage of mono- or polyinnervation at P10 (Figures 3.8 and 3.9) 
(Two-way ANOVA with Sidak correction, p > 0.7). For example, in the LALr, 69.82 
± 1.09% of endplates were monoinnervated, which was not significantly altered by 
P53 reduction, where 75.48 ± 1.63% of endplates were monoinnervated. It was 
interesting to note that there were significant regional variations in NMJ maturation at 
P10, which have been discussed in terms of their role in altering synaptic stability in 
Chapter 1 (Fig. 3.9). Such differences were no longer apparent, nor significant, at P14 
(Two-way ANOVA, p > 0.08). For the purpose of this chapter, regional differences in 
the rate of synapse elimination will not be discussed. 
 
Overall, synaptic loss during development is unaffected when P53 levels are reduced. 
It therefore appears that P53-independence is a common feature of synaptic 
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Figure 3.7: Synapse elimination is P53-independent at P14. (A) Confocal 
micrographs showing NMJs labelled with antibodies against neurofilament (NF, 
green) and synaptic vesicle protein 2 (SV2, green), and α-bungarotoxin (BTX, red) in 
the LALr and AS of control and P53-floxed mice at P14. Scale bar: 20μm. (B) 
Quantification of the percentage of monoinnervated inputs in a range of cranial 
muscles from wild-type animals at P10 under conditions of normal versus reduced P53 
(P53+ (black bars) and P53- (grey bars) respectively). Note that there is no significant 
difference between these groups in either case. Ns = not significant, p > 0.4; two-way 
ANOVA with Sidak correction. N = 4 and 6 muscles for the P53+ and P53- groups 
respectively. Error bars represent mean ± SEM. 
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Figure 3.8: Levels of mono- and polyinnervation are unaffected by P53 reduction at 
P10 in a range of different muscles. Confocal micrographs showing NMJs labelled 
with antibodies against neurofilament (NF, green) and synaptic vesicle protein 2 (SV2, 
green), and α-bungarotoxin (BTX, red) in a range of cranial muscles and TVA of 
control and P53-floxed mice at P10. Note that P53 reduction does not appear to affect 




Figure 3.9: The rate of synapse elimination is not affected by P53 reduction at P10 
in a range of different muscles. Quantification of the percentage of endplates with 1, 
2 or 3+ inputs in a range of cranial muscles from wild-type animals at P10 under 
conditions of normal versus reduced P53 (P53+ and P53- respectively). 
Monoinnervated endplates (with 1 input) are represented by black, whilst those with 2 
inputs are grey, and those with 3 or more are white. Note that there is no significant 
difference between these groups in any case. Ns = not significant, p > 0.7 in all 
categories; Two-way ANOVA with Sidak correction. N = 8 muscles in all cases. Error 
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1.28.5 Analysis of transcripts implicated as being regulated by P53 
 
In previous work by Merlo et al., genes involved in controlling synaptic function 
emerged as being the top pathway regulated by P53 (Merlo et al., 2014). Since P53 
signalling has been shown to be upregulated in mouse models of SMA (Zhang et al., 
2008, Staropoli et al., 2015, Murray et al., 2015, Jangi et al., 2017, Baumer et al., 
2009), I aimed to investigate transcript levels of Bin1, Mef2c and Picalm in the Smn2B/- 
mouse model of SMA to determine whether these synaptic genes were dysregulated.  
 
In symptomatic Smn2B/- mice (P15), it was found that there were no significant 
differences in the relative normalised expression of Bin1, Mef2c or Picalm, suggesting 
that these genes are not disrupted by SMN loss in this model (two-way ANOVA with 
Sidak correction, p > 0.8) (Fig. 3.10).  Despite upregulations of P53 transcripts in this 
mouse (Murray et al., 2015), expression of these synaptic genes were unaffected; 
upregulations in P53 therefore do not appear to correlate with alterations to these 
synaptic genes, suggesting their expression is P53-independent. 
 
I further confirmed P53-independence by examining the levels of Bin1, Mef2c and 
Picalm in Smn+/+ mice when P53 was reduced through cre-mediated recombination of 
P53. P53 reduction had no effect on the expression levels of these transcripts, 
suggesting that these synaptic genes are not regulated by P53 (Two-way ANOVA with 
Sidak correction, p > 0.2) (Fig. 3.11).  
 
Overall, it is concluded that transcript levels of Bin1, Mef2c and Picalm are unaffected 
by reduced SMN or altered P53 levels, suggesting that their regulation is both SMN- 
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Figure 3.10: Expression of genes involved in synaptic function are unaffected by 
loss of SMN protein as assessed by RT-qPCR and 2-∆∆CT method in Smn2B/- mice. 
Using RT-qPCR, the expression levels of Bin1, Mef2c and Picalm were analysed at 
P15 in spinal cords of Smn2B/- mice. The disease model is represented by a pink bar, 
whilst control mice are represented by a blue bar. Note that no significant differences 
were detected in the expression of these genes. Data is expressed normalised to Actin, 
Gapdh and Ywhaz and relative to the 2B/+P53+ control group. Ns = not significant, p 
> 0.8; two-way ANOVA with Sidak correction. N = 4 biological replicates. Error bars 
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Figure 3.11: Expression of genes involved in synaptic function are not affected by 
reduced P53 levels as assessed by RT-qPCR and 2-∆∆CT method in P53-floxed mice. 
Using RT-qPCR, the expression levels of Bin1, Mef2c and Picalm were analysed at 
P15 in spinal cords following P53 recombination. The control group, with normal P53 
levels are represented by a dark blue bar, whilst the experimental group with reduced 
P53 are represented by a paler blue bar. Note that no significant differences were 
detected in the expression of these genes. Data is expressed normalised to Actin, 
Gapdh and Ywhaz and relative to the 2B/+ P53+ control group. Ns = not significant, p 
> 0.2; two-way ANOVA with Sidak correction. N = 4, 3 biological replicates for 
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1.29 Discussion 
 
1.29.1 Overview of Results 
 
In this chapter I investigated the role of P53 in morphologically distinct types of 
degeneration, including in the contexts of injury, disease and during development. I 
firstly demonstrated that postnatal Cre-LoxP-mediated recombination could 
significantly reduce P53 levels and prevent upregulation of apoptotic-associated 
markers in a range of tissues. I demonstrated that P53 reduction had no effect on levels 
of synaptic loss across a range of different muscles in a murine ex vivo model of 
peripheral nerve injury. Similarly, P53 reduction had no effect on levels of synaptic 
loss across different muscles in a mouse model of SMA. P53 reduction also had no 
effect on levels of polyinnervation across a range of different muscles, suggesting that 
synapse elimination is also P53-independent. Synaptic genes that are thought to be 
regulated by P53, including Bin1, Mef2c and Picalm, were not dysregulated in SMA 
mice, nor were transcript levels altered when P53 was reduced in wild-type mice, 
suggesting that their regulation is SMN- and P53-independent. 
 
1.29.2 Is the reduction in P53 levels sufficient? 
 
Here, I utilised an inducible, P53-floxed mouse model to investigate the role of P53 in 
different physiological scenarios. I utilised an inducible mouse model, which I have 
demonstrated undergoes Cre-LoxP-mediated recombination to express significantly 
reduced levels of P53 following postnatal treatment with tamoxifen. In this model, P53 
expression was reduced by 2.3-fold compared to mice that do not express the floxed 
allele.  
 
It must therefore be acknowledged that this model does not represent a complete 
knockout. This raises the question as to whether this level of P53 reduction is sufficient 
to cause measurable changes in P53-dependent processes? To address this, we 
examined levels of AC3 positive cells in a mouse model of SMA in a range of tissues. 
Caspase-3 plays a role in co-ordinating the destruction of cellular structures and is 
activated in cells that are undergoing apoptotic cell death, thus AC3 is considered a 
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biomarker of apoptosis (McIlwain et al., 2013). In Smn2B/- mice, we see a significant 
increase in the number of AC3 positive cells in skeletal muscle and spinal cord. In 
tamoxifen-treated, P53-floxed Smn2B/- mice, the number of AC3 positive cells is 
reduced back to baseline levels, suggesting that P53 reduction is sufficient to prevent 
upregulations in apoptosis. 
 
There are other models that may have been utilised that could have provided a more 
complete knockout. Gene targeting in embryonic stem cells is one such approach 
(Tong et al., 2010). A P53-germline knockout model could have been generated, 
however, there were several reasons why this was not selected. Firstly, numerous 
studies have suggested that P53 disruption can lead to developmental anomalies and 
malignancies, including the development of neural tube defects, and high rates of 
embryonic lethality (Armstrong et al., 1995, Sah et al., 1995, Kawamata and Ochiya, 
2012). P53 has been labelled ‘the guardian of the genome’, and has also been defined 
as a ‘guardian of embryogenesis,’ playing a crucial role in maintaining embryonic stem 
cell quality and genomic integrity (Kawamata and Ochiya, 2012). P53-null embryonic 
stem cells exhibit several abnormal features, including blockade of differentiation and 
severe chromosomal instability (Kawamata and Ochiya, 2012). 
 
It is also possible that knockout of P53 at the germline level could have resulted in 
embryonic-derived compensatory events to compensate for a lack of P53, which could 
have masked consequences of P53 reduction. Several studies have demonstrated that 
there are phenotypic differences between knockout and knockdown models (El-
Brolosy and Stainier, 2017). Deleterious mutations in zebrafish have been shown to 
result in profound phenotypic differences compared to gene knockdown (Rossi et al., 
2015). For example, whilst mutant zebrafish with an endothelial gene knocked out 
appear normal, knockdown of this endothelial gene leads to severe vascular defects 
(Rossi et al., 2015); proteomic and transcriptomic comparisons between knockout and 
knockdown zebrafish revealed compensatory gene activation in knockouts that could 
be responsible for such phenotypic disparity (Rossi et al., 2015). Genetic 
compensation has also been described in murine knockout models. For example, 
mutations in the cellular prion protein gene (Prnp), should be lethal, however a second 
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gene – Sprn – can compensate. Only when this compensatory gene is also knocked 
out, is lethality seen (Daude et al., 2012). Overall, it appears that compensatory 
networks in knockout animals may buffer against deleterious mutations, but less so in 
knockdown scenarios. In this respect, postnatal induction of P53 loss would reduce the 
chance of confounding, compensatory events that could mask the effects of P53 
reduction. Recently published work has also suggested that germline knockout of P53 
fails to prevent motor neuron loss or extend lifespan in an SMA mouse model, 
providing further support for work presented here (Reedich et al., 2021). 
 
I could also have induced P53 knockout pharmacologically, such as by using the small 
molecule pifithrin-α, however previous work in our lab, and that of others, has 
demonstrated that pharmacological inhibition of P53 does not inhibit all aspects of P53 
function (Zhu et al., 2020). Overall, although our postnatal P53 knockout is 
incomplete, data suggest that this is sufficient to prevent upregulations in apoptosis 
peripherally and centrally, whilst reducing the likelihood of genetic compensation. In 
future work, validation of P53 reduction at the protein level would be valuable. 
 
1.29.3 The role of P53 in axons and synapses 
 
In a murine ex vivo model of peripheral nerve injury, I found that P53 reduction had 
no effect on the level of synaptic loss after 24 hr when compared to control in a range 
of different muscles. In a P53-floxed mouse model of SMA, there were also no 
improvements in the percentage of fully occupied NMJs in a range of different 
muscles. I also demonstrated that P53 reduction did not prevent synaptic elimination 
during early postnatal development. A selection of synaptic genes also demonstrated 
P53-independent expression. My data collectively indicate that reductions in P53 do 
not reduce levels of synaptic loss in different physiological scenarios. There is 
evidence that has indicated that local P53 signalling at synapses can induce apoptosis 
(Mattson, 2000), therefore it is intriguing that P53 reduction does not improve synaptic 
retention in these contexts. Since P53 reduction does not prevent synaptic loss, what 
role does P53 play in axons and synapses? 
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It has been suggested that P53 could play a fundamental role in axonal outgrowth and 
regeneration following damage. Previous work has demonstrated that P53 is present 
at the synapse and that P53 signalling is progressively upregulated across in the distal 
axon following injury (Yao et al., 2013, Gilman et al., 2003). Compared to wild-type 
controls, P53 knockout mice show reduced levels of spontaneous regeneration 
following transection, whilst cell survival is unaffected, suggesting that P53 is required 
for regeneration (Di Giovanni et al., 2006, Tedeschi and Di Giovanni, 2009). P53 is 
required for neurite outgrowth in vitro in primary neurons and in vivo in mice. For 
example, P53 drives the expression of pro-regenerative responses, including through 
activating actin-binding protein Coronin 1b and the GTPase Rab13, which associate 
with the cytoskeleton and regulate neurite outgrowth (Di Giovanni et al., 2006). Di 
Giovanni et al., demonstrate that acetylation of P53 on lysine 320 is a requirement for 
neurite outgrowth and axonal regeneration (Di Giovanni et al., 2006). Regeneration 
could be hindered by a lack of removal of damaged cells, therefore P53’s role in DNA 
repair and elimination of damaged cells also appears to be critical to regenerative 
efforts. To ensure successful outgrowth and regeneration, axon guidance and 
pathfinding are also essential. The role of P53 in these processes remains unclear, 
however there is evidence that suggests that P53 can drive the expression of various 
factors that regulate axon guidance, including semaphorins (Futamura et al., 2007, 
Ochi et al., 2002, Arakawa, 2005, Barallobre et al., 2005, Harel and Strittmatter, 2006, 
Pasterkamp and Verhaagen, 2006). Overall, P53 may therefore contribute to and 
coordinate axonal regenerative efforts.  
 
Interestingly, it has been reported that 80% of mice can develop normally despite P53 
knockout, which draws the role of P53 in development into question (Tedeschi and Di 
Giovanni, 2009). However, it has been proposed that other P53 family members, like 
P63 or P73, may compensate for the loss of P53. Truncated isoforms of P73 have been 
shown to protect neurons from cell death following apoptotic stimuli in both the CNS 
and PNS (Pozniak et al., 2000, Pozniak et al., 2002). It has been proposed that P73 
may even counteract the pro-apoptotic functions of P53 in developing neurons, with 
increased levels of truncated P73 found to rescue neurons from apoptosis induced by 
trophic withdrawal or P53 overexpression (Pozniak et al., 2000). Studies investigating 
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P53 and P63 deletion have demonstrated that full-length P63 is required and sufficient 
to induce cell death following trophic withdrawal, and that absence of P53 does not 
affect P63-induced apoptosis (Jacobs et al., 2005). In the context of the work presented 
here, this may suggest that other P53 family members could be influencing, or 
exhibiting compensatory actions, independently of P53 at the synapse too. Although 
the role of different members of the P53 family have been investigated in terms of 
embryonic development and in cancer, their postnatal roles and interaction remain 
unclear (Van Nostrand et al., 2017). Investigating the role of other P53 family 
members in synaptic degeneration following different insults will be an important 
consideration for future work if we are to fully understand its role. 
 
Apoptotic pathways converge on caspases, such as caspase 3 which is described as 
being an ‘executioner of apoptosis’ (Elmore, 2007, Simon et al., 2012). Manipulation 
of executioner caspases could provide greater insight into the role of pro-apoptotic 
pathways in different contexts. Previous in vitro work has demonstrated that caspase-
3 knockout is protective against axon degeneration that is induced by trophic factor 
withdrawal in vitro, and can delay axon pruning of exuberant retinocollicular axons 
during development in vivo (Simon et al., 2012). Inhibition of caspase 3, has also been 
shown to rescue motor neurons cultured from SMA patient-iPSCs (Sareen et al., 2012). 
However, caspase-3 deletion does not protect against WD following axon transection, 
indicating that caspase-3 is not involved in WD (Simon et al., 2012). Manipulating 
caspase-3 may provide further insight into the role of pro-apoptotic pathways in 
synaptic degeneration under different degenerative scenarios. Overall, the role of P53 
is undoubtedly complex, due to its ability to influence pro- and anti-apoptotic 
pathways. More work is clearly required if we are to fully appreciate the role of P53 












1.30 Overview of Results 
 
Work presented within this thesis has explored factors that can influence the rate of 
degeneration under different degenerative scenarios, including following injury, 
during disease and during postnatal development. 
 
In Chapter 1, I expanded an ex vivo model of peripheral nerve injury which I 
subsequently applied to a range of different scenarios. I demonstrated that 
developmental regulation and selective vulnerability are features of WD in the murine 
cranial muscles, and described a remarkable resistance to degeneration following 
injury in the thoracoabdominal musculature. Patterns of selective vulnerability in WD 
were found to be distinct from those described during a die-back in the Smn2B/- mouse 
model of SMA. Using preparations from the Smn2B/- mouse, I applied the ex vivo assay 
to demonstrate that WD is Smn-independent, and that the presence of a die-back can 
accelerate synaptic loss following injury. Work presented in this chapter favours the 
conclusion that there is convergence in degenerative mechanisms in WD and dying-
back pathology. 
 
In Chapter 2, I analysed two independent proteomic datasets to demonstrate that there 
were common and consistent increases in mitochondrial proteins across early postnatal 
development in the deep lumbrical and tibialis anterior muscles, that coincide with 
accelerations in the rate of synaptic degeneration following injury across the first few 
weeks of life in mice. I demonstrated that these proteomic changes could be accounted 
for by an increase in mitochondrial number in nerve, but not in muscle. I expanded 
this analysis to assess whether mitochondrial number or protein levels could explain 
differences in synaptic vulnerability in a range of other nerves and muscles. I found 
that changes in mitochondrial complex protein levels did not correlate with 






Differential rates of synaptic degeneration between muscles did not correlate with 
changes in mitochondrial number in muscle or nerve. However, differential rates of 
synaptic degeneration in different muscles did correlate with CI levels in nerve. 
Overall, data presented in this chapter suggest that although there are global changes 
in mitochondrial proteins across P15 to 24, these do not correlate with accelerations in 
the rate of synaptic degeneration following injury across early postnatal development 
in muscle, although changes in nerve may play a role in conferring selective 
vulnerability. 
 
In Chapter 3, I used a P53-floxed inducible mouse model to assess the role of P53 
under different degenerative scenarios. Application of the ex vivo model demonstrated 
that P53 reductions had no effect on the level of synaptic loss following injury, 
suggesting that WD is P53-independent. In the Smn2B/- mouse model, I demonstrated 
that P53 reduction had no effect on the level of NMJ loss in a range of different 
muscles at a late-symptomatic stage. This suggests that dying-back pathology in SMA 
is also P53-independent. P53 reduction had no effect on levels of polyinnervation 
during postnatal development, suggesting that synapse elimination is also P53-
independent. Finally, I demonstrated that neither P53 nor SMN reductions had any 
effect on the expression of a selection of synaptic genes. Overall, data presented within 
this chapter suggest that P53-independence is a common feature across 
morphologically distinct types of synaptic and axonal degeneration. 
 
1.31 A valuable tool for mechanistic insight: ex vivo applications  
 
In this work, I have expanded an ex vivo model and subsequently demonstrated that 
this can be applied to effectively test various hypotheses. For example, I applied the 
ex vivo assay to test whether the developmental phenomenon of acceleration in 
synaptic degeneration was present in a range of other muscles. This assay also revealed 
that selective vulnerability is a feature of WD. Selective vulnerability has not been 
described in WD before, and future work could exploit intermuscular differences as a 







Through application of the ex vivo model, I have demonstrated that in a muscle with 
extensive dying-back pathology induced by reduced Smn, injury-induced synaptic loss 
is accelerated. This demonstrates that the presence of a die-back can accelerate WD, 
suggesting that mechanistic convergence exists. This supports the hypothesis that there 
are common mechanisms involved in synaptic degeneration in morphologically 
distinct types of synaptic degeneration. To further test this, preparations from other 
models that exhibit a die-back could be tested in the ex vivo system. It is hypothesised 
that similar accelerations in synaptic loss would be seen in other models that exhibit 
dying-back pathology, such as in the SOD1 mouse model of ALS. This would be 
consistent with convergent degenerative pathways being responsible for dying-back 
and WD, and could facilitate the identification of common targets of 
neurodegeneration which could have efficacy across different diseases where dying-
back is a pathological feature.  
 
To address the debate over mechanistic divergence, we could also introduce 
preparations from mouse models where WldS has previously failed to confer 
protection. For example, we could introduce preparations from the pmn mouse (Ferri 
et al., 2003) or myelin protein zero mouse (Samsam et al., 2003) and assess levels of 
synaptic loss after injury. If the rate of WD is unaffected, then this would indicate that 
different pathways are responsible for dying-back, and ultimately motor neuron death, 
in these scenarios, despite morphological similarities. It would also be interesting to 
assess the level of synaptic loss in Wst mice. In Wst mice, loss of eEF1A2 results in a 
die-back, and significantly delays synaptic loss induced by axotomy in the DL muscles 
in vivo (Murray et al., 2008b). It would be interesting to assess whether the loss of 
eEF1A2 expression, and the consequent presence of a die-back, can similarly delay 
injury-induced synaptic loss in other muscles. We could test this by introducing Wst 
preparations to the ex vivo system. If the rate of WD is delayed, then this would support 
the hypotheses that opposing mechanisms exist, as the presence of a die-back induced 
by loss of eEF1A2 would be sufficient to block WD. Overall, using this ex vivo model, 
we can begin to categorise synaptic degeneration into pathologies which can accelerate 






categorisation will help us to identify diseases where common therapeutic approaches 
could be utilised. 
 
The nature of ex vivo experimentation, where preparations are suspended in a 
physiological solution, facilitates easy manipulation of variables pharmacologically. I 
have demonstrated that there is a lack of correlation between changes in mitochondrial 
proteins or number and accelerations in the rate of synaptic loss during early postnatal 
development. This conclusion could be further supported through ex vivo application 
of pharmacological agents that target oxidative phosphorylation. We have previously 
demonstrated that in vitro application of an inhibitor of CI (rotenone) can reduce 
axonal loss in DRG cultures (Kline et al., 2019). Based on results presented in Chapter 
2, it could be hypothesised that rotenone application would not delay synaptic loss in 
the cranial or thoracoabdominal musculature in an ex vivo injury scenario. In addition, 
although I have demonstrated that increases in CI cannot account for developmental 
regulation, I found that CI changes in nerve did correlate with patterns of selective 
vulnerability following injury. It would therefore be interesting to assess whether 
rotenone application ex vivo could alter levels of synaptic loss following injury across 
different muscles. If rotenone application can modify the pattern of injury-induced 
selective vulnerability, then this would be consistent with the hypothesis that increases 
in CI are responsible for intermuscular differences. Pharmacological intervention ex 
vivo is also clearly not restricted to oxidative phosphorylation, and other factors could 
be manipulated through the inclusion of pharmacological agents in the suspension 
buffer. By utilising cranial muscle/facial nerve preparations as described in Chapter 1, 
we could simultaneously assess the impact of stimulation or inhibition of different 
targets on selective vulnerability and developmental regulation following injury. 
Notably, however, there are limitations to pharmacological manipulation, including 
that inhibition could be incomplete or have off-target effects. Genetic manipulation 
through the introduction of mutant preparations to the ex vivo, following the workflow 
described in Chapter 3, may therefore provide a more powerful tool to test hypotheses 







1.32 A workflow for investigating common pathways of synaptic degeneration 
 
Ex vivo assaying allows us to deliver reproducible injuries that can be performed across 
various mouse models with different loss- or gain-of-function mutations. I have 
provided an example of this by applying the ex vivo assay to test the hypothesis that 
P53 reduction can reduce synaptic loss following injury in mice. Although the data 
from P53 work is negative, this underlines the value of the ex vivo model and scope to 
test other scenarios to elucidate factors that can influence rates of degeneration. Whilst 
P53 does not appear to be a convergent regulator of synaptic degeneration, the 
workflow implemented in Chapter 3 has described an approach to investigate 
morphologically distinct types of degeneration. Ex vivo assaying permits reproducible 
injuries which can be performed across various mouse models with different loss- or 
gain-of-function mutations. A similar workflow could be implemented to assess the 
involvement of other pathways in synaptic degeneration.  
 
For example, this could be implemented to investigate the role of ubiquitination 
pathways which have been implicated in synaptic degeneration (Gillingwater and 
Wishart, 2013). Ubiquitin-mediated protein degradation, also known as the ubiquitin 
proteasome system, is an evolutionarily conserved and tightly regulated biochemical 
pathway (Ding and Shen, 2008, Schlesinger and Goldstein, 1975). Ubiquitination 
processes are most well-known for their role in targeting proteins for degradation, 
however it is widely accepted that ubiquitination is a post-translational modification 
that can influence protein activity and localisation (Kim and Rao, 2006, Pickart and 
Fushman, 2004). At the synapse, such post-translational changes have been shown to 
regulate many functions, including endocytosis (Schwarz and Patrick, 2012, d'Azzo et 
al., 2005), pre- and post-synaptic neurotransmission (Speese et al., 2003, Dreier et al., 
2005), and, perhaps most relevant for this discussion, axon pruning and synapse 
elimination (Zhai et al., 2003, Kuo et al., 2006). Inhibiting the ubiquitin proteasome 
system through pharmacologic or genetic means has been shown to delay axonal 
degeneration following nerve transection (Zhai et al., 2003). Increased levels of E1-
ubiquitin activating enzyme (Ube1) are also reported in proteomic screens in WldS, 






Mutations in an Ube1 have also been linked to pathogenesis in SMA (Ramser et al., 
2008). Mutations in other members of the ubiquitin family have been linked to many 
other neurodegenerative diseases (Gillingwater and Wishart, 2013).  
 
There is therefore evidence that ubiquitin pathways are involved in the regulation of 
synaptic stability. If ubiquitin pathways are commonly involved in determining the 
rate of synaptic degeneration, and since increased levels are reported in WldS, then it 
could be hypothesised that loss of Ube1 would accelerate synaptic loss under different 
physiological scenarios. This could be tested in a similar way as I have described for 
P53. For example, we could utilise Ube1 knockout mice to assess how Ube1 knockout 
can influence the rate of synaptic degeneration in morphologically distinct scenarios. 
We could introduce Ube1 knockout preparations to the ex vivo system to assess how 
loss of Ube1 impacts synaptic loss in different muscles following injury. We could 
also cross this knockout mutation into Smn2B/- mice to assess whether Ube1 knockout 
improves synaptic retention at late-symptomatic time points. Finally, we could assess 
whether the loss of Ube1 could delay synapse elimination in early postnatal 
development in different muscles. In this way, the hypothesis that Ube1 is a convergent 
regulator of synaptic degeneration can be effectively tested. This exemplifies how ex 
vivo assaying can be applied to test another pathway, however ubiquitination pathways 
are not the only candidate.  
 
Another example could be to test the hypothesis that Rho-kinase (ROCK) signalling 
pathway inhibition could promote synaptic retention in different contexts. As reviewed 
by Koch et al., 2018, pathophysiological changes in ROCK signalling have been 
implicated in a wide range of neurodegenerative diseases, and there is also evidence 
to support that ROCK activity plays an important role in regulating synaptic function; 
inhibition of ROCK signalling has been shown to interfere with the induction of 
apoptotic pathways, and so inhibition of ROCK signalling could have neuroprotective 
effects (Koch et al., 2018). I have therefore described a workflow which provides the 
basis to investigate the involvement of other pathways that may influence the rate of 







1.33 Concluding remarks 
 
This work has expanded an ex vivo model of peripheral nerve injury that provides an 
invaluable tool with which to investigate mechanisms of axonal and synaptic 
degeneration. I have demonstrated that this model can be applied to provide novel 
insight into the mechanistic underpinnings of synaptic and axonal degeneration. 
Application of this model has allowed me to demonstrate that mechanistic 
commonality exists between dying-back pathology and WD, which will contribute 
towards resolving the debate surrounding mechanistic convergence and divergence in 
morphologically distinct forms of synaptic degeneration. I would like to conclude by 
reiterating that the importance of understanding mechanisms of synaptic degeneration 
under different physiological scenarios cannot be understated; by identifying common 
factors that can alter the rate of synaptic degeneration in different scenarios, we move 









Aloyz RS, Bamji SX, Pozniak CD, et al. (1998) p53 is essential for 
developmental neuron death as regulated by the TrkA and p75 
neurotrophin receptors. J Cell Biol, 143, 1691-703. 
Arakawa H (2005) p53, apoptosis and axon-guidance molecules. Cell Death 
Differ, 12, 1057-65. 
Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency 
developmental abnormalities in p53-deficient mice. Curr Biol, 5, 931-6. 
Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A (2018) How does p53 
induce apoptosis and how does this relate to p53-mediated tumour 
suppression? Cell Death Differ, 25, 104-113. 
Avery MA, Rooney TM, Pandya JD, et al. (2012) WldS prevents axon 
degeneration through increased mitochondrial flux and enhanced 
mitochondrial Ca2+ buffering. Curr Biol, 22, 596-600. 
Avery MA, Sheehan AE, Kerr KS, Wang J, Freeman MR (2009) Wld S requires 
Nmnat1 enzymatic activity and N16-VCP interactions to suppress 
Wallerian degeneration. J Cell Biol, 184, 501-13. 
Babetto E, Beirowski B, Janeckova L, et al. (2010) Targeting NMNAT1 to 
axons and synapses transforms its neuroprotective potency in vivo. J 
Neurosci, 30, 13291-304. 
Ballatori N, Krance SM, Notenboom S, Shi S, Tieu K, Hammond CL (2009) 
Glutathione dysregulation and the etiology and progression of human 
diseases. Biol Chem, 390, 191-214. 
Bandmann O, Burton EA (2010) Genetic zebrafish models of 
neurodegenerative diseases. Neurobiol Dis, 40, 58-65. 
Barallobre MJ, Pascual M, Del Rio JA, Soriano E (2005) The Netrin family of 
guidance factors: emphasis on Netrin-1 signalling. Brain Res Brain Res 
Rev, 49, 22-47. 
Barkeeva LE, Chentsov YS, Skulachev, VP (1981) Ontogenesis of 
mitochondrial reticulum in rat diaphragm muscle. Eur J Cell Biol, 25, 
175-81. 
Barrientos SA, Martinez NW, Yoo S, et al. (2011) Axonal degeneration is 
mediated by the mitochondrial permeability transition pore. J Neurosci, 
31, 966-78. 
Battaglia G, Princivalle A, Forti F, Lizier C, Zeviani M (1997) Expression of the 
SMN gene, the spinal muscular atrophy determining gene, in the 
mammalian central nervous system. Hum Mol Genet, 6, 1961-71. 
Baumer D, Lee S, Nicholson G, et al. (2009) Alternative splicing events are a 
late feature of pathology in a mouse model of spinal muscular atrophy. 
PLoS Genet, 5, e1000773. 
Beal MF (2002) Oxidatively modified proteins in aging and disease. Free Radic 
Biol Med, 32, 797-803. 
Bear MF, Connor BW, Paradiso MA (2007) Neuroscience: Exploring the Brain, 






Bebee TW, Dominguez CE, Chandler DS (2012) Mouse models of SMA: tools 
for disease characterization and therapeutic development. Hum Genet, 
131, 1277-93. 
Becker TS, Rinkwitz S (2012) Zebrafish as a genomics model for human 
neurological and polygenic disorders. Dev Neurobiol, 72, 415-28. 
Bede P, Pradat PF (2019) Editorial: Biomarkers and Clinical Indicators in Motor 
Neuron Disease. Front Neurol, 10, 1318. 
Beirowski B, Adalbert R, Wagner D, et al. (2005) The progressive nature of 
Wallerian degeneration in wild-type and slow Wallerian degeneration 
(WldS) nerves. BMC Neurosci, 6, 6. 
Beirowski B, Babetto E, Gilley J, et al. (2009) Non-nuclear Wld(S) determines 
its neuroprotective efficacy for axons and synapses in vivo. J Neurosci, 
29, 653-68. 
Beirowski B, Berek L, Adalbert R, et al. (2004) Quantitative and qualitative 
analysis of Wallerian degeneration using restricted axonal labelling in 
YFP-H mice. J Neurosci Methods, 134, 23-35. 
Benard G. Bellance N, Jose C, Rossignol R (2011) Relationships between 
mitochondrial dynamics and bioenergetics. In Mitochondrial Dynamics 
and Neurodegeneration, Lu B, Ed; Springer Science + Business Media 
B.V: Dordrecht, Netherlans, 47-68. 
Bendszus M, Stoll G (2003) Caught in the act: in vivo mapping of macrophage 
infiltration in nerve injury by magnetic resonance imaging. J Neurosci, 
23, 10892-6. 
Billger M, Wallin M, Karlsson JO (1988) Proteolysis of tubulin and microtubule-
associated proteins 1 and 2 by calpain I and II. Difference in sensitivity 
of assembled and disassembled microtubules. Cell Calcium, 9, 33-44. 
Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative 
stress and antioxidant defense. World Allergy Organ J, 5, 9-19. 
Bishop DL, Misgeld T, Walsh MK, Gan WB, Lichtman JW (2004) Axon branch 
removal at developing synapses by axosome shedding. Neuron, 44, 
651-61. 
Bowerman M, Murray LM, Beauvais A, Pinheiro B, Kothary R (2012) A critical 
smn threshold in mice dictates onset of an intermediate spinal muscular 
atrophy phenotype associated with a distinct neuromuscular junction 
pathology. Neuromuscul Disord, 22, 263-76. 
Boyd PJ, Tu WY, Shorrock HK, et al. (2017) Bioenergetic status modulates 
motor neuron vulnerability and pathogenesis in a zebrafish model of 
spinal muscular atrophy. PLoS Genet, 13, e1006744. 
Brand MD (2010) The sites and topology of mitochondrial superoxide 
production. Exp Gerontol, 45, 466-72. 
Brockington A, Ning K, Heath PR, et al. (2013) Unravelling the enigma of 
selective vulnerability in neurodegeneration: motor neurons resistant to 
degeneration in ALS show distinct gene expression characteristics and 
decreased susceptibility to excitotoxicity. Acta Neuropathol, 125, 95-
109. 
Brodsky MH, Nordstrom W, Tsang G, Kwan E, Rubin GM, Abrams JM (2000) 
Drosophila p53 binds a damage response element at the reaper locus. 






Brown R, Hynes-Allen A, Swan AJ, Dissanayake KN, Gillingwater TH, 
Ribchester RR (2015) Activity-dependent degeneration of axotomized 
neuromuscular synapses in Wld S mice. Neuroscience, 290, 300-20. 
Caillaud M, Richard L, Vallat JM, Desmouliere A, Billet F (2019) Peripheral 
nerve regeneration and intraneural revascularization. Neural Regen 
Res, 14, 24-33. 
Calixto A, Jara JS, Court FA (2012) Diapause formation and downregulation 
of insulin-like signaling via DAF-16/FOXO delays axonal degeneration 
and neuronal loss. PLoS Genet, 8, e1003141. 
Calliari A, Bobba N, Escande C, Chini EN (2014) Resveratrol delays Wallerian 
degeneration in a NAD(+) and DBC1 dependent manner. Exp Neurol, 
251, 91-100. 
Calucho M, Bernal S, Alias L, et al. (2018) Correlation between SMA type and 
SMN2 copy number revisited: An analysis of 625 unrelated Spanish 
patients and a compilation of 2834 reported cases. Neuromuscul 
Disord, 28, 208-215. 
Casanova B, Martinez-Bisbal MC, Valero C, et al. (2003) Evidence of 
Wallerian degeneration in normal appearing white matter in the early 
stages of relapsing-remitting multiple sclerosis: a HMRS study. J 
Neurol, 250, 22-8. 
Cavanagh JB (1964) The significance of the "dying back" process in 
experimental and human neurological disease. Int Rev Exp Pathol, 3, 
219-67. 
Chaytow H, Huang YT, Gillingwater TH, Faller KME (2018) The role of survival 
motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci, 
75, 3877-3894. 
Chen X, Gays D, Santoro MM (2016) Transgenic Zebrafish. Methods Mol Biol, 
1464, 107-114. 
Chhabra A, Ahlawat S, Belzberg A, Andreseik G (2014) Peripheral nerve injury 
grading simplified on MR neurography: As referenced to Seddon and 
Sunderland classifications. Indian J Radiol Imaging, 24, 217-24. 
Chio A, Logroscino G, Hardiman O, et al. (2009) Prognostic factors in ALS: A 
critical review. Amyotroph Lateral Scler, 10, 310-23. 
Ciccarelli O, Werring DJ, Barker GJ, et al. (2003) A study of the mechanisms 
of normal-appearing white matter damage in multiple sclerosis using 
diffusion tensor imaging--evidence of Wallerian degeneration. J Neurol, 
250, 287-92. 
Coady TH, Lorson CL (2011) SMN in spinal muscular atrophy and snRNP 
biogenesis. Wiley Interdiscip Rev RNA, 2, 546-64. 
Coleman M (2005) Axon degeneration mechanisms: commonality amid 
diversity. Nat Rev Neurosci, 6, 889-98. 
Coleman MP, Conforti L, Buckmaster EA, et al. (1998) An 85-kb tandem 
triplication in the slow Wallerian degeneration (Wlds) mouse. Proc Natl 
Acad Sci U S A, 95, 9985-90. 
Coleman MP, Freeman MR (2010) Wallerian degeneration, wld(s), and nmnat. 






Comley L, Allodi I, Nichterwitz S, et al. (2015) Motor neurons with differential 
vulnerability to degeneration show distinct protein signatures in health 
and ALS. Neuroscience, 291, 216-29. 
Comley LH, Nijssen J, Frost-Nylen J, Hedlund E (2016) Cross-disease 
comparison of amyotrophic lateral sclerosis and spinal muscular 
atrophy reveals conservation of selective vulnerability but differential 
neuromuscular junction pathology. J Comp Neurol, 524, 1424-42. 
Conforti L, Gilley J, Coleman MP (2014) Wallerian degeneration: an emerging 
axon death pathway linking injury and disease. Nat Rev Neurosci, 15, 
394-409. 
Conforti L, Wilbrey A, Morreale G, et al. (2009) Wld S protein requires Nmnat 
activity and a short N-terminal sequence to protect axons in mice. J Cell 
Biol, 184, 491-500. 
Costanzo EM, Barry JA, Ribchester RR (2000) Competition at silent synapses 
in reinnervated skeletal muscle. Nat Neurosci, 3, 694-700. 
Courtney NL, Mole AJ, Thomson AK, Murray LM (2019) Reduced P53 levels 
ameliorate neuromuscular junction loss without affecting motor neuron 
pathology in a mouse model of spinal muscular atrophy. Cell Death Dis, 
10, 515. 
Crawford TO, Hsieh ST, Schryer BL, Glass JD (1995) Prolonged axonal 
survival in transected nerves of C57BL/Ola mice is independent of age. 
J Neurocytol, 24, 333-40. 
Cross CE, Halliwell B, Borish ET, et al. (1987) Oxygen radicals and human 
disease. Ann Intern Med, 107, 526-45. 
Culmsee C, Mattson MP (2005) p53 in neuronal apoptosis. Biochem Biophys 
Res Commun, 331, 761-77. 
d'Azzo A, Bongiovanni A, Nastasi T (2005) E3 ubiquitin ligases as regulators 
of membrane protein trafficking and degradation. Traffic, 6, 429-41. 
Daude N, Wohlgemuth S, Brown R, et al. (2012) Knockout of the prion protein 
(PrP)-like Sprn gene does not produce embryonic lethality in 
combination with PrP(C)-deficiency. Proc Natl Acad Sci U S A, 109, 
9035-40. 
David S, Ousman SS (2002) Recruiting the immune response to promote axon 
regeneration in the injured spinal cord. Neuroscientist, 8, 33-41. 
Di Giovanni S, Knights CD, Rao M, et al. (2006) The tumor suppressor protein 
p53 is required for neurite outgrowth and axon regeneration. EMBO J, 
25, 4084-96. 
Di Stefano M, Nascimento-Ferreira I, Orsomando G, et al. (2015) A rise in NAD 
precursor nicotinamide mononucleotide (NMN) after injury promotes 
axon degeneration. Cell Death Differ, 22, 731-42. 
DiDonato CJ, Lorson CL, De Repentigny Y, et al. (2001) Regulation of murine 
survival motor neuron (Smn) protein levels by modifying Smn exon 7 
splicing. Hum Mol Genet, 10, 2727-36. 
Ding M, Shen K (2008) The role of the ubiquitin proteasome system in synapse 
remodeling and neurodegenerative diseases. Bioessays, 30, 1075-83. 
Dreier L, Burbea M, Kaplan JM (2005) LIN-23-mediated degradation of beta-
catenin regulates the abundance of GLR-1 glutamate receptors in the 






Du H, Guo L, Yan S, Sosunov AA, McKhann GM, Yan SS (2010) Early deficits 
in synaptic mitochondria in an Alzheimer's disease mouse model. Proc 
Natl Acad Sci U S A, 107, 18670-5. 
Ducker GS, Rabinowitz JD (2017) One-Carbon Metabolism in Health and 
Disease. Cell Metab, 25, 27-42. 
Eizenberg O, Faber-Elman A, Gottlieb E, Oren M, Rotter V, Schwartz M (1996) 
p53 plays a regulatory role in differentiation and apoptosis of central 
nervous system-associated cells. Mol Cell Biol, 16, 5178-85. 
El-Brolosy MA, Stainier DYR (2017) Genetic compensation: A phenomenon in 
search of mechanisms. PLoS Genet, 13, e1006780. 
Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989) Wild-type 
p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci 
U S A, 86, 8763-7. 
Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicol Pathol, 
35, 495-516. 
Elsheikh B, Prior T, Zhang X, et al. (2009) An analysis of disease severity 
based on SMN2 copy number in adults with spinal muscular atrophy. 
Muscle Nerve, 40, 652-6. 
Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J (2017) 
The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic 
NAD(+) Cleavage Activity that Promotes Pathological Axonal 
Degeneration. Neuron, 93, 1334-1343 e5. 
Ferrer I, Lopez-Gonzalez I, Carmona M, Dalfo E, Pujol A, Martinez A (2012) 
Neurochemistry and the non-motor aspects of PD. Neurobiol Dis, 46, 
508-26. 
Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC (2003) Inhibiting 
axon degeneration and synapse loss attenuates apoptosis and disease 
progression in a mouse model of motoneuron disease. Curr Biol, 13, 
669-73. 
Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a 
suppressor of transformation. Cell, 57, 1083-93. 
Fischer LR, Culver DG, Davis AA, et al. (2005) The WldS gene modestly 
prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis, 19, 
293-300. 
Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene, 22, 
9030-40. 
Futamura M, Kamino H, Miyamoto Y, et al. (2007) Possible role of semaphorin 
3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated 
tumor angiogenesis suppression. Cancer Res, 67, 1451-60. 
Geden MJ, Deshmukh M (2016) Axon degeneration: context defines distinct 
pathways. Curr Opin Neurobiol, 39, 108-15. 
George EB, Glass JD, Griffin JW (1995) Axotomy-induced axonal 
degeneration is mediated by calcium influx through ion-specific 
channels. J Neurosci, 15, 6445-52. 
Giachin G, Bouverot R, Acajjaoui S, Pantalone S, Soler-Lopez M (2016) 
Dynamics of Human Mitochondrial Complex I Assembly: Implications 






Giavazzi A, Setola V, Simonati A, Battaglia G (2006) Neuronal-specific roles 
of the survival motor neuron protein: evidence from survival motor 
neuron expression patterns in the developing human central nervous 
system. J Neuropathol Exp Neurol, 65, 267-77. 
Gilley J, Adalbert R, Yu G, Coleman MP (2013) Rescue of peripheral and CNS 
axon defects in mice lacking NMNAT2. J Neurosci, 33, 13410-24. 
Gilley J, Coleman MP (2010) Endogenous Nmnat2 is an essential survival 
factor for maintenance of healthy axons. PLoS Biol, 8, e1000300. 
Gilley J, Orsomando G, Nascimento-Ferreira I, Coleman MP (2015) Absence 
of SARM1 rescues development and survival of NMNAT2-deficient 
axons. Cell Rep, 10, 1974-81. 
Gillingwater TH, Haley JE, Ribchester RR, Horsburgh K (2004) 
Neuroprotection after transient global cerebral ischemia in Wld(s) 
mutant mice. J Cereb Blood Flow Metab, 24, 62-6. 
Gillingwater TH, Ingham CA, Coleman MP, Ribchester RR (2003) 
Ultrastructural correlates of synapse withdrawal at axotomized 
neuromuscular junctions in mutant and transgenic mice expressing the 
Wld gene. J Anat, 203, 265-76. 
Gillingwater TH, Ingham CA, Parry KE, et al. (2006) Delayed synaptic 
degeneration in the CNS of Wlds mice after cortical lesion. Brain, 129, 
1546-56. 
Gillingwater TH, Ribchester RR (2001) Compartmental neurodegeneration 
and synaptic plasticity in the Wld(s) mutant mouse. J Physiol, 534, 627-
39. 
Gillingwater TH, Ribchester RR (2003) The relationship of neuromuscular 
synapse elimination to synaptic degeneration and pathology: insights 
from WldS and other mutant mice. J Neurocytol, 32, 863-81. 
Gillingwater TH, Thomson D, Mack TG, et al. (2002) Age-dependent synapse 
withdrawal at axotomised neuromuscular junctions in Wld(s) mutant 
and Ube4b/Nmnat transgenic mice. J Physiol, 543, 739-55. 
Gillingwater TH, Wishart TM (2013) Mechanisms underlying synaptic 
vulnerability and degeneration in neurodegenerative disease. 
Neuropathol Appl Neurobiol, 39, 320-34. 
Gilman CP, Chan SL, Guo Z, Zhu X, Greig N, Mattson MP (2003) p53 is 
present in synapses where it mediates mitochondrial dysfunction and 
synaptic degeneration in response to DNA damage, and oxidative and 
excitotoxic insults. Neuromolecular Med, 3, 159-72. 
Gilman CP, Mattson MP (2002) Do apoptotic mechanisms regulate synaptic 
plasticity and growth-cone motility? Neuromolecular Med, 2, 197-214. 
Glancy B, Hartnell LM, Malide D, Yu Z, Combs CA, Connelly PS, 
Subramaniam S, Balaban RS (2015) Mitochondrial reticulum for cellular 
energy distribution in muscle. Nature, 523, 617-20. 
Glass JD, Schryer BL, Griffin JW (1994) Calcium-mediated degeneration of 
the axonal cytoskeleton in the Ola mouse. J Neurochem, 62, 2472-5. 
Goda Y, Davis GW (2003) Mechanisms of synapse assembly and 
disassembly. Neuron, 40, 243-64. 
Golubitzky A, Dan P, Weissman S, Link G, Wikstrom JD, Saada A (2011) 






deficient patient's fibroblasts, reveals AICAR as the most beneficial 
compound. PLoS One, 6, e26883. 
Goulet BB, Kothary R, Parks RJ (2013) At the "junction" of spinal muscular 
atrophy pathogenesis: the role of neuromuscular junction dysfunction in 
SMA disease progression. Curr Mol Med, 13, 1160-74. 
Graham LC, Eaton SL, Brunton PJ, et al. (2017) Proteomic profiling of 
neuronal mitochondria reveals modulators of synaptic architecture. Mol 
Neurodegener, 12, 77. 
Griffin JW, George EB, Hsieh ST, Glass JD (1995) Axonal degeneration and 
disorders of the axonal cytoskeleton. In The Axon: Structure, Function 
and Pathophysiology (eds Waxman SG, Kocsis JD, Stys PK), pp. 375-
390. NY: Oxford University Press. 
Hagenacker T, Wurster CD, Gunther R, et al. (2020) Nusinersen in adults with 
5q spinal muscular atrophy: a non-interventional, multicentre, 
observational cohort study. Lancet Neurol, 19, 317-325. 
Hahnen E, Forkert R, Marke C, et al. (1995) Molecular analysis of candidate 
genes on chromosome 5q13 in autosomal recessive spinal muscular 
atrophy: evidence of homozygous deletions of the SMN gene in 
unaffected individuals. Hum Mol Genet, 4, 1927-33. 
Hamilton G, Gillingwater TH (2013) Spinal muscular atrophy: going beyond the 
motor neuron. Trends Mol Med, 19, 40-50. 
Hammond SM, Gogliotti RG, Rao V, Beauvais A, Kothary R, DiDonato CJ 
(2010) Mouse survival motor neuron alleles that mimic SMN2 splicing 
and are inducible rescue embryonic lethality early in development but 
not late. PLoS One, 5, e15887. 
Han C, Jan LY, Jan YN (2011) Enhancer-driven membrane markers for 
analysis of nonautonomous mechanisms reveal neuron-glia 
interactions in Drosophila. Proc Natl Acad Sci U S A, 108, 9673-8. 
Harel NY, Strittmatter SM (2006) Can regenerating axons recapitulate 
developmental guidance during recovery from spinal cord injury? Nat 
Rev Neurosci, 7, 603-16. 
Harrington AW, Ginty DD (2013) Long-distance retrograde neurotrophic factor 
signalling in neurons. Nat Rev Neurosci, 14, 177-87. 
Hedlund E, Karlsson M, Osborn T, Ludwig W, Isacson O (2010) Global gene 
expression profiling of somatic motor neuron populations with different 
vulnerability identify molecules and pathways of degeneration and 
protection. Brain, 133, 2313-30. 
Hinerfeld D, Traini MD, Weinberger RP, et al. (2004) Endogenous 
mitochondrial oxidative stress: neurodegeneration, proteomic analysis, 
specific respiratory chain defects, and efficacious antioxidant therapy in 
superoxide dismutase 2 null mice. J Neurochem, 88, 657-67. 
Hirsch NP (2007) Neuromuscular junction in health and disease. Br J Anaesth, 
99, 132-8. 
Horner PJ, Gage FH (2000) Regenerating the damaged central nervous 
system. Nature, 407, 963-70. 
Hsieh-Li HM, Chang JG, Jong YJ, et al. (2000) A mouse model for spinal 






Huang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative 
analysis of large gene lists using DAVID bioinformatics resources. Nat 
Protoc, 4, 44-57. 
Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development 
and function. Annu Rev Neurosci, 24, 677-736. 
Huang YT, van der Hoorn D, Ledahawsky LM, et al. (2019) Robust 
Comparison of Protein Levels Across Tissues and Throughout 
Development Using Standardized Quantitative Western Blotting. J Vis 
Exp. 
Hussain G, Wang J, Rasul A, et al. (2020) Current Status of Therapeutic 
Approaches against Peripheral Nerve Injuries: A Detailed Story from 
Injury to Recovery. Int J Biol Sci, 16, 116-134. 
Jacobs WB, Govoni G, Ho D, et al. (2005) p63 is an essential proapoptotic 
protein during neural development. Neuron, 48, 743-56. 
Jager S, Handschin C, St-Pierre J, Spiegelman BM (2007) AMP-activated 
protein kinase (AMPK) action in skeletal muscle via direct 
phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A, 104, 12017-
22. 
Jangi M, Fleet C, Cullen P, et al. (2017) SMN deficiency in severe models of 
spinal muscular atrophy causes widespread intron retention and DNA 
damage. Proc Natl Acad Sci U S A, 114, E2347-E2356. 
Jedrzejowska M, Borkowska J, Zimowski J, et al. (2008) Unaffected patients 
with a homozygous absence of the SMN1 gene. Eur J Hum Genet, 16, 
930-4. 
Jin S, Martinek S, Joo WS, et al. (2000) Identification and characterization of 
a p53 homologue in Drosophila melanogaster. Proc Natl Acad Sci U S 
A, 97, 7301-6. 
Johnson GV, Litersky JM, Jope RS (1991) Degradation of microtubule-
associated protein 2 and brain spectrin by calpain: a comparative study. 
J Neurochem, 56, 1630-8. 
Kampfl A, Posmantur R, Nixon R, et al. (1996) mu-calpain activation and 
calpain-mediated cytoskeletal proteolysis following traumatic brain 
injury. J Neurochem, 67, 1575-83. 
Kaplan A, Spiller KJ, Towne C, et al. (2014) Neuronal matrix 
metalloproteinase-9 is a determinant of selective neurodegeneration. 
Neuron, 81, 333-48. 
Kaplan DR, Miller FD (2000) Neurotrophin signal transduction in the nervous 
system. Curr Opin Neurobiol, 10, 381-91. 
Kariya S, Mauricio R, Dai Y, Monani UR (2009) The neuroprotective factor 
Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) 
defects in mouse models of spinal muscular atrophy. Neurosci Lett, 
449, 246-51. 
Kariya S, Park GH, Maeno-Hikichi Y, et al. (2008) Reduced SMN protein 
impairs maturation of the neuromuscular junctions in mouse models of 
spinal muscular atrophy. Hum Mol Genet, 17, 2552-69. 
Kawamata M, Ochiya T (2012) Two distinct knockout approaches highlight a 






Kerschensteiner M, Schwab ME, Lichtman JW, Misgeld T (2005) In vivo 
imaging of axonal degeneration and regeneration in the injured spinal 
cord. Nat Med, 11, 572-7. 
Kim I, Rao H (2006) What's Ub chain linkage got to do with it? Sci STKE, 2006, 
pe18. 
Kim Y, Yang DS, Katti P, Glancy B (2019) Protein composition of the muscle 
mitochondrial reticulum during postnatal development. J Physiol, 597, 
2707-2727. 
Kline RA, Dissanayake KN, Hurtado ML, et al. (2019) Altered mitochondrial 
bioenergetics are responsible for the delay in Wallerian degeneration 
observed in neonatal mice. Neurobiol Dis, 130, 104496. 
Kline RA, Kaifer KA, Osman EY, et al. (2017) Comparison of independent 
screens on differentially vulnerable motor neurons reveals alpha-
synuclein as a common modifier in motor neuron diseases. PLoS 
Genet, 13, e1006680. 
Knoferle J, Koch JC, Ostendorf T, et al. (2010) Mechanisms of acute axonal 
degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A, 107, 
6064-9. 
Koch JC, Tatenhorst L, Roser AE, Saal KA, Tonges L, Lingor P (2018) ROCK 
inhibition in models of neurodegeneration and its potential for clinical 
translation. Pharmacol Ther, 189, 1-21. 
Kolb SJ, Kissel JT (2015) Spinal Muscular Atrophy. Neurol Clin, 33, 831-46. 
Kowaltowski AJ, de Souza-Pinto NC, Castilho RF, Vercesi AE (2009) 
Mitochondria and reactive oxygen species. Free Radic Biol Med, 47, 
333-43. 
Kuo CT, Zhu S, Younger S, Jan LY, Jan YN (2006) Identification of E2/E3 
ubiquitinating enzymes and caspase activity regulating Drosophila 
sensory neuron dendrite pruning. Neuron, 51, 283-90. 
Lanuza MA, Tomas J, Garcia N, Cilleros V, Borras L, Tomas M (2018) Axonal 
competition and synapse elimination during neuromuscular junction 
development. Curr Opin in Physiology, 4, 25-31. 
Larsen S, Nielsen J, Hansen CN, et al. (2012) Biomarkers of mitochondrial 
content in skeletal muscle of healthy young human subjects. J Physiol, 
590, 3349-60. 
Le TT, Pham LT, Butchbach ME, et al. (2005) SMNDelta7, the major product 
of the centromeric survival motor neuron (SMN2) gene, extends survival 
in mice with spinal muscular atrophy and associates with full-length 
SMN. Hum Mol Genet, 14, 845-57. 
Lee SH, Kim KR, Ryu SY, et al. (2012) Impaired short-term plasticity in mossy 
fiber synapses caused by mitochondrial dysfunction of dentate granule 
cells is the earliest synaptic deficit in a mouse model of Alzheimer's 
disease. J Neurosci, 32, 5953-63. 
Lee YI (2020) Developmental neuromuscular synapse elimination: Activity-
dependence and potential downstream effector mechanisms. Neurosci 
Lett, 718, 134724. 
Lefebvre S, Burglen L, Reboullet S, et al. (1995) Identification and 







Li J, Yuan J (2008) Caspases in apoptosis and beyond. Oncogene, 27, 6194-
206. 
Li R, Liu Z, Pan Y, Chen L, Zhang Z, Lu L (2014) Peripheral nerve injuries 
treatment: a systematic review. Cell Biochem Biophys, 68, 449-54. 
Li Y, Park JS, Deng JH, Bai Y (2006) Cytochrome c oxidase subunit IV is 
essential for assembly and respiratory function of the enzyme complex. 
J Bioenerg Biomembr, 38, 283-91. 
Lichtman JW, Colman H (2000) Synapse elimination and indelible memory. 
Neuron, 25, 269-78. 
Lienhart WD, Gudipati V, Macheroux P (2013) The human flavoproteome. 
Arch Biochem Biophys, 535, 150-62. 
Liu P, Peng J, Han GH, et al. (2019) Role of macrophages in peripheral nerve 
injury and repair. Neural Regen Res, 14, 1335-1342. 
Llavero Hurtado M, Fuller HR, Wong AMS, et al. (2017) Proteomic mapping of 
differentially vulnerable pre-synaptic populations identifies regulators of 
neuronal stability in vivo. Sci Rep, 7, 12412. 
Llobet Rosell A, Neukomm LJ (2019) Axon death signalling in Wallerian 
degeneration among species and in disease. Open Biol, 9, 190118. 
Lopez-Erauskin J, Fourcade S, Galino J, et al. (2011) Antioxidants halt axonal 
degeneration in a mouse model of X-adrenoleukodystrophy. Ann 
Neurol, 70, 84-92. 
Loreto A, Hill CS, Hewitt VL, et al. (2020) Mitochondrial impairment activates 
the Wallerian pathway through depletion of NMNAT2 leading to 
SARM1-dependent axon degeneration. Neurobiol Dis, 134, 104678. 
Luiro K, Kopra O, Blom T, et al. (2006) Batten disease (JNCL) is linked to 
disturbances in mitochondrial, cytoskeletal, and synaptic 
compartments. J Neurosci Res, 84, 1124-38. 
Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S (1989) Absence of 
Wallerian Degeneration does not Hinder Regeneration in Peripheral 
Nerve. Eur J Neurosci, 1, 27-33. 
Lunn MR, Wang CH (2008) Spinal muscular atrophy. Lancet, 371, 2120-33. 
Luo L, O'Leary DD (2005) Axon retraction and degeneration in development 
and disease. Annu Rev Neurosci, 28, 127-56. 
Mack TG, Reiner M, Beirowski B, et al. (2001) Wallerian degeneration of 
injured axons and synapses is delayed by a Ube4b/Nmnat chimeric 
gene. Nat Neurosci, 4, 1199-206. 
Malek MH, Huttemann M, Lee I (2018) Mitochondrial Structure, Function, and 
Dynamics: The Common Thread across Organs, Disease, and Aging. 
Oxid Med Cell Longev, 2018, 1863414. 
Malik AN, Czajka A (2013) Is mitochondrial DNA content a potential biomarker 
of mitochondrial dysfunction? Mitochondrion, 13, 481-92. 
Maor-Nof M, Romi E, Sar Shalom H, et al. (2016) Axonal Degeneration Is 
Regulated by a Transcriptional Program that Coordinates Expression of 
Pro- and Anti-degenerative Factors. Neuron, 92, 991-1006. 
Maor-Nof M, Yaron A (2013) Neurite pruning and neuronal cell death: spatial 







Marino S, Vooijs M, van Der Gulden H, Jonkers J, Berns A (2000) Induction of 
medulloblastomas in p53-null mutant mice by somatic inactivation of Rb 
in the external granular layer cells of the cerebellum. Genes Dev, 14, 
994-1004. 
Martin LJ, Liu Z, Chen K, et al. (2007) Motor neuron degeneration in 
amyotrophic lateral sclerosis mutant superoxide dismutase-1 
transgenic mice: mechanisms of mitochondriopathy and cell death. J 
Comp Neurol, 500, 20-46. 
Martineau E, Di Polo A, Vande Velde C, Robitaille R (2018) Dynamic 
neuromuscular remodeling precedes motor-unit loss in a mouse model 
of ALS. Elife, 7. 
Martinez-Hernandez R, Bernal S, Also-Rallo E, et al. (2013) Synaptic defects 
in type I spinal muscular atrophy in human development. J Pathol, 229, 
49-61. 
Mattson MP (2000) Apoptotic and anti-apoptotic synaptic signaling 
mechanisms. Brain Pathol, 10, 300-12. 
McGurk L, Berson A, Bonini NM (2015) Drosophila as an In Vivo Model for 
Human Neurodegenerative Disease. Genetics, 201, 377-402. 
McIlwain DR, Berger T, Mak TW (2013) Caspase functions in cell death and 
disease. Cold Spring Harb Perspect Biol, 5, a008656. 
McWhorter ML, Monani UR, Burghes AH, Beattie CE (2003) Knockdown of the 
survival motor neuron (Smn) protein in zebrafish causes defects in 
motor axon outgrowth and pathfinding. J Cell Biol, 162, 919-31. 
Melov S, Doctrow SR, Schneider JA, et al. (2001) Lifespan extension and 
rescue of spongiform encephalopathy in superoxide dismutase 2 
nullizygous mice treated with superoxide dismutase-catalase mimetics. 
J Neurosci, 21, 8348-53. 
Melov S, Schneider JA, Day BJ, et al. (1998) A novel neurological phenotype 
in mice lacking mitochondrial manganese superoxide dismutase. Nat 
Genet, 18, 159-63. 
Mendell JR, Al-Zaidy S, Shell R, et al. (2017a) AVXS-101 phase 1 gene 
therapy clinical trial in SMA Type 1: end-of-Study event free survival 
and achievement of developmental milestones. Neuromuscul Disord, 
27, S208. 
Mendell JR, Al-Zaidy S, Shell R, et al. (2017b) Single-Dose Gene-
Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med, 377, 
1713-1722. 
Menorca RM, Fussell TS, Elfar JC (2013) Nerve physiology: mechanisms of 
injury and recovery. Hand Clin, 29, 317-30. 
Menzies FM, Ince PG, Shaw PJ (2002) Mitochondrial involvement in 
amyotrophic lateral sclerosis. Neurochem Int, 40, 543-51. 
Mercuri E, Finkel RS, Kirschner J, et al. (2017) Efficacy and safety of 
nusinersen in children with later-onset spinal muscular atrophy (SMA): 
end of study results from the phase 3 CHERISH study. Neuromuscul 
Disord, 27, S210. 
Merlo P, Frost B, Peng S, Yang YJ, Park PJ, Feany M (2014) p53 prevents 
neurodegeneration by regulating synaptic genes. Proc Natl Acad Sci U 






Mi W, Beirowski B, Gillingwater TH, et al. (2005) The slow Wallerian 
degeneration gene, WldS, inhibits axonal spheroid pathology in gracile 
axonal dystrophy mice. Brain, 128, 405-16. 
Milde S, Gilley J, Coleman MP (2013) Subcellular localization determines the 
stability and axon protective capacity of axon survival factor Nmnat2. 
PLoS Biol, 11, e1001539. 
Miledi R, Slater CR (1968) Electrophysiology and electron-microscopy of rat 
neuromuscular junctions after nerve degeneration. Proc R Soc Lond B 
Biol Sci, 169, 289-306. 
Miledi R, Slater CR (1970) On the degeneration of rat neuromuscular junctions 
after nerve section. J Physiol, 207, 507-28. 
Miller BR, Press C, Daniels RW, Sasaki Y, Milbrandt J, DiAntonio A (2009) A 
dual leucine kinase-dependent axon self-destruction program promotes 
Wallerian degeneration. Nat Neurosci, 12, 387-9. 
Miller N, Shi H, Zelikovich AS, Ma YC (2016) Motor neuron mitochondrial 
dysfunction in spinal muscular atrophy. Hum Mol Genet, 25, 3395-3406. 
Mitchell J, Paul P, Chen HJ, et al. (2010) Familial amyotrophic lateral sclerosis 
is associated with a mutation in D-amino acid oxidase. Proc Natl Acad 
Sci U S A, 107, 7556-61. 
Moldovan M, Alvarez S, Krarup C (2009) Motor axon excitability during 
Wallerian degeneration. Brain, 132, 511-23. 
Mole AJ, Bell S, Thomson AK, Dissanayake KN, Ribchester RR, Murray LM 
(2020) Synaptic withdrawal following nerve injury is influenced by 
postnatal maturity, muscle-specific properties, and the presence of 
underlying pathology in mice. J Anat. 
Monani UR (2005) Spinal muscular atrophy: a deficiency in a ubiquitous 
protein; a motor neuron-specific disease. Neuron, 48, 885-96. 
Monani UR, De Vivo DC (2014) Neurodegeneration in spinal muscular 
atrophy: from disease phenotype and animal models to therapeutic 
strategies and beyond. Future Neurol, 9, 49-65. 
Monani UR, Sendtner M, Coovert DD, et al. (2000) The human centromeric 
survival motor neuron gene (SMN2) rescues embryonic lethality in 
Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum 
Mol Genet, 9, 333-9. 
Murray L, Gillingwater TH, Kothary R (2014) Dissection of the transversus 
abdominis muscle for whole-mount neuromuscular junction analysis. J 
Vis Exp, e51162. 
Murray LM, Beauvais A, Bhanot K, Kothary R (2013) Defects in neuromuscular 
junction remodelling in the Smn(2B/-) mouse model of spinal muscular 
atrophy. Neurobiol Dis, 49, 57-67. 
Murray LM, Beauvais A, Gibeault S, Courtney NL, Kothary R (2015) 
Transcriptional profiling of differentially vulnerable motor neurons at 
pre-symptomatic stage in the Smn (2b/-) mouse model of spinal 
muscular atrophy. Acta Neuropathol Commun, 3, 55. 
Murray LM, Comley LH, Gillingwater TH, Parson SH (2011) The response of 
neuromuscular junctions to injury is developmentally regulated. FASEB 






Murray LM, Comley LH, Thomson D, Parkinson N, Talbot K, Gillingwater TH 
(2008a) Selective vulnerability of motor neurons and dissociation of pre- 
and post-synaptic pathology at the neuromuscular junction in mouse 
models of spinal muscular atrophy. Hum Mol Genet, 17, 949-62. 
Murray LM, Gillingwater TH, Parson SH (2010) Using mouse cranial muscles 
to investigate neuromuscular pathology in vivo. Neuromuscul Disord, 
20, 740-3. 
Murray LM, Thomson D, Conklin A, Wishart TM, Gillingwater TH (2008b) Loss 
of translation elongation factor (eEF1A2) expression in vivo 
differentiates between Wallerian degeneration and dying-back neuronal 
pathology. J Anat, 213, 633-45. 
Neary MT, Ng KE, Ludtmann MH, et al. (2014) Hypoxia signaling controls 
postnatal changes in cardiac mitochondrial morphology and function. J 
Mol Cell Cardiol, 74, 340-52. 
Neve A, Trub J, Saxena S, Schumperli D (2016) Central and peripheral defects 
in motor units of the diaphragm of spinal muscular atrophy mice. Mol 
Cell Neurosci, 70, 30-41. 
Newbery HJ, Gillingwater TH, Dharmasaroja P, et al. (2005) Progressive loss 
of motor neuron function in wasted mice: effects of a spontaneous null 
mutation in the gene for the eEF1 A2 translation factor. J Neuropathol 
Exp Neurol, 64, 295-303. 
Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M (2009) APP binds 
DR6 to trigger axon pruning and neuron death via distinct caspases. 
Nature, 457, 981-9. 
O'Donnell KC, Vargas ME, Sagasti A (2013) WldS and PGC-1alpha regulate 
mitochondrial transport and oxidation state after axonal injury. J 
Neurosci, 33, 14778-90. 
Ochi K, Mori T, Toyama Y, Nakamura Y, Arakawa H (2002) Identification of 
semaphorin3B as a direct target of p53. Neoplasia, 4, 82-7. 
Ollmann M, Young LM, Di Como CJ, et al. (2000) Drosophila p53 is a structural 
and functional homolog of the tumor suppressor p53. Cell, 101, 91-101. 
Oprea GE, Krober S, McWhorter ML, et al. (2008) Plastin 3 is a protective 
modifier of autosomal recessive spinal muscular atrophy. Science, 320, 
524-7. 
Osman EY, Rietz A, Kline RA, et al. (2019) Intraperitoneal delivery of a novel 
drug-like compound improves disease severity in severe and 
intermediate mouse models of Spinal Muscular Atrophy. Sci Rep, 9, 
1633. 
Osterloh JM, Yang J, Rooney TM, et al. (2012) dSarm/Sarm1 is required for 
activation of an injury-induced axon death pathway. Science, 337, 481-
4. 
Oyebode OR, Hartley R, Singhota J, Thomson D, Ribchester RR (2012) 
Differential protection of neuromuscular sensory and motor axons and 
their endings in Wld(S) mutant mice. Neuroscience, 200, 142-58. 
Park JY, Jang SY, Shin YK, et al. (2013) Mitochondrial swelling and 
microtubule depolymerization are associated with energy depletion in 






Parson SH, Mackintosh CL, Ribchester RR (1997) Elimination of motor nerve 
terminals in neonatal mice expressing a gene for slow wallerian 
degeneration (C57Bl/Wlds). Eur J Neurosci, 9, 1586-92. 
Pasterkamp RJ, Verhaagen J (2006) Semaphorins in axon regeneration: 
developmental guidance molecules gone wrong? Philos Trans R Soc 
Lond B Biol Sci, 361, 1499-511. 
Perry VH, Brown MC, Tsao JW (1992) The Effectiveness of the Gene Which 
Slows the Rate of Wallerian Degeneration in C57BL/Ola Mice Declines 
With Age. Eur J Neurosci, 4, 1000-2. 
Personius KE, Slusher BS, Udin SB (2016) Neuromuscular NMDA Receptors 
Modulate Developmental Synapse Elimination. J Neurosci, 36, 8783-9. 
Picard M, Hepple RT, Burelle Y (2012) Mitochondrial functional specialization 
in glycolytic and oxidative muscle fibers: tailoring the organelle for 
optimal function. Am J Physiol Cell Physiol, 302, C629-41. 
Pickart CM, Fushman D (2004) Polyubiquitin chains: polymeric protein signals. 
Curr Opin Chem Biol, 8, 610-6. 
Portera-Cailliau C, Weimer RM, De Paola V, Caroni P, Svoboda K (2005) 
Diverse modes of axon elaboration in the developing neocortex. PLoS 
Biol, 3, e272. 
Pozniak CD, Barnabe-Heider F, Rymar VV, Lee AF, Sadikot AF, Miller FD 
(2002) p73 is required for survival and maintenance of CNS neurons. J 
Neurosci, 22, 9800-9. 
Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD (2000) An 
anti-apoptotic role for the p53 family member, p73, during 
developmental neuron death. Science, 289, 304-6. 
Press C, Milbrandt J (2008) Nmnat delays axonal degeneration caused by 
mitochondrial and oxidative stress. J Neurosci, 28, 4861-71. 
Prior TW, Krainer AR, Hua Y, et al. (2009) A positive modifier of spinal 
muscular atrophy in the SMN2 gene. Am J Hum Genet, 85, 408-13. 
Puente BN, Kimura W, Muralidhar SA, et al. (2014) The oxygen-rich postnatal 
environment induces cardiomyocyte cell-cycle arrest through DNA 
damage response. Cell, 157, 565-79. 
Quiros PM, Goyal A, Jha P, Auwerx J (2017) Analysis of mtDNA/nDNA Ratio 
in Mice. Curr Protoc Mouse Biol, 7, 47-54. 
Raff MC, Whitmore AV, Finn JT (2002) Axonal self-destruction and 
neurodegeneration. Science, 296, 868-71. 
Ramser J, Ahearn ME, Lenski C, et al. (2008) Rare missense and synonymous 
variants in UBE1 are associated with X-linked infantile spinal muscular 
atrophy. Am J Hum Genet, 82, 188-93. 
Ratni H, Ebeling M, Baird J, et al. (2018) Discovery of Risdiplam, a Selective 
Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the 
Treatment of Spinal Muscular Atrophy (SMA). J Med Chem, 61, 6501-
6517. 
Redfern PA (1970) Neuromuscular transmission in new-born rats. J Physiol, 
209, 701-9. 
Reedich EJ, Kalski M, Armijo N, Cox GA, DiDonato C (2021) Spinal motor 






the Smn2B/- mouse model of spinal muscular atrophy. Experimental 
Neurology, 337, 113587. 
Ribchester RR, Tsao JW, Barry JA, Asgari-Jirhandeh N, Perry VH, Brown MC 
(1995) Persistence of neuromuscular junctions after axotomy in mice 
with slow Wallerian degeneration (C57BL/WldS). Eur J Neurosci, 7, 
1641-50. 
Rochette CF, Gilbert N, Simard LR (2001) SMN gene duplication and the 
emergence of the SMN2 gene occurred in distinct hominids: SMN2 is 
unique to Homo sapiens. Hum Genet, 108, 255-66. 
Rodrigues NR, Owen N, Talbot K, Ignatius J, Dubowitz V, Davies KE (1995) 
Deletions in the survival motor neuron gene on 5q13 in autosomal 
recessive spinal muscular atrophy. Hum Mol Genet, 4, 631-4. 
Rose FF, Jr., Meehan PW, Coady TH, Garcia VB, Garcia ML, Lorson CL 
(2008) The Wallerian degeneration slow (Wld(s)) gene does not 
attenuate disease in a mouse model of spinal muscular atrophy. 
Biochem Biophys Res Commun, 375, 119-23. 
Rosenthal JL, Taraskevich PS (1977) Reduction of multiaxonal innervation at 
the neuromuscular junction of the rat during development. J Physiol, 
270, 299-310. 
Rossi A, Kontarakis Z, Gerri C, et al. (2015) Genetic compensation induced by 
deleterious mutations but not gene knockdowns. Nature, 524, 230-3. 
Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T (1995) A 
subset of p53-deficient embryos exhibit exencephaly. Nat Genet, 10, 
175-80. 
Sajadi A, Schneider BL, Aebischer P (2004) Wlds-mediated protection of 
dopaminergic fibers in an animal model of Parkinson disease. Curr Biol, 
14, 326-30. 
Samsam M, Mi W, Wessig C, et al. (2003) The Wlds mutation delays robust 
loss of motor and sensory axons in a genetic model for myelin-related 
axonopathy. J Neurosci, 23, 2833-9. 
Sanes JR, Lichtman JW (1999) Development of the vertebrate neuromuscular 
junction. Annu Rev Neurosci, 22, 389-442. 
Sanes JR, Lichtman JW (2001) Induction, assembly, maturation and 
maintenance of a postsynaptic apparatus. Nat Rev Neurosci, 2, 791-
805. 
Sareen D, Ebert AD, Heins BM, McGivern JV, Ornelas L, Svendsen CN (2012) 
Inhibition of apoptosis blocks human motor neuron cell death in a stem 
cell model of spinal muscular atrophy. PLoS One, 7, e39113. 
Sasaki Y, Nakagawa T, Mao X, DiAntonio A, Milbrandt J (2016) NMNAT1 
inhibits axon degeneration via blockade of SARM1-mediated NAD(+) 
depletion. Elife, 5. 
Saxena S, Caroni P (2007) Mechanisms of axon degeneration: from 
development to disease. Prog Neurobiol, 83, 174-91. 
Schlaepfer WW, Bunge RP (1973) Effects of calcium ion concentration on the 
degeneration of amputated axons in tissue culture. J Cell Biol, 59, 456-
70. 
Schlesinger DH, Goldstein G (1975) Molecular conservation of 74 amino acid 






Schrank B, Gotz R, Gunnersen JM, et al. (1997) Inactivation of the survival 
motor neuron gene, a candidate gene for human spinal muscular 
atrophy, leads to massive cell death in early mouse embryos. Proc Natl 
Acad Sci U S A, 94, 9920-5. 
Schuler M, Green DR (2001) Mechanisms of p53-dependent apoptosis. 
Biochem Soc Trans, 29, 684-8. 
Schwarz LA, Patrick GN (2012) Ubiquitin-dependent endocytosis, trafficking 
and turnover of neuronal membrane proteins. Mol Cell Neurosci, 49, 
387-93. 
Seddon HJ (1943) Peripheral Nerve Injuries. Glasgow Med J, 139, 61-75. 
Seddon HJ (1948) A review of work on peripheral nerve injuries in Great Britain 
during World War II. J Nerv Ment Dis, 108, 160-8. 
Seddon HJ, Medawar PB, Smith H (1943) Rate of regeneration of peripheral 
nerves in man. J Physiol, 102, 191-215. 
Sena LA, Chandel NS (2012) Physiological roles of mitochondrial reactive 
oxygen species. Mol Cell, 48, 158-67. 
Shababi M, Lorson CL, Rudnik-Schoneborn SS (2014) Spinal muscular 
atrophy: a motor neuron disorder or a multi-organ disease? J Anat, 224, 
15-28. 
Shan B, Pan H, Najafov A, Yuan J (2018) Necroptosis in development and 
diseases. Genes Dev, 32, 327-340. 
Sherer TB, Betarbet R, Testa CM, et al. (2003) Mechanism of toxicity in 
rotenone models of Parkinson's disease. J Neurosci, 23, 10756-64. 
Shi L, Fu AK, Ip NY (2012) Molecular mechanisms underlying maturation and 
maintenance of the vertebrate neuromuscular junction. Trends 
Neurosci, 35, 441-53. 
Shultz LD, Sweet HO, Davisson MT, Coman DR (1982) 'Wasted', a new 
mutant of the mouse with abnormalities characteristic to ataxia 
telangiectasia. Nature, 297, 402-4. 
Simic G, Seso-Simic D, Lucassen PJ, et al. (2000) Ultrastructural analysis and 
TUNEL demonstrate motor neuron apoptosis in Werdnig-Hoffmann 
disease. J Neuropathol Exp Neurol, 59, 398-407. 
Simon CM, Dai Y, Van Alstyne M, et al. (2017) Converging Mechanisms of p53 
Activation Drive Motor Neuron Degeneration in Spinal Muscular 
Atrophy. Cell Rep, 21, 3767-3780. 
Simon DJ, Weimer RM, McLaughlin T, et al. (2012) A caspase cascade 
regulating developmental axon degeneration. J Neurosci, 32, 17540-
53. 
Simon HU, Haj-Yehia A, Levi-Schaffer F (2000a) Role of reactive oxygen 
species (ROS) in apoptosis induction. Apoptosis, 5, 415-8. 
Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N (2000b) A Wallerian 
degeneration pattern in patients at risk for MS. Neurology, 54, 1155-60. 
Sine SM (2012) End-plate acetylcholine receptor: structure, mechanism, 
pharmacology, and disease. Physiol Rev, 92, 1189-234. 
Singh RN, Singh NN (2018) Mechanism of Splicing Regulation of Spinal 






Sleigh JN, Burgess RW, Gillingwater TH, Cader MZ (2014a) Morphological 
analysis of neuromuscular junction development and degeneration in 
rodent lumbrical muscles. J Neurosci Methods, 227, 159-65. 
Sleigh JN, Grice SJ, Burgess RW, Talbot K, Cader MZ (2014b) Neuromuscular 
junction maturation defects precede impaired lower motor neuron 
connectivity in Charcot-Marie-Tooth type 2D mice. Hum Mol Genet, 23, 
2639-50. 
Smith RS, Bisby MA (1993) Persistence of axonal transport in isolated axons 
of the mouse. Eur J Neurosci, 5, 1127-35. 
Speese SD, Trotta N, Rodesch CK, Aravamudan B, Broadie K (2003) The 
ubiquitin proteasome system acutely regulates presynaptic protein 
turnover and synaptic efficacy. Curr Biol, 13, 899-910. 
Spira ME, Oren R, Dormann A, Gitler D (2003) Critical calpain-dependent 
ultrastructural alterations underlie the transformation of an axonal 
segment into a growth cone after axotomy of cultured Aplysia neurons. 
J Comp Neurol, 457, 293-312. 
Spring AM, Raimer AC, Hamilton CD, Schillinger MJ, Matera AG (2019) 
Comprehensive Modeling of Spinal Muscular Atrophy in Drosophila 
melanogaster. Front Mol Neurosci, 12, 113. 
Staropoli JF, Li H, Chun SJ, et al. (2015) Rescue of gene-expression changes 
in an induced mouse model of spinal muscular atrophy by an antisense 
oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics, 
105, 220-8. 
Sunderland S (1951) A classification of peripheral nerve injuries producing loss 
of function. Brain, 74, 491-516. 
Tapia JC, Wylie JD, Kasthuri N, et al. (2012) Pervasive synaptic branch 
removal in the mammalian neuromuscular system at birth. Neuron, 74, 
816-29. 
Tedeschi A, Di Giovanni S (2009) The non-apoptotic role of p53 in neuronal 
biology: enlightening the dark side of the moon. EMBO Rep, 10, 576-
83. 
Telford JE, Kilbride SM, Davey GP (2009) Complex I is rate-limiting for oxygen 
consumption in the nerve terminal. J Biol Chem, 284, 9109-14. 
Tello JF (1907) Degeneration et regeneration des plagues motrices. Trav Lab 
Rech Biol Univ Madrit, 5, 117-149. 
Teskey G, Abrahem R, Cao R, et al. (2018) Glutathione as a Marker for Human 
Disease. Adv Clin Chem, 87, 141-159. 
Testa CM, Sherer TB, Greenamyre JT (2005) Rotenone induces oxidative 
stress and dopaminergic neuron damage in organotypic substantia 
nigra cultures. Brain Res Mol Brain Res, 134, 109-18. 
Thomson SR, Nahon JE, Mutsaers CA, et al. (2012) Morphological 
characteristics of motor neurons do not determine their relative 
susceptibility to degeneration in a mouse model of severe spinal 
muscular atrophy. PLoS One, 7, e52605. 
Tisdale S, Pellizzoni L (2015) Disease mechanisms and therapeutic 
approaches in spinal muscular atrophy. J Neurosci, 35, 8691-700. 
Tomas J, Garcia N, Lanuza MA, et al. (2017) Presynaptic Membrane 






Elimination during Neuromuscular Junction Development. Front Mol 
Neurosci, 10, 132. 
Tong C, Li P, Wu NL, Yan Y, Ying QL (2010) Production of p53 gene knockout 
rats by homologous recombination in embryonic stem cells. Nature, 
467, 211-3. 
Tsao JW, Brown MC, Carden MJ, McLean WG, Perry VH (1994) Loss of the 
compound action potential: an electrophysiological, biochemical and 
morphological study of early events in axonal degeneration in the 
C57BL/Ola mouse. Eur J Neurosci, 6, 516-24. 
Tsao JW, George EB, Griffin JW (1999) Temperature modulation reveals three 
distinct stages of Wallerian degeneration. J Neurosci, 19, 4718-26. 
Turner BJ, Alfazema N, Sheean RK, et al. (2014) Overexpression of survival 
motor neuron improves neuromuscular function and motor neuron 
survival in mutant SOD1 mice. Neurobiol Aging, 35, 906-15. 
Turner BJ, Parkinson NJ, Davies KE, Talbot K (2009) Survival motor neuron 
deficiency enhances progression in an amyotrophic lateral sclerosis 
mouse model. Neurobiol Dis, 34, 511-7. 
Van Nostrand JL, Bowen ME, Vogel H, Barna M, Attardi LD (2017) The p53 
family members have distinct roles during mammalian embryonic 
development. Cell Death Differ, 24, 575-579. 
Vande Velde C, Garcia ML, Yin X, Trapp BD, Cleveland DW (2004) The 
neuroprotective factor Wlds does not attenuate mutant SOD1-mediated 
motor neuron disease. Neuromolecular Med, 5, 193-203. 
Vendemiale G, Grattagliano I, Altomare E (1999) An update on the role of free 
radicals and antioxidant defense in human disease. Int J Clin Lab Res, 
29, 49-55. 
Verhaart IEC, Robertson A, Leary R, et al. (2017) A multi-source approach to 
determine SMA incidence and research ready population. J Neurol, 
264, 1465-1473. 
Villegas R, Martinez NW, Lillo J, et al. (2014) Calcium release from intra-
axonal endoplasmic reticulum leads to axon degeneration through 
mitochondrial dysfunction. J Neurosci, 34, 7179-89. 
Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature, 408, 
307-10. 
Vousden KH (2000) p53: death star. Cell, 103, 691-4. 
Wadman RI, Vrancken AF, van den Berg LH, van der Pol WL (2012) 
Dysfunction of the neuromuscular junction in spinal muscular atrophy 
types 2 and 3. Neurology, 79, 2050-5. 
Wagner R, Heckman HM, Myers RR (1998) Wallerian degeneration and 
hyperalgesia after peripheral nerve injury are glutathione-dependent. 
Pain, 77, 173-9. 
Waller A (1851) Experiments on the Section of the Glosso-Pharyngeal and 
Hypoglossal Nerves of the Frog, and Observations of the Alterations 
Produced Thereby in the Structure of Their Primitive Fibres. Edinb Med 
Surg J, 76, 369-376. 
Wang JT, Medress ZA, Barres BA (2012) Axon degeneration: molecular 






Wang MS, Fang G, Culver DG, Davis AA, Rich MM, Glass JD (2001) The WldS 
protein protects against axonal degeneration: a model of gene therapy 
for peripheral neuropathy. Ann Neurol, 50, 773-9. 
Wang MS, Wu Y, Culver DG, Glass JD (2000) Pathogenesis of axonal 
degeneration: parallels between Wallerian degeneration and vincristine 
neuropathy. J Neuropathol Exp Neurol, 59, 599-606. 
Watts RJ, Hoopfer ED, Luo L (2003) Axon pruning during Drosophila 
metamorphosis: evidence for local degeneration and requirement of the 
ubiquitin-proteasome system. Neuron, 38, 871-85. 
Watts RJ, Schuldiner O, Perrino J, Larsen C, Luo L (2004) Glia engulf 
degenerating axons during developmental axon pruning. Curr Biol, 14, 
678-84. 
Williams AB, Schumacher B (2016) p53 in the DNA-Damage-Repair Process. 
Cold Spring Harb Perspect Med, 6. 
Williams DW, Kondo S, Krzyzanowska A, Hiromi Y, Truman JW (2006) Local 
caspase activity directs engulfment of dendrites during pruning. Nat 
Neurosci, 9, 1234-6. 
Williams DW, Truman JW (2005) Cellular mechanisms of dendrite pruning in 
Drosophila: insights from in vivo time-lapse of remodeling dendritic 
arborizing sensory neurons. Development, 132, 3631-42. 
Winlow W, Usherwood PN (1975) Ultrastructural studies of normal and 
degenerating mouse neuromuscular junctions. J Neurocytol, 4, 377-94. 
Wirth B, Brichta L, Hahnen E (2006a) Spinal muscular atrophy and therapeutic 
prospects. Prog Mol Subcell Biol, 44, 109-32. 
Wirth B, Brichta L, Hahnen E (2006b) Spinal muscular atrophy: from gene to 
therapy. Semin Pediatr Neurol, 13, 121-31. 
Wirth B, Brichta L, Schrank B, et al. (2006c) Mildly affected patients with spinal 
muscular atrophy are partially protected by an increased SMN2 copy 
number. Hum Genet, 119, 422-8. 
Wishart TM, Parson SH, Gillingwater TH (2006) Synaptic vulnerability in 
neurodegenerative disease. J Neuropathol Exp Neurol, 65, 733-9. 
Wishart TM, Paterson JM, Short DM, et al. (2007) Differential proteomics 
analysis of synaptic proteins identifies potential cellular targets and 
protein mediators of synaptic neuroprotection conferred by the slow 
Wallerian degeneration (Wlds) gene. Mol Cell Proteomics, 6, 1318-30. 
Wong F, Fan L, Wells S, et al. (2009) Axonal and neuromuscular synaptic 
phenotypes in Wld(S), SOD1(G93A) and ostes mutant mice identified 
by fiber-optic confocal microendoscopy. Mol Cell Neurosci, 42, 296-
307. 
Workman E, Kolb SJ, Battle DJ (2012) Spliceosomal small nuclear 
ribonucleoprotein biogenesis defects and motor neuron selectivity in 
spinal muscular atrophy. Brain Res, 1462, 93-9. 
Wyatt RM, Balice-Gordon RJ (2003) Activity-dependent elimination of 
neuromuscular synapses. J Neurocytol, 32, 777-94. 
Xi Y, Noble S, Ekker M (2011) Modeling neurodegeneration in zebrafish. Curr 






Yan T, Feng Y, Zheng J, et al. (2010) Nmnat2 delays axon degeneration in 
superior cervical ganglia dependent on its NAD synthesis activity. 
Neurochem Int, 56, 101-6. 
Yao D, Li M, Shen D, et al. (2013) Expression changes and bioinformatic 
analysis of Wallerian degeneration after sciatic nerve injury in rat. 
Neurosci Bull, 29, 321-32. 
Yaron A, Schuldiner O (2016) Common and Divergent Mechanisms in 
Developmental Neuronal Remodeling and Dying Back 
Neurodegeneration. Curr Biol, 26, R628-R639. 
Zerres K, Rudnik-Schoneborn S (1995) Natural history in proximal spinal 
muscular atrophy. Clinical analysis of 445 patients and suggestions for 
a modification of existing classifications. Arch Neurol, 52, 518-23. 
Zhai Q, Wang J, Kim A, et al. (2003) Involvement of the ubiquitin-proteasome 
system in the early stages of wallerian degeneration. Neuron, 39, 217-
25. 
Zhang Z, Lotti F, Dittmar K, et al. (2008) SMN deficiency causes tissue-specific 
perturbations in the repertoire of snRNAs and widespread defects in 
splicing. Cell, 133, 585-600. 
Zhang Z, Pinto AM, Wan L, et al. (2013) Dysregulation of synaptogenesis 
genes antecedes motor neuron pathology in spinal muscular atrophy. 
Proc Natl Acad Sci U S A, 110, 19348-53. 
Zhao RZ, Jiang S, Zhang L, Yu ZB (2019) Mitochondrial electron transport 
chain, ROS generation and uncoupling (Review). Int J Mol Med, 44, 3-
15. 
Zheleznyakova GY, Kiselev AV, Vakharlovsky VG, et al. (2011) Genetic and 
expression studies of SMN2 gene in Russian patients with spinal 
muscular atrophy type II and III. BMC Med Genet, 12, 96. 
Zhu J, Singh M, Selivanova G, Peuget S (2020) Pifithrin-alpha alters p53 post-
translational modifications pattern and differentially inhibits p53 target 











































































































































































































































































1.37 Appendix 4: Mitochondrial protein levels, number and activity at P15 versus 

















Figure A1: Mitochondrial protein levels, number and activity at P12 versus P24 in 
spinal cord. (A) Western blot result using antibodies against Complex I, II, III, IV and 
V subunits on spinal cord from P15 and P24 mice, with total protein staining used as 
a loading control.  (B) Quantification of western blot against different complex 
subunits in spinal cord. Data is expressed normalised to loading control and relative to 
levels at P15. Ns = not significant, p > 0.1, * p = 0.04, *** p = 0.0004; one-sample t-
test. (C) Relative normalised quantity of mtDNA as determined by qPCR and 2-∆∆CT 
method in spinal cord at P15 versus P24. Note that no increase in mtDNA is seen. Data 
is normalised to H19 and expressed relative to P15. ** P = 0.0039; one-sample t-test 
(D) Complex I activity as determined by enzyme linked immunosorbent assay 
(ELISA) at P15 versus P24 in spinal cord. NADH dehydrogenase activity was 
measured kinetically over 60 min and the rate was determined as a change in optical 
density over time, and expressed normalised to P15. Ns = not significant, p = 0.80. In 

























Figure A2: Mitochondrial protein levels, number and activity at P12 versus P24 in 
brain. (A) Western blot result using antibodies against Complex I, II, III, IV and V 
subunits on brain from P15 and P24 mice, with total protein staining used as a loading 
control.  (B) Quantification of western blot against different complex subunits in brain. 
Data is expressed normalised to loading control and relative to levels at P15. Ns = not 
significant, p > 0.1, * p = 0.047, ** p = 0.008; one-sample t-test. (C) Relative 
normalised quantity of mtDNA as determined by qPCR and 2-∆∆CT method in brain at 
P15 versus P24. Note that no increase in mtDNA is seen. Data is normalised to H19 
and expressed relative to P15. ** P = 0.0039; one-sample t-test (D) Quantification of 
Complex I activity as determined by enzyme linked immunosorbent assay (ELISA) at 
P15 versus P24 in brain. NADH dehydrogenase activity was measured kinetically over 
60 min and the rate was determined as a change in optical density over time, and 
expressed normalised to P15. Ns = not significant, p = 0.46. In all cases, n=3 biological 
replicates. Error bars represent mean ± SEM. 
